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Abstract 
In unstimulated cells, the transcription factor NF-KB is held in the 
cytoplasm in an inactive state by IKB inhibitor proteins. Activation of NF--KB is 
mediated by signal induced degradation of IicBa via the ubiquitin proteasome- 
dependent pathway. Targeting the proteins for ubiquitin-mediated proteolysis is an 
irrevocable decision, and as such, the process needs to be highly specific and tightly 
regulated. This task is achieved by conjugation and deconjugation enzymes that act 
in a dynamic and coordinated mechanism. 
In a yeast two hybrid screen designed to identify proteins involved in ItcBa 
signalling Ubch9 was found to interact with the N-terminal regulatory region of 
I1Ba. Although Ubch9 is an enzyme homologous to E2 ubiquitin conjugating 
enzymes we have shown that is unable to form a thioester with ubiquitin but it is 
capable to form a thioester with the small ubiquitin-like protein SUMO- 1. To fully 
characterise the SUMO-1 modification reaction we have purified the proteins and 
cloned the genes encoding the SUMO-1 activating enzyme (SAEl/SAE2) and 
shown that it is homologous to enzymes involved in the activation of ubiquitin, 
Smt3p, the yeast SUMO-1 homologue, and Rublp/Nedd8, another ubiquitin-like 
protein. SUMO-1 is conjugated to target proteins by a pathway that is distinct from, 
but analogous to, ubiquitin conjugation. 
SUMO-1 was efficiently conjugated, both in vivo and in vitro, to IxBa on 
lysine 21, which is also utilised for ubiquitin modification. Thus, by blocking 
ubiquitination SUMO-1 modification acts antagonistically to generate a pool of 
IKBa resistant to proteasome-mediated degradation which consequently inhibits 
NF--KB dependent transcription activation. 
In view of several lines of similarity between NF-kB and p53, the 
involvement of SUMO-1 modification in the metabolism of the tumour supressor 
p53 was investigated. We have shown that p53 is modified by SUMO-1 at a single 
15 
site, lysine 386 in the C-terminus of p53. Although p53 is regulated by 
ubiquitination, SUMO-1 and ubiquitin modification do not compete for the same 
lysine in p53. However, overexpression of SUMO-1 activates the transcriptional 
activity of wild type p53, but not K386R p53 where the SUMO-1 acceptor site has 
been mutated. 
A consensus sequence was obtained by comparison of the sequences 
surrounding the SUMO-1 acceptor lysine in proteins that have been shown to be 
modified by SUMO-1 and revealed a possible recognition site for SUMO-1 
conjugation machinery. 
Tagging of proteins with SUMO-1 regulates transcriptional activation, either 
by interfering with subcellular location or with the ubiquitination pathway. The 
pathway may represent a novel target for drug development. 
16 
1. INTRODUCTION 
17 
I. I. Rel/NF-KB family of transcription factors 
Regulated eukaryotic gene transcription involves the assembly of an 
initiation complex at the core promoter region and a coordinated binding of multiple 
transcription factors and regulatory complexes to the promoter-enhancer region; 
many of these transcription factors are regulated by distinct signal transduction 
pathways. The activity of a particular transcription factor can be modulated in a 
number of different ways: by changing the rate of synthesis or degradation of the 
protein; by post-translational modification of the transcription factor or by altering 
its subcellular localisation. Rel/ NF-KB is a ubiquitous transcription factor subject to 
regulatory mechanisms that involves each one of the mentioned levels: protein- 
protein interaction, covalent modification, proteolytic degradation and 
nucleocytoplasmic translocation. 
Although the transcription factor NF-KB was originally identified as a tissue 
specific enhancer-binding protein involved in the activation of x light chain gene 
expression in mature B lymphocytes (Sen and Baltimore, 1986) subsequent studies 
demonstrated that it is one member of a ubiquitously expressed family of Rel-related 
transcription factors that serve as critical regulators of the inducible expression of 
many genes. The Rel/NF-xB transcription factors regulate the expression of genes 
involved in immune, acute phase, inflammatory and survival response. In addition, 
the early promoters of many viral genomes such as the HIV-1 provirus are regulated 
by Rel/NF-xB. 
In humans the Rel/ NF-KB family comprises NF-KB 1 (p50/p 105), NF-, KB 2 
(p52/pl00), p65 (also known as ReIA), C-Rel and Re1B. Rel A, C-Rel and Re1B 
are produced as transcriptionally active proteins, whereas NF-KB 1 (Palombella et 
al., 1994) and NF-iB2 are synthesised as longer percursor molecules of 105 KDa 
and 100 KDa respectively, which are unable to bind DNA but are processed to 
smaller DNA binding forms. All members of this family contain a conserved 300 
residue amino-terminal region called Rel-homology domain (RHD) which is 
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required for sequence specific DNA-binding, dimerisation, nuclear localisation 
(NLS) and interaction with inhibitory proteins. NF-KB binds to DNA as dimers 
composed of different combinations of the family members. Crystal structures of 
p50, p52 and p65 homodimers and p65/p50 heterodimers bound to DNA have been 
determined (Chen et a!., 1998; Cramer et al., 1997; Ghosh et al., 1995; Muller et 
al., 1995). The structures of the RHDs of p50 and p65 bound to DNA show that 
each consists of two domains with immunoglobulin-like folds. C-terminal domains 
are responsible for dimer formation with other Rel family proteins and although 
both domains are involved in DNA binding, sequence-specific interactions come 
primarily from loops in the N-terminal domain (Chen et al., 1998). While almost all 
combinations of homo- and heterodimer can exist, the typical form of NF-icB that is 
activated in response to extracellular signals is a heterodimer p50 and p65. Each 
NF-KB complex displays distinct affinities for the different DNA binding sites 
present in the promoters of NF-icB-regulated genes, and this may contribute to 
some of the specificity exhibited by this family. (Baeuerle and Baltimore, 1996; 
Baldwin, 1996; May and Ghosh, 1998; Mercurio and Manning, 1999). 
1.1.1.1KB family 
NF--KB exists in the cytoplasm of unstimulated cells in an inactive form 
associated with the IxB family of inhibitor proteins which include, to date, seven 
different but structurally and functionally related, molecules: IiBcx (Haskill et al., 
1991), IiB(3 (Thompson et al., 1995), IiBe (Whiteside et al., 1997a), Bc13 (Ohno 
et al., 1990), p 100, p 105 and the drosophilia protein cactus. p 100 and p 105, the 
percursors of p50 and p52, respectively, contain IiB-like regions in the C-terminal 
half of the polypeptide and are known as IiBy (Blank et al., 1991; Inoue et al., 
1992; Liou et al., 1992) and IKB8 (Mercurio et al., 1993) respectively. All IKB 
family members share six or more ankyrin-like repeat domains (30-33 amino acid) 
and regulate the DNA binding (Zabel and Baeuerle, 1990) and subcellular 
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localisation of Rel-NF-icB proteins. This is accomplished by masking the nuclear 
localisation signals of NF-KB subunits which prevents their nuclear translocation. 
(Beg c't al., 1992; Henkel et al., 1992). Specificity of inhibition is due to different 
IxB family members inhibiting NF-kB/Rel family members to varying degree. For 
example, IkBa and IkBI3 associate predominantly with p50/p65 and p50/C-Rel 
heterodimers (Thompson et al., 1995), whereas IkBe binds to p65 and C-Rel 
homodimers (Whiteside et al., 1997b), and Bcl-3 interacts with p50 and p52 
homodimers (Franzoso cat al., 1992; Nolan et al., 1993). 
The best-characterised IicB protein is IxBa, composed of three main 
regions (Jaffray et at., 1995): an N-terminal region, which regulates signal- 
dependent degradation; an ankyrin repeat domain ; and the C-terminal PEST region, 
which is a target for casein kinase II (CKII) phosphorylation (Barroga et at., 1995) 
and regulates basal degradation (Ernst et at., 1995; Lin et at., 1996; Schwarz et at., 
1996). Both amino- and carboxyl- terminal regions are required for signal - induced 
degradation of IiBa (Brown et at., 1997; Kroll et at., 1997; Rodriguez et at., 
1995). The structure of the IxBa ankyrin repeat domain bound to NF-kB p50/p65 
heterodimer has been determined by X-ray crystallography (Huxford et at., 1998; 
Jacobs and Harrison, 1998) and clarified the structural basis by which both nuclear 
entry and DNA binding of NF-KB are inhibited by IKB a. The contact area of the 
ankyrin repeats with NF-KB is large , with the most significant contribution 
from 
the dimerised Ig-like domain of the p50/p65 RHD and repeats 3 to 5 of IicBa. 
Cytoplasmic retention is achieved by the first two ankyrin repeats of IKB a which 
recognise the sequences of the NF-KB NLSs and appear to inhibit nuclear 
localisation by sterically impeding NLS access to the nuclear import machinery. In 
the presence of IKB a, the p65 subunit of NF-KB adopts a remarkable change in 
conformation which impedes NF-xB DNA binding through the occlusion of basic 
DNA-contacting surfaces and permits optimal IiB a/ NF-KB complex formation 
(Huxford et al., 1998; Jacobs and Harrison, 1998). 
20 
1.1.2. NF-xB activation pathway 
The range of stimuli that activate members of Rel family is extensive and 
growing, giving emphase to their central role in transcriptional responses. Potent 
inducers of NF--KB include: cytokines such as interleukin (IL)-1(3 and tumour 
necrosis factor (TNF)a; bacterial and viral products such as lipopolysaccharide 
(LPS), sphingomyelinase, double strand RNA and the Tax protein from human T- 
cell leukemia virus 1 (HTLV-1); and pro-apoptotic and necrotic stimuli such as 
oxygen free radicals, ultraviolet light and y-irradiation. These diverse incoming 
signals, originating from different signal transduction pathways, converge in a key 
molecular structure - the cytosolic NF-KB-IxB complex. 
Activation of NF-KB is mediated by signal induced degradation of IiB a in 
the cytoplasm, which allows the active transcription factor to translocate into the 
nucleus and activate transcription of a large number of responsive genes. As part of 
an autoregulatory loop, NF-KB induces efficient resynthesis of IxBa through the 
activation of IxBa mRNA transcription (LeBail et al., 1993; Sun et al., 1993). 
Newly synthesised IxBoc accumulates transiently in the nucleus, where it is 
resistant to signal-induced degradation (Rodriguez et al., 1999) and negatively 
regulates NF-KB dependent transcription (Arenzana-Seisdedos et al., 1995). IKBcL 
mediates transport of the NF-KB/ IKBa complex back to the cytoplasm (Arenzana- 
Seisdedos et al., 1997) in a nuclear export sequence (NES) -dependent process that 
is sensitive to Leptomycine B (LMB) (Rodriguez et al., 1999). Nuclear export of 
IiBa and many other proteins that shuttle between the nucleus and the cytoplasm is 
mediated by a leucine-rich NES that is recognised by CRM1/exportin 1 (Fomerod et 
al., 1997; Fukuda et al., 1997; Ossareh-Nazari et al., 1997; Stade et al., 1997). The 
formation of CRM1/NES complex is facilitated by the presence of Ran in its GTP- 
bound form. It has been proposed that this ternary complex is transported through 
21 
the nuclear pore complex and dissociates in the cytoplasm due to GTP hydrolysis 
by Ran-GAP (Figure 1 A) (Fornerod et al., 1997). 
Nuclear import of NF-KB-free IicBa does not result from passive diffusion 
but from a specific energy-dependent transport process that requires the ankyrin 
repeats of IKBa, importins a and ß as well as the small GTPase Ran (Sachdev et 
al., 1998; Turpin et al., 1999). Importin a binds to NLS-containing proteins and, 
through interaction with importin ß, mediates the docking of the NLS-containing 
protein to nucleoporins and the subsequent translocation of the NLS-containing 
protein to the nucleus (Figure 1B). 
IiBa lacks a classical basic nuclear localisation sequence (NLS) involved in 
the importin a-(3-mediated import pathway but a novel class of cis-acting nuclear 
import sequences was identified within the second ankyrin repeat of IicB a which 
mediates the nuclear localisation of newly synthesised IiBa (Sachdev et al., 1998). 
Although the second ankyrin repeat is the predominant nuclear import sequence, 
ankyrin repeats also contribute to the nuclear localisation of IiBa by interaction 
with additional protein (s) containing a basic NLS (Turpin et al., 1999). NF-KB 
retains IicB oc in the cytoplasm by masking its ankyrin repeats, which are essential 
for nuclear import. In unstirnulated cells, cytoplasmic retention of NF-KB. IkBoc 
complexes are therefore caused by a mutual masking of the sequences responsible 
for the nuclear import of both proteins. IxBa, shuttling between the cytoplasm and 
the nucleus regulates both the activation and inactivation of gene transcription 
through its association with NF-iB. 
The signal transduction cascades from the cell surface to NF--KB activation 
has been subject of intense investigation and they have been further elucidated with 
the identification of the IKB Kinases IKKc (or IKK1) and IKKß (or IKK2), IKK 
signalsome, which mediate signal induced phosphorylation of IKBoc on Ser 32 and 
Ser 36 (DiDonato et al., 1997; Mercurio et al., 1997; Regnier et al., 1997; Zandi et 
al., 1997). Mutation of these residues by site-directed mutagenesis was found to 
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block phosphorylation of IKBa in response to activating signals, thereby preventing 
subsequent degradation of the protein (Brockman et al., 1995; Brown et al., 1995; 
Traenckner et al., 1995). Specific inhibition of the proteolytic activity of the 
proteasome prevents NF-KB activation and results in the accumulation of 
ubiquitinated forms of IxBa, indicating that IiBa is targeted for degradation by a 
phosphorylation-dependent ubiquitination process which occurs in two adjacent-N- 
terminal lysine residues at positions 21 and 22 (Alkalay et al., 1995; Chen et al., 
1995; Rodriguez et al., 1996; Roff et al., 1996). Phosphorylation of IKB(x serves 
as a molecular tag leading to rapid ubiquitination and degradation of IxBoc by the 
recently identified SCFßT`CP ligase complex and other components of the ubiquitin- 
proteasome pathway (discussed later). Neither phosphorylation, nor ubiquitination 
alone is sufficient to dissociate the NF-KB/ IKBa complex. Free NF-KB is only 
released after degradation of IiBa by the 26S proteasome (Didonato et al., 1995). 
This process exposes the NLS, thereby freeing NF-KB to interact with the nuclear 
import machinery and translocate to the nucleus (Henkel et al., 1992), where it 
binds its target genes to initiate transcription. 
1.1.3. IKK signalsome complex 
1.1.3.1. Identification 
It is well established that the critical event which targets the 
polyubiquitination and degradation of IKBs via the 26S proteasome is their 
stimulus-dependent phosphorylation at two serine residues that are located within 
their conserved N-terminal regulatory region (DiDonato et al., 1996). A protein 
kinase with such substrate requirements remained unidentified for many years and 
many candidates were identified, such as protein kinase C (Diaz-Meco et al., 
1994), casein kinase II (Barroga et al., 1995), and ribosomal S6 kinase (pp90rs'`) 
(Schouten et al., 1997). Although most of these kinases phosphorylate IicB proteins 
in vitro on different serine, threonine or tyrosine residues, they were all unable to 
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phosphorylate the two regulatory serines that target the degradation of IxBs in a 
stimulus-dependent manner. DiDonato et al. (DiDonato et al., 1997)purified a 
cytokine-activated protein kinase complex of 900 KDa , named IKK for IKB 
kinase, with such requirements. Two components of IKK were molecularly cloned 
and identified as two closely related protein serine kinases, IKKa (IKKl) and 
IKKI (IKK2) (DiDonato et al., 1997; Woronicz et al., 1997). IKKot is identical in 
sequence to the putative serine/ threonine kinase CHUCK, whose function and 
mechanism of regulation were previously unknown (Connelly and Marcu, 1995). 
In this case however the purified components were able to phosphorylate 
specifically I-KBa (Ser32 and Ser36) and IiB(3 (Ser19 and Ser23) (Zandi et al., 
1997). IKK(x was also isolated by a two hybrid screen as a NIK (NF-KB inducing 
kinase) interacting protein (Regnier et al., 1997). NIK is a member of the MEK 
kinase (MEKK) family that was identified as a TRAF2-interacting protein which is 
required for TNF-induced NF-KB activation (Rothe et al., 1995). NIK has the 
ability to potently stimulate NF-KB activity in transiently transfected cells (Malinin 
et al., 1997) and catalytically inactive mutants of NIK behave as dominant-negative 
inhibitors that supress TNF-, IL-I-, TRADD-1-, TRAF2-, TRAF5-, TRAF6- 
induced NF-KB activation. NIK seems to be a common mediator in the NF--KB 
signalling cascades triggered by TNF and IL-1 downstream of TRAFs and other 
receptor-associated signalling proteins (Song et al., 1997). The inhibition of IKKa 
expression by the use of an antisense RNA expression vector and a catalytic inactive 
mutant of this kinase resulted in inhibition of NF-KB activation by TNF or ELI 
(DiDonato et al., 1997; Regnier et al., 1997). The same effect was observed with a 
kinase-defective mutant of IKK(3 (Mercurio et al., 1997) consistent with a critical 
role for both IKKa and IKK(3 in the NF-KB pathway. 
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1.1.3.2. Composition 
The main components of the IKK complex - IKKa and IKK(3 - have a 
similar overall structure and are 51% identical. They contain a Ser/Thr kinase 
domain in their N-terminal half and a leucine zipper as well as a helix-loop-helix 
protein interaction motif in their C-terminal region. Immunoprecipitation studies 
have demonstrated that IKKa and IKK(3 can form homo- or heterodimers and 
mutational analysis has shown that these interactions are mediated by the leucine 
zipper motif (Mercurio et al., 1997; Woronicz et at., 1997; Zandi et al., 1997). By 
contrast, the helix loop helix motif does not affect the interaction between the two 
subunits but seems to be important for the kinase activity (Zandi et al., 1997). 
Although heterodimers seems to be the favoured conformation, the precise nature of 
the interactions between IKKa and IKKI3 in vivo are not yet clear. 
Using a monoclonal antibody against IKKa, a new subunit of the IKK 
complex was purified and identified as a regulatory protein required for the 
activation of the IKK complex (Rothwarf et at., 1998). This subunit denominated 
IKK, y binds preferentially to IKK(3 and is a glutamine-rich protein that lacks a 
known catalytic domain but contains several coiled-coil interaction motifs, including 
a Leucine zipper (LZ) next to the C-terminus. A C-terminally truncated form of 
IKK, y lacking the LZ can still bind to IKK(3 but blocks activation of IKK and NF- 
xB (Rothwarf et al., 1998). This subunit was named IKKAPI by a different group, 
for IKK associated protein-1, and identified in two different IKK complexes in 
vivo- one containing a heterodimer of IKKa and IKK(3, the other containing an 
homodimer of IKK(3 (Mercurio et al., 1999). IKKy was also identified in a screen 
for genes that are able to complement a cell line that is unresponsive to multiple NF- 
-KB activating stimuli including TNF, IL-1, LPS, phorbol myristylate acetate 
(PMA), dsRNA and the Tax transactivator protein of human T cell leukemia virus 
(HTLV). A cDNA was found which could reconstitute activation of NF--KB by all 
of these inducers upon its stimulation. Consistent with its essential role as a NF-KB 
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modulator it was named NEMO (NF-KB essential modulator) and is the mouse 
homologue of IKKy (Yamaoka et al., 1998). 
Another component of the IKK signalsome was identified and named IKAP 
(IKK-complex associated protein). It is a 150 KDa protein containing several WD 
protein-interaction motifs which can bind NIK and IKKs and assemble them into an 
active kinase complex (Cohen et al., 1998). The interaction of IKAP with IKKa 
and IKK(3 seems to be transient and it remains to be determined whether IKAP is 
required for IKK activation. As a scaffolding protein more biochemical analysis will 
be needed to determine whether IKAP assembles the same complex in response to 
different IKK-inducing stimuli. 
Although the composition of the IKK signalsome is becoming elucidated, a 
definitive function for each of its subunit is still not clear. 
1.1.3.4. Regulation 
Although the specific roles of each IKK subunit in the regulation of IKK 
activity are not well understood, IKK is activated by phosphorylation, since 
treatment with phosphatase PP2A results in its inactivation (DiDonato et al., 1997). 
Analysis of the protein kinase domains of IKKa and IKKI3 reveals potential 
phosphorylation sites in the activation loop. Mutations at those sites to alanine in 
IKKI3 results in a kinase-inactive form and mutation of these residues to glutamate, 
which mimic to some degree the phosphoserine, yields a constitutively active 
kinase. However, elimination of equivalent sites in IKKa, did not interfere with 
IKK activation (Ling et al., 1998; Mercurio et al., 1997). So far these sites have not 
been shown to be phosphorylated in a cytokine mediated fashion and it is not clear 
whether phosphorylation of these sites occurs through autophosphorylation or by 
one or more upstream activating kinases, which are likely to be members of the 
mitogen-activating protein kinase kinase kinase (MAPKKK or MEKKS) family of 
enzymes. NIK and MEKK1, a protein involved in the activation of c-Jun N- 
terminal kinase (JNK)(Lee et al., 1997) appear to be involved in the IKK activation 
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and overexpression of either of these kinases in cells leads to activation of both 
IKKa and IKKß, with NIK displaying a preference for IKKa and MEKK-1 a 
preference for IKK(3 (Nakano et al., 1998). It has also been shown that IKK 
activity can be stimulated by Tax, a transforming and transactivating protein of 
Human T cell leukemia virus (HTLV) (Geleziunas et al., 1998; Yin et al., 1998). 
Although the mechanism is not well understood Tax apparently binds to the N- 
terminus of MEKK1 and stimulates its kinase activity (Yin et al., 1998). 
If it is important to activate IKK and NF-KB in response to infection it is 
also crucial to rapidly terminate their activities once the inflammatory stimulus has 
disappeared. The phosphorylation of the C-terminal serine cluster of IKK(3 by 
autophosphorylation has a negative regulatory function and seems to be involved in 
preventing prolonged IKK activation (Delhase et al., 1999). The C-terminal serine 
cluster is located next to the HLH motif, mutations in which diminish kinase activity 
(Zandi et al., 1998) suggesting that this motif is required for IKK activation through 
an intramolecular interaction with the kinase domain. It is likely that the C-terminal 
portion of IKKI3, including the HLH motif interacts with the kinase domain and that 
this interaction is required for full activity of the IKK in addition to phosphorylation 
of the T-loop. Phosphorylation of the C-terminal serine cluster may weaken this 
interaction, causing a conformational change which results in lower kinase activity 
(Delhase et al., 1999). Structural data will help to understand these possible 
mechanisms. Also, the identification of new signalling molecules that directly or 
indirectly interact with the IKK complex will help to understand better the signalling 
pathways that activate NF-KB. Very recently, Akt, a serine/threonine kinase that is 
activated in response to platelet-derived growth-factor (PDGF) treatment of cells by 
a mechanism involving phosphoinositide 3-OH kinase PI(3)K signalling pathway 
(Marte and Downward, 1997), was shown to be involved in the activation of NF- 
-KB through controversial mechanisms. Romashkova and Marakov (Romashkova 
and Makarov, 1999) showed a direct association between Akt and IKK and using 
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dominant-negative mutants of the IKK subunits, IKK(3 was shown to be the 
subunit involved in the PDGF-induced activation of NF--KB (Romashkova and 
Makarov, 1999). NF-KB was shown to be a target of the anti-apoptotic 
Ras/PI(3)K/Akt pathway (Kauffmann-Zeh et al., 1997; Kennedy et al., 1997) 
which does not seem to be activated after TNF stimulation (Romashkova and 
Makarov, 1999). By contrast, Ozes et al. (Ozes et al., 1999), in epithelial cells 
showed that TNF activates phosphatidylinositol-3-OH kinase (PI(3)K) and its 
downstream target Akt (protein kinase B) (Ozes et al., 1999) which promotes NF- 
KB activation by phosphorylation of threonine 23 in IKKa. These authors 
suggested that TNF activates NF--KB by two different signalling pathways that 
converge on IKKa. Akt, via PI(3)k , and NIK, via TRAF2, phosphorylate IKKa 
at threonine 23 and serine 176, respectively (Ozes et al. nature, 1999)(Ling et al., 
1998). While there is an agreement on the activation of NF-kB by Akt serine 
threonine kinase via IKK, there is less agreement on the mechanism involved in this 
activation. A cell-type specific process could explain the controversial nature of 
these data. 
To better elucidate the biological functions of IKKa and IKK(3, mouse 
mutants lacking either IKKa or IKK(3 were generated (Hu et al., 1999; Li et al., 
1999; Takeda et al., 1999). Most of the biochemical results already described were 
confirmed: IKKa is not required for activation of IKK in response to 
proinflammatory stimuli, where as IKK(3 is absolutely essential for this response. 
IKKc -I- mice are born alive but die within 30 minutes. These animals demonstrate 
striking development abnormalities: defective proliferation and differentiation of 
skin epidermal cells (keratinocytes) and defective limb and skeletal patterning (Hu et 
al., 1999; Takeda et al., 1999). These phenotypes although never observed in mice 
lacking individual members of the NF-kB/Rel transcription factor family (Ghosh et 
al., 1998), suggest that NF-KB is important for embryonic development. The 
activation of IKK and NF-KB by TNF or IL-1 in embryonic fibroblasts and 
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thymocytes of IKKa -I- mice seems to be normal indicating that IKKa is not 
essential for cytokine-induced activation of NF-KB (Hu et al., 1999; Takeda et al., 
1999). By contrast IKK(3 -I- mice die in utero at day 12 to 13 of gestation from 
extensive loss of liver cells due to apoptosis (Li ei al., 1999). Their phenotype is 
similar to that observed for p65 (Re1A) - deficient mice (Beg et al., 1995b). Mouse 
embryonic fibroblast cells that were isolated from IKKP -I- embryos were defective 
in activation of IKK and NF-kB in response to TNF and IL-1, which confirms the 
importance of IKKP for IKK activation. Although IKKa and IKKP have a very 
similar overall structure and they are tightly associated in most cell types, these two 
protein kinases play different regulatory and functional roles in the NF-KB 
pathway. 
It remains to be clarified if the complex which contains IKKa and IKKP is 
the unique integrator of all signals that activate NF-KB or if different stimuli utilise 
alternative pathways in which the IKK complex is not involved. In certain cases 
NF-KB activation does not seem to involve IKB phosphorylation by IKK or even 
IxB degradation. Short-wavelength UV radiation (UV-C) activates NF-KB through 
IiB a degradation, however neither IKK activation nor the phosphorylation of 
IiBa on Ser32 and Ser36 was observed after UV-irradiation (Bender et al., 1998; 
Li and Karin, 1998). Phosphorylation of tyrosine 42 in IxBa, either by treatment 
with pervanadate or upon reoxygenation of hypoxic cells, has been linked to aiding 
the release of IxB a from NF--KB by a mechanism which does not require 
degradation (Imbert et al., 1996). The role of tyrosine phosphorylation of IicBa is 
somewhat controversial however. Imbert et al. (Imbert et al., 1996) showed that if 
IiBa is phosphorylated on tyrosine 42 it dissociates from NF-KB thus releasing the 
DNA binding form of NF-KB. However a subsequent report by Singh et al showed 
that NF-KB is not transcriptionally activated under these conditions (Singh et al., 
1996). 
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Overall regulation of NF-xB is a complex situation with many stimuli and 
many pathways contributing to the activation and deactivation of a single 
transcription factor. The role of many proteins involved in these processes are not 
yet fully understood and although the discovery of the IKK signalsome and the 
IiBa E3 ligase in the last couple of years gave an amazing contribution to the area, 
there are still many open questions to be answered to further elucidate the NF--KB 
activation. 
A general mechanism of NF-KB activation can be described as shown in 
figure 2 and figure 5 where extracellular stimuli cause phosphorylation of IiB on 
serines 32 and 36 via the IKK complex, targeting the protein for specific 
ubiquitination on lysines 21 and 22 by the SCFOT`cP complex followed by 
degradation of polyubiquitinated IiBa by the 26S proteasome and translocation of 
active NF-KB into the nucleus allowing transcription of responsive genes. 
1.1.4. Clinical relevance 
It has been well documented that activation of Rel-NF-KB plays an 
important role in many cellular processes, including inflammation, cell proliferation 
and apoptosis (Foo and Nolan, 1999). Rel-NF-xB family of transcription factors 
coordinately controls the expression of genes involved in disease processes and 
thus NF-KB has been linked to a variety of diseases such as autoimmunity, 
dysplasias or even oncogenesis. Knockout mouse studies have also confirmed the 
key role of this transcription factor family in broad physiological processes, 
including limb development, immune function and metabolic processes such as 
bone remodelling (Baeuerle and Baltimore, 1996; Baldwin, 1996). 
There is growing evidence that NF-KB is involved in regulating apoptosis. 
p65 and IKK(3 knockout mice die from extensive loss of liver cells due to apoptosis 
(Beg et al., 1995b; Li et al., 1999). The Rel- NF-KB family of transcription factors 
upregulates the expression of genes that directly rescue cells from apoptosis - anti- 
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Figure 2. Schematic overview of components of the NF-kB signal transduction pathway. 
See text for details . Abbreviations of signaling components: IL-1, interleukin 1; IL-IR, IL-I type I receptor; 
IL-IRAcP, IL-IR acessory protein; IRAK, IL-I receptor-associated kinase; CD4L, CD4 ligand; TNF, tumor 
necrosis factor; TNFRI, TNF receptor subtype 1; TRADD, TNFR I -associated death domain protein; FADD, 
Fas-associated protein death domain protein; TRAF, TNFR-associated factor; RIP, ring finger interacting 
protein; PDGF, platelet-derived growth factor; PI(3)k, phosphatidylinositol-3-OH kinase; NIK, NF-kB- 
inducing kinase; MEKKI, mitogen-activated protein kinase; Akt, protein kinase B; IKKa/IKKP, IKB-kinase 
ot- and P- subunits; IKAP, IKK-complex-associated protein; NEMO, NF-kB essential factor. 
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apoptotic genes, such as Fast. (Kasibhatla et al., 1999), IEXI (Wu et at., 1998) 
and IAP (Chu et al., 1997; You et al., 1997). Persistent NF-KB activity protect cells 
from apoptosis and thereby contributes to the dysregulation of growth that is 
essential to oncogenesis. Pro-apoptotic extracellular signals can also induce NF-KB 
which in turn will induce expression of anti-apoptotic genes. (Wang et al., 1998). It 
is not clear whether NF-KB normally functions as a pro-apoptotic factor or if it 
protects against cell death. The anti-apoptotic effect of NF-icB may be more general 
and inhibition of NF-KB could be used to make cancer therapies more effective 
although this process must be accompanied by a procedure that directs cell death 
only in specific cells. It is also now clear that several human cancers contain 
rearrangements, amplifications or mutations that alter the expression or function of 
cellular Rel family transcription factors (Cabannes et al., 1999; Sovak et al., 1997; 
Wood et al., 1998). 
Given the impact of NF--KB in physiological processes, the development of 
new modalities for chemotherapeutic, immuno-modulatory and anti-inflammatory 
drugs, involving the NF-KB pathway is an area of increasing pharmaceutical 
interest. Commercially available glucocorticoids, well known for their anti- 
inflammatory and immunosuppressive properties have a repressive effect on NF-KB 
- mediated gene expression. Two possible mechanisms can be involved in this 
process. Glucocorticoids can either act via direct interaction of the glucocorticoide 
receptors with NF-KB, inhibiting transactivation capacity of both proteins or 
inducing the synthesis of IKB a, which will remove NF-KB from its DNA binding 
site. These mechanisms are not mutually exclusive but it remains to investigated 
which mechanism predominates under particular conditions or in certain cell types 
(Dumont et al., 1998). 
Understanding the mechanisms which regulate NF-KB activity and the 
identification of specific Rel/ NF-KB-regulated target genes that control various 
processes will provide new insights into signalling pathway. This will be of 
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particular importance in the development of selective inhibitors of the NF-KB 
pathway. At present, the most specific targets for the inhibition of NF-KB activity 
are the components of the IKK complex since the recently identified IKBcc ligase - 
SCFO'`cP, can ubiquitinate several proteins (Maniatis, 1999). 
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1.2. The ubiquitin-proteasome system 
Cellular proteins exist in a dynamic equilibrium. Their steady-state levels are 
maintained by a tightly controlled and highly regulated balance of synthesis and 
degradation. A selective and programmed way of targeting many proteins for 
degradation, in eukaryotic cells, is carried out by the ubiquitin proteasome system. 
Ubiquitin, one of the most highly conserved proteins, is a 76-residue 
protein that exists in cells either free or covalently linked to other proteins. It was 
first isolated by Goldstein and co-workers from the thymus and was thought to be a 
thymic hormone (Goldstein et al., 1975) but in subsequent work it was found in all 
tissues and eukaryotic organism and hence its name. In addition to degrading 
damaged, misfold, or misassembled proteins, the ubiquitin system targets many 
cellular proteins, including transcription factors, cell growth modulators, signal 
transducers, cell cycle regulators, tumour supressors, oncoproteins, short-lived 
enzymes, viral gene products, membrane polypeptide receptors for degradation 
(Hershko and Ciechanover, 1998). With the multiple cellular targets, it is not 
surprising that the system is involved in the regulation of many basic cellular 
processes such as cell cycle and division, differentiation and development, the 
response to stress and extracellular modulators, morphogenesis of neuronal 
networks, modulation of cell surface receptors, DNA repair, regulation of the 
immune and inflammatory responses and apoptosis. 
Degradation of a protein via the ubiquitin pathway involves two distinct and 
successive steps: covalent attachment of multiple ubiquitin molecules to the protein 
substrate, and degradation of the tagged protein by the 26S proteasome. Ubiquitin 
conjugation is catalysed by an enzymatic cascade that begins with the ATP- 
dependent activation of the C-terminus of ubiquitin by the ubiquitin-activating 
enzyme (EI). The C-terminus of ubiquitin is first adenylated with release of 
pyrophosphate. This is followed by formation of a high energy thioester linkage 
between the side chain of a cysteine residue in El and the C-terrninal carboxyl 
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group of the ubiquitin protein with release of AMP. In a transesterification reaction, 
the ubiquitin is transferred from the El to a conserved cysteine residue in a family 
of ubiquitin -conjugating enzymes (E2). Ubiquitin is then transferred from the E2 
enzyme to the ultimate protein acceptor via an isopeptide linkage with the e amino 
group of a lysine in the target protein. In many cases this final step requires the 
participation of ubiquitin protein ligase (133) which may act either as the ultimate 
ubiquitin donor or in substrate recognition (Hershko and Ciechanover, 1998). 
Proteins destined for degradation or processing via the 26S proteasome are coupled 
to multiple copies of ubiquitin by formation of further isopeptide bonds between 
additional ubiquitin molecules and lysine residues in previously conjugated 
ubiquitin (see Figure 3). 
The structure of this system appears to be hierarchical: a single El carries 
out activation of ubiquitin required for all modifications. Several major species of 
E2 enzymes were characterised in mammalian cells, plants and yeast. The E2s act in 
concert with E3s, and it appears that each E2 can act with one or more E3. Finally, 
the E3 ligases belong to a large , still growing family of enzymes. The mechanisms 
that underlie the high specificity and selectivity of the ubiquitin system are still an 
unsolved problem but the exponential increase of information on this system has 
demonstrated that E3 ligases are probably the main family of enzymes responsible 
for these properties. Nevertheless post-translational modifications such as 
phosphorylation of either the target protein or involved enzymes also play an 
important role in the recognition process . 
An additional conjugation factor, named E4 was recently described as being 
involved in the multiubiquitin chain assembly (Koegl et al., 1999). Although E4 
function does not participate in the ubiquitin-enzyme thioester cascade and in 
contrast to E3s, does not interact with substrate directly it may be part of a large, not 
yet identified family of regulatory factors which together with E3s give more 
specificity to the ubiquitin degradation pathway. 
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Figure 3. The Ubiquitin-proteasome degradation pathway. 
(1) Activation of ubiquitin (Ub) by the Ubiquitin activating enzyme -131- in an ATP dependent fashion. (2) 
Transfer of activated ubiquitin from El to the active cysteine residue of a member of the ubiquitin 
conjugating enzymes- E2. (3,4) Transfer of activated ubiquitin directly or indirectly from E2 to a protein- 
substrate via ubiquitin protein ligase -E3. In somes cases, (4A) E3 accepts the activated ubiquitin from an E2 
and binds it as a thioester intermediate prior to transfer to protein, while in others (4B) the E3 helps to transfer 
ubiquitin directly from E2 to a protein, by tight binding of E2 and the protein substrate. Repeated conjugation 
of ubiquitin to Lysine residues of formely bound ubiquitin moieties leads to the formation of multi-ubiquitin 
chains. (5) Binding of the polyubiquitinated substrate to the ubiquitin receptor subunit in the 19S complex of 
the 26S proteasome and degradation of the substrate to short peptides by the 20S complex. (6) Recycling of 
ubiquitin via the action of isopeptidases. 
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1.2.1. El 
EI catalyses the first step in ubiquitin conjugation. A single EI enzyme has 
been characterised and has been detected in both cytoplasm and nucleus of 
eukaryotic cells but is phosphorylated and localised to the nucleus in a cell cycle- 
dependent manner (Stephen et al., 1996). It is possible that El and other 
components of ubiquitin system may perform distinct, essential roles by localising 
to different subcellular compartments within the cell (Trausch et al., 1993). The El 
gene is essential for cell viability (McGrath et al., 1991). Because the El is unique, 
it does not appear to play a role in selecting protein substrates for ubiquitination. 
However, ubiquitin co-exists with a number of ubiquitin-like molecules, and the El 
enzyme must distinguish between these molecules. 
1.2.2. E2/UBC 
E2s are relatively small molecules, mostly 14-25 kDa, that share a 
conserved ubiquitin conjugating domain (UBC) which contains a catalytic cysteine 
residue that accepts the activated ubiquitin from El. In addition to the core UBC 
domain, some E2s have unique C- or N-tern-tinal extensions that may be involved 
respectively in the substrate recognition and EI interaction (Liu et al., 1999). 
The genome of Saccharomyces cerevisiae encodes for 13 E2s and E2-like 
proteins, and many more have been described in mammals. Specific functions of 
this class of enzymes may be the result of their association with specific E3s, which 
in turn bind their specific protein substrates. There is not much experimental 
evidence for the direct binding of E2s to protein substrates with the exception of the 
E2-like Ubc9. Ubc9 was originally described as an essential yeast protein required 
for cell-cycle progression at the G2- or early M-phase and it was proposed that the 
proteolytic pathway that degrades B-type cyclins involves Ubc9 (Seufert et al., 
1995). However in subsequent work it was demonstrated that the conjugation of 
cyclin B to ubiquitin in a cell-free system from Xenopus eggs could not be 
supported by a Xenopus homologue of ubc9 (King et al., 1995). Ubc9 was 
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identified as an interacting protein in yeast two-hybrid screens with a surprisingly 
large number of proteins, but evidence that the protein has ubiquitin conjugating 
activity in a thioester assay was never reported. 
1.2.3. E3 
Given the range of substrates and the requirement for specificity, the E3 
enzymes or ubiquitin protein ligases, which mediate substrate recognition must be 
highly selective. 
The mechanism of transfer of activated ubiquitin from a thioester 
intermediate to the amino group of a lysine acceptor in the target protein appear to 
differ in various types of E3s. In some cases, E3 accepts the activated ubiquitin 
from an E2 and binds it as a thioester intermediate prior to transfer to protein, while 
in others a ligase may help to transfer ubiquitin directly from E2 to a protein, by 
tight binding of E2 and the protein substrate. Thus, the definition of E3 has been 
changing with the discovering of new members of this class of enzymes and 
although it remains unclear, the best definition so far is that E3 is an enzyme that 
binds, directly or indirectly, specific protein substrates and promotes the transfer of 
ubiquitin, directly or indirectly, from a thioester inten-nediate to the ultimate protein 
acceptor via an isopeptide linkage with the F_ an-tino group of a lysine in the target 
protein. Specificity derives from the high-fidelity protein-protein interactions 
between the E3 and substrate but details of E3-substrate interaction and how the 
activity of an E3 is modulated and what controls E2-E3 interactions are still an open 
door in the ubiquitin field. So far, four different classes of E3 ubiquitin ligases have 
been defined: UbrI (Bartel et al., 1990), the HECT domain family(Huibregtse et 
al., 1995), the SCF family (Feldman et al., 1997; Skowyra et al., 1997) and the 
anaphase promoting complex (APQ/ cyclosome (King et al., 1995). 
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1.2.3.1. E3a/UBR1 
Although the majority of cellular proteins are targeted through different 
signals a few proteins may be recognised by their free and "destabil i sing" N- 
terminal residue. Moc, the mammalian homologue of UBRI and E3P recognise 
protein substrates via their N-terminal residue(Varshavsky, 1995). Ma recognises 
basic or bulky-hydrophobic N-ten-ninal amino acid residues and E3P may be 
specific for proteins with small and uncharged N-terminal amino acid residues 
(Hershko and Ciechanover, 1998). The N-end rule recognition mechanism is highly 
conserved, but its cellular substrates and physiological roles are still obscure. 
1.2.3.2. HECT family 
The HECT (homologous to E6-AP C-terminus) domain proteins have E3 
activity and they are characterised by sequence similarity of their C-terrninal regions 
to the C terminus of E6-AP (E6 associated protein), the first member of this family 
involved in the human papillomavirus E6-induced ubiquitination of p53. E6-AP 
does not bind directly to p53 but rather binds indirectly via E6, which binds to both 
p53 and E6-AP- The mechanism used by E6-AP involves the formation of a 
thioester complex between E6-AP and ubiquitin in the presence of El and distinct 
E2 ubiquitin-conjugating enzymes including human ubcH5 or Arabidopsis thaliana 
AtUBC8. Ubiquitin is then transferred directly from E6-AP to the substrate. E6-AP 
was the first E3 ubiquitin ligase identified with ability to form a thioester with 
ubiquitin (Scheffner et al., 1995). A large fai-nily of proteins that contain an 
approximately 350 an-iino-acid C-terrninal region homologous to that of E6-AP, the 
HECT domain family, has been identified in many eukaryotic organisms and they 
all contain a conserved active site Cys residue near the C-terminus (Huibregtse et 
al., 1995). Although the function of these proteins is unknown most HECT domain 
proteins are likely E3 enzymes with ability to form thioesters with ubiquitin. 
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1.2.3.3. The SCF (S-kpI-Cdc53/CULI-F-box protein) family 
Different mernbers of this family of multisubunit ubiquitin-protein ligases 
use different adapters that recruit the target protein to a complex containing an E2 
enzyme. This E3 family is not involved directly in ubiquitin transfer and targets 
different substrates such as cell cycle regulators, including mitotic cyclins (CIn2p) 
and CDK inhibitors (Sic I p) and transcription regulators such as I-KB and P-catenin, 
among many others, to proteasome degradation (Maniatis, 1999; Patton et al., 
1998). The common feature of all these substrates is that phosphorylation converts 
the substrate to a form susceptible to the action of the E3 complex. 
The SCF is named for three of its core components, Skpl, Cdc53/cullin and 
an F-box containing protein but they may also have other components specific for 
certain protein substrates. Skpl and F-box proteins interact through the F-box 
motif. Cdc53 functions as a bridging molecule to bind the Skp I /F box complex to 
the E2 (Figure 4). The mechanism of the SCF ubiquitin 11ýýase system was initially 
discovered in studies of the cell cycle in yeast for the Cdc34-dependent degradation 
of phosphorylated Siclp and GI cyclins, Clnlp and Cln2p. Sic1p is a B-type cyclin 
kinase inhibitor, the degradation of which is essential for the GI-S transition in the 
budding yeast. Sic1p after being phosphorylated by a GI Cyclin-activated protein 
kinase (Cln/Cdc28) (Schneider et al., 1996) is targeted for degradation by a 
complex including Cdc4p, Skplp and Cdc53. Cdc4p binds to the phosphorylated 
substrate Sic1p through its WD repeats and an F-box motif in Cdc4p mediates the 
connection to the ubiquitin-proteasome machinery by interacting with Skplp. Grr1p 
is the F-box protein involved in the On Ip and Cln2p ubiquitination. Association of 
Grrl with Clns is mediated by autophosphorylation that allows activation of On 
kinases to eventually turn themselves off to reset the balance for the next GI 
(Feldman et al., 1997; King et al., 1996a; Skowyra et al., 1997; Verma et al., 1997; 
Willems et al., 1996). 
Skpl, Cdc53/cullin and F Box proteins are not the only essential 
components of SCF complexes. In yeast, the recently identified protein Rbxl/Roc I, 
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Figure 4. SCF complex, an E3 ubiquitin ligase superfamily. 
The complex is composed of a set of adapter proteins that recruit different binding partners 
through specific protein-protein interactions. SkpI and F-box proteins interact through the F-box 
motif. Cdc53/CULI functions as a bridging molecule to bind the Skpl/F-box complex to the E2 
(Cdc34). The newly discovered Rbxl/Rocl plays an integral role in tethering components to 
each other and maybe involved in the E2 recruitment. 
which contains a RING-1-12 fingerlike motif termed the R box, is a subunit and 
potent activator of the SCF complex required for Sicl and On ubiquitination in 
vitro (Kamura et al., 1999; Seol et al., 1999; Skowyra et al., 1999). Mammalian 
Rbxl/Roc1 was discovered as part of the von Hippel-Lindau (VHL) tumour 
supressor complex. This complex includes Elongin B, Elongin C, and Cullin-2, 
proteins associated with transcriptional elongation and ubiquitination (Kamura et 
al., 1999). The core structure of Elongin B is highly similar to that of ubiquitin, 
Elongin C is a Skp I homolog and Cullin-2 is a homolog of Cdc53 and therefore the 
VHL is structurally analogous to SCF complex. Rbxl/Roc1 is a component of 
VHL, SCF Cdc4 and SCF G, 1 complexes (Kamura et al., 1999; Skowyra et al., 1999) 
and since they have very high structural similarity it is tempting to speculate that the 
VHL complex may function as ubiquitin ligase for as yet unidentified target proteins 
(Tyers and Willems, 1999). Rbxl/Roc I may define a new class of E3-associated 
proteins which may act as an adapter to recruit the E2 Cdc34 to Cdc53 or SCF 
complexes by bridging or stabilising the Cdc34-Cdc53 interaction (Seol et al., 
1999; Skowyra et al., 1999; Tyers and Willems, 1999). In vitro reconstitution of 
the phosphorylation-dependent ubiquitination of IKB(X have demonstrated that Roc I 
is recruited by cullinl/Cdc53 to form a complex with SCF HOS/PTrCP (Tan et al., 
1999). 
Although the mechanism of this family of E3 ubiquitin ligases is mainly 
based on studies in yeast, the components of these machineries are conserved in 
evolution. Over the past few years, F-box proteins and other components of the 
SCF/Cdc34 pathway have been identified in many eukaryotes and linked to diverse 
cellular processes. Recently a Drosophila F-box protein, Slimb, and its mammalian 
hornolog P-TrCP (a-iransducin repeat-containing-protein) have been identified as a 
subunit of a SCF complex (SCF PTrCP) implicated in the regulation of three different 
signal transduction pathways: NF-xB, Wnt/ Wingless (Wnt/Wg) and Hedgehog 
(Maniatis, 1999). SCF complexes couple protein kinase signalling pathways to the 
control of the stability of substrate proteins (Skowyra et al., 1997). Given the large 
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number of protein kinases and the possible SCFs, this may be one of the main 
pathways in the control of protein abundance. The dynamic nature of this type of 
complex is not well defined and it is not known whether and how these 
multisubunit complexes are regulated. Their assembly and disassembly may 
i-cpresent another possible mechanism to control the rate of degradation of their 
target proteins. 
1.2.3.4. Cyclosome/anaphase-promoting ýýomplex (APQ 
Cyclosome(Sudakm et al., 1995) or anaphase-promoting complex (King et 
al., 1995) is another E3 ubiquitin ligase that uses different adapters to target 
different substrates specific for cell-cycle regulatory proteins including n-fitotic 
cyclins and other proteins that regulate mitosis (Peters, 1998). Many of these 
substrates contain a conserved 9-residue motif called the "destruction box" and all 
of them are degraded during mitosis. This ubiquitin ligase is a high-molecular- 
weight complex composed of 12 subunits in budding yeast (Zachariae et al., 1998a; 
Zachariae et al., 1996) and at least 10 subunits in mammals and Xenopus (Yu et al., 
1998). Among many core subunits of unknown function, some turned out to be 
homologous to subunits of the SCF complexes supporting a possible parallel 
mechanism between APC and SCF complexes with a major difference in the type of 
substrate. SCF substrates are recognised after substrate phosphorylation which 
does not occur with APC substrates. Apc2, subunit of the APC is homolog to 
Cdc53 (Zachariae et al., 1998b) and the APC also contains an RbxI/Roc I related 
protein, Apc 11, which is required for CIb2 ubiquitination in vitro (Zachariae et al., 
1998b) and interacts with cullin Apc2 suggesting its possible involvement in the E2 
recruitment (Ohta et al., 1999). 
1.2.4. IKB a Ubiquitination - The SCF 
PTrCP 
complex 
Until very recently the E3 responsible for the ubiquitination of I-KBu has 
remained unknown and just a partially purified activity had been isolated which was 
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able to support the phosphorylation and ubiquitination of IKBa in an in vitro system 
in presence of ATP, ubiquitin, EI and an E2 protein (ubcH5 or UbcH7) (Alkalay et 
al., 1995-, Chen et al., 1995; Chen et al., 1996; Kroll et al., 1997). 
Using different strategies, independent groups identified P-TrCP as a 
specific component of the IKB ubiquitin ligase complex (Hatakeyama et al., 1999; 
Spencer et al., 1999; Vuillard et al., 1999; Winston et al., 1999; Yaron et al., 
1998). P-TrCP is a mammalian homolog of the Drosophila Slimb protein (Jiang and 
Struhl, 1998) and is an F-box/WD40 repeat protein that appears to act as the 
receptor for recruitment of phosphorylated substrates. Slimb negatively regulates 
both the Hedgehog and Wnt/Wingless pathways (Jiang and Struhl, 1998). Human 
P-TrCP was isolated as a protein interacting with Vpu, a small human 
immunodeficiency virus (HIV)-encoded protein that interacts with CD4 in the 
endoplasmic reticulum. and targets it for degradation (Margottin et al., 1998). P- 
TrCP also interacts directly with ý-catenin, a component of the Wingless/, Vvnt 
pathway, in a phosphorylation dependent manner, (Hart et al., 1999; Kitagawa et 
al., 1999; Latres et al., 1999; Winston et al., 1999). There is a common structural 
feature among 1KBa, P-catenin and Vpu: signal induced phosphorylation occurs on 
two closely located serines at positions 32 and 36 (I-KBu, ), 33 and 37 (P-catenin) 
and 52 and 56 (Vpu) suggesting that P-TrCP recognises a very similar motif, with 
minimal sequence consensus of DS*GX-S*, where S* represents phosphoserine 
and Xa hydrophobic residue. Further studies are required to determine whether any 
of the many proteins containing the above motif are also substrates of P-TrCP. 
The first group that identified P-TrCP as a specific component of the I-KB 
ubiquitin ligase took advantage of its high affinity for phosphorylated I'KBCC 
(pi-KB(x) and devised an immunoaffinity purification method to isolate the protein 
from HeLa cells (Yaron et al., 1998). Later studies showed that P-TrCP protein 
functions as the F-box protein of an SCF complex containing Skpl and 
Cdc53/Cull, which recognises pl-KB(x bound to NF-KB (Spencer et al., 1999; 
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Winston et al., 1999) or a phosphorylated peptide substrate representing residues 
20-43 of I-KB(x (Vuillard et al., 1999). While there is general agreement in the 
subunits that composed the SCF PTrCP complex, there is less agreement on the E2 
involved in the polyubiquitination of IKB(x. Many SCF complexes involved in cell 
cycle protein ubiquitination appear to utilise Cdc34 as the E2 for ubiquitination and 
this is consistent with data indicating that Cdc34 is responsible for ubiquitination of 
pIKB(x(Tan et al., 1999; Vuillard et al., 1999). However, in other studies in vitro 
ubiquitination Of PIKBa was achieved using either UbcH5 (Spencer et al., 1999; 
Yaron et al., 1998) or yeast extracts as a source of E2 activity (Winston et al., 
1999). The recently identified protein RbxI/RocI as a novel subunit of SCFP-TrCP 
complex (Tan et al., 1999) and possible involvement in the recruitment of Cdc34 to 
the SCF complexes strengthens the hypothesis that Cdc34 is the E2 required for the 
phosphorylation dependent ubiquitination of I-KBcc in vitro and raises the possibility 
of others factors being involved in the specificity of the SCF complexes. 
Nevertheless it remains to be detennined which E2 (or E2s) functions in the signal- 
induced ubiquitination of IKBoc in vivo. 
In P-TrCP 
, 
both the F-box and the AID domain are protein-protein 
interaction motifs. WD repeats at the C-terrrunus mediate binding to the substrate, 
and an F-box near the N-terminus is involved in interaction with Skplp, which in 
turn is bound to Cdc53. The P-TrCP F-box is necessary for IKBcc ubiquitination in 
vitro and an F-box deletion mutant of P-TrCP, which is still able to bind to plKB(x 
but fails to promote its ubiquitination in vitro, acts in vivo as a dominant-negative, 
inhibiting the degradation of pIKBoc and consequently NF-KIE3 activation (Spencer et 
al., 1999; Yaron et al., 1998). The F-box deleted form of P-TrCP has the same 
effect on Vpu-mediated CD4 degradation (Margottin et al., 1998) and blocks P- 
catenin degradation in human cells (Hart et al., 1999; Kitagawa et al., 1999; Latres 
et al., 1999). The SCF PTrCP is involved in the phosphorylation dependent ubiquitin- 
mediated proteolysis of IKB(x, P-catenin and CD4 (through HIV Vpu) suggesting 
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that a single F-box is capable of recognising different substrate with identical 
destruction motifs. 
The model proposed for signal induced ubiquitination of I-KB(x through the 
SCPT'cP complex is shown in figure 5. 
1.2.5. The 26S proteasome 
The proteasome is an ATP-dependent multicatalytic protease complex which 
recognises and specifically degrades cytosolic and nuclear proteins, most of which 
are ubiquitin tagged. It is composed of the 20S core catalytic complex flanked on 
both sides by the 19S regulatory complexes which seem to be responsible for 
recognition and unfolding of the ubi quitin -tagged target protein. 
Groll et al. solved the crystal structure of the Saccharomyces cerevisiae 20S 
proteasome to 2.4 A resolution giving an important development in studies of this 
complex structure. The eukaryotic 20S core catalytic is composed of 14 pairs of 
different, but related, protein subunits which assemble into a single structure 
arranged into four seven-membered rings with the a -type subunits forming the two 
outer rings guarding an inner pair the P -type subunit rings, " 1-7 P 1-7 P 1-7 ()C 1-7 
(Groll et al., 1997). The ot subunits do not seem to be catalytic, but they can self 
assemble while the P subunits which cannot self assemble possess proteolytic 
activity. The three major peptidase activities of eukaryotic proteasomes, present on 
some of the P subunits, are: a chymotryps in -like activity, which cleaves after 
hydrophobic residues, a trypsin-like activity, which cleaves after basic residues and 
a peptidylglutarnyl peptide hydrolysing activity which cleaves after acidic residues 
(Baumeister et al., 1998). The proteolytic mechanism of the 20S complex involves 
the utilisation of the hydroxyl group of the terminal threonine residue of the P 
subunit as the catalytic nucleophile that attacks peptide bounds. 
Knowledge about the sizes of peptides generated by proteasomes during 
protein degradation is essential to fully understand their degradative mechanisms 
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Figure 5. Model for the phosphorylation-dependent degradation Of IKBcc. 
A variety of signals lead to the activation of an IKB kinase complex which specifically 
phosphorylates Ser 32 and Ser 36 at the amino terminus of IKBct. This phosphorylated form 
associated to NF-KB (p50/p65) is recognised by an E3 ubiquitin ligase complex (SCFPTrCP), 
described in figure 4. This complex promotes the site-specific ubiquitination Of IKBcc at lysines 21 
and 22 in an El and E2 dependent reaction. Polyubiquitinated IKBoc is then targeted to the 26S 
proteasome for degradation, resulting in the release and Duclear translocatiOD of NF-KB. 
and the subsequent steps in protein turnover and generation of major 
histocompatibility complex class I antigenic peptides. The size of peptides generated 
ranges in length from 3 to 22 residues. (Ki sselev et al., 1998; Kisselev et al., 1999). 
Other peptidases must function after the proteasome to complete the turnover of cell 
proteins to amino acids. 
The main role of the (x subunits seems to be involved in the stabilisation of 
the two-ring structure of the P chains and in the binding of the 19S "cap" regulatory 
complexes (Groll et al., 1997). The openings that give access to the inner cavities of 
the proteasome, involved in the entry of substrates and exit of proteolysis products, 
are apparently different in the yeast and Thermoplasma proteasome structure. In the 
Thennoplasma proteasome there are two entry pores at the ends of the cylinder 
which in the yeast 20S proteasome seem to be occluded by the N-terminal residues 
of the a subunits. On the other hand, the yeast proteasome has small side orifices at 
the interface between a and P rings which are unlikely to be used for the entry of 
the substrate but they may have a role in discharging degradation products. Entry 
from the ends is probably only possible after ATP-dependent rearrangements that 
may occur in the 19S complexes rendering ubiquitinated proteins into a fonn 
competent for degradation by the 20S core complex. 
The 19S complex is composed by at least 15 subunits, six of which are 
ATPases and members of the AAA-ATPase family (ATPases associated with a 
variety of cellular activities) (Baumeister et al., 1998). The precise role of these 
ATPases, that is, the energy dependent step in the degradation of proteins, and the 
functions of the most of the non-ATPase subunits are still unknown but they may 
be involved in the recognition and unfolding of the target proteins helping in their 
translocation into the 20S inner proteolytic complex. 
An additional regulator that associates with the 20S proteasome in an ATP- 
independent fashion is the I IS complex. This complex is a ring-shaped hexamer, 
composed of alternating a and P subunits. It does not stimulate the degradation of 
proteins or of ubiquitin-protein conjugates but is y-interferon inducible and is 
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apparently involved in the immune response, more specifically in the antigen 
processing (Groettrup et al., 1995). Under the influence of 'Y-interferon there is no 
indications for an influence on the subunit composition of the 19S complex but 
three proteolytically active P-subunits of the 20S proteasome are replaced 
(Groettrup et al., 1996a; Groettrup et al., 1996b). The subcomponents of the 26S 
proteasome are dynamic structures and its is likely that changes in the subunit 
composition reflect adaptation to current cellular conditions and influence protease 
specificity. 
Specific proteasome inhibitors have been developed and they have become 
powerful research tools in probing the structure and function of the proteasome and 
ubiquitin pathway. Most of them act as pseudosubstrates that become linked 
covalently to the active site hydroxyl groups in threonine of the P subunits and as a 
result the chymotryptic and trypic-like activities are inactivated. Examples of these 
inhibitors most widely used are: peptide aldehydes like MG132, MG115, ALLN 
and natural products like lactacystin (Lee and Goldberg, 1998). In addition to being 
useful research tools, proteasome inhibitors have also potential use in the treatment 
of human diseases in which the ubiquitin proteolytic pathway is involved. 
1.2.6. Deubiquitination enzymes 
Ubiquitination of target proteins is a dynamic process and appears to be a 
reversible reaction that is catalysed by processing proteases known as 
deubiquitination enzymes (DUB). Although the main regulation of this modification 
occurs at the level of the ubiquitin conjugation, deubiquitination, or removal of this 
modification, is being recognised as an important regulatory strategy. 
Deubiquitination enzymes are cysteine proteases that specifically hydrolyse ester, 
thiol ester and amido bonds to the carboxyl group of G76 of ubiquitin. This family 
of enzymes can be sub-classified into at least two gene families that are structurally 
unrelated: the UCH (ubiquitin C-terminal hydrolases) family and the UBP 
(ubiquitin processing proteases) family (Wilkinson, 1997). More than 60 full length 
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DUB sequences have been identified so far and although little is known about their 
biological role, they are the largest family of enzymes in the ubiquitin system 
suggesting that they may be involved in the recognition of different types of 
ubiquitin conjugates. These enzymes act at different levels in the ubiquitin pathway: 
in the generation of free ubiquitin by processing of polyubiquitin chains either from 
linear precursor fusion proteins or from already branched-chain polyubiquitin, in 
the removal of ubiquitin from ubiquitinated target protein avoiding protein 
degradation by the 26S proteasome and finally in clearing the proteasome of peptide 
remnants conjugated to ubiquitin chains (D'Andrea and Pellman, 1998). 
In addition to ubiquitin, all eukaryotic cells contain several other ubiquitin- 
like proteins that can also be conjugated to proteins and they are synthesised as 
fusion proteins that must be processed by enzymes similar to DUBs. It is likely that 
some of the known deubiquitinating enzymes will be responsible for processing 
these fusions proteins and disassembling the conjugated ubiquitin like proteins. 
1.2.7. Ubiquitin and Human diseases 
Given the broad range of substrates and processes in which the ubiquitin 
proteolytic pathway is involved, it is not suprising that aberrations in the process 
have been implicated in the pathogenesis of several diseases either by stabilisation 
or accelerated degradation of the protein target. Regulated proteolysis by the 
ubiquitin-proteasome system has a critical function in memory storage and is part of 
the molecular switch that converts short-term synaptic plasticity to long term. 
Learning induces a neuron-specific ubiquitin C-terminal hydrolase which associates 
with the proteasome and increases its proteolytic activity. The resulting up- 
regulation of the ubiquitin pathway enhances the degradation of proteins that inhibit 
long-term memory storage (Hegde et al., 1997). 
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1.2-8. Ubiquitin-like modifications 
In some instances protein ubiquitination functions not as a signal for 
degradation, but to alter the properties of the linked protein. Thus histone 
ubiquitination alters chromatin structure (Bradbury, 1992) while ubiquitination of a 
plasma membrane receptor modifies ligand-stimulated endocytosis (Hicke and 
Riezman, 1996). Whereas addition of multiple copies of ubiquitin targets proteins 
for degradation it is now widely recognised that covalent attachment of other 
ubiquitin related molecules does not result in degradation of the modified protein. 
The protein UCRP, which contains two ubiquitin-like domains is conjugated to a 
number of intracellular proteins by a series of reactions that are separate from 
ubiquitination (Haas et al., 1987; Narasimhan et al., 1996). Recently a small 
ubiquitin-like protein variously known as sentrin, GMP1, SUMO-1, UBLI and 
PICI has been found covalently linked to Ran GTPase activating protein I 
(RanGAPI) and associated with a variety of other proteins (Boddy et al., 1996; 
Kamitani et al., 1997b; Mahajan et al., 1997; Matunis et al., 1996; Shen et al., 
1996a). Covalent modification of RanGAP1 appears to be necessary for its 
interaction with the Ran-GTP-binding protein RanBP2 at the cytoplasmic face of the 
nuclear pore complex (Mahajan et al., 1997; Saitoh et al., 1997) while SUMO-1 
modification of PML targets the protein to PML nuclear bodies (Muller et al., 1998; 
Stemsdorf et al., 1997). SUMO- I and Smt3p, a yeast homologue of SUMO- 1, are 
conjugated to target proteins by a pathway that is distinct from, but analogous to, 
ubiquitin conjugation. Recently an additional protein modification pathway 
involving the ubiquitin-like protein Rub lp has been characterised in Saccharomyces 
cerevisiae (Lammer et al., 1998; Liakopoulos et al., 1998). A major substrate for 
Rublp is CDC53/cullin which is a common component of SCF ubiquitin ligase 
complexes. In this system the products of the ULAI and UBA3 genes act as a 
heterodimeric El enzyme while the product of the UBC12 gene acts as the E2 
conjugating enzyme. It also appears that this conjugation system is active in higher 
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eukaryotes with the Rublp homologue Nedd8 also being conjugated to CDC53 
(Hochstrasser, 1998; Kamitani et al., 1997a). 
SUMO-l/Smt3p and NEDD8/Rublp are processed proteolytically at the C- 
terminus to generate a free C-terminal -Gly-Gly, which like the C-terminal -Gly76 
of ubiquitin is essential for conjugation (Kamitani et al., 1997b). 
In all of the above cases the protein conjugated has been similar to ubiquitin. 
However a separate protein conjugation system, which is required for autophagy in 
Saccharomyces cerevisiae, involves conjugation of a protein unrelated to ubiquitin. 
In this case the C-terminus of Apgl2, a 186 residue protein, is conjugated to a 
lysine side chain in Apg5. Although Apg 12 is unrelated to ubiquitin it appears that it 
is activated by Apg7, which is homologous to ubiquitin El enzymes, and 
conjugated by Apg 10, an E2 equivalent (Mizushima et al., 1998). 
UCH-L3, a putative ubiquitin C-terminal hydrolase, was recently identify as 
a NEDD8 (Karnitani et al., 1997a)-interacting protein, able to cleave the C terminus 
of NEDD8 but not bind to sentrin- 1, sentrin-2 or sentrin-3 (Wada et al., 1998). 
Conjugation of the ubiquitin-like proteins raises several questions related to 
the chemical nature of the adduct, the identity of the conjugating and deconjugating 
enzyme(s) and the specificity of substrate targeting. The expanding number of 
ubiquitin-like proteins and intracellular targets suggest that the understanding of 
how much ubiquitin and ubiquitin-like proteins can do, it is just in the beginning of 
an intriguing field. 
1.3 Aims of the project 
Inside the cell, post-translational protein modifications modulate protein 
function by altering protein activity, subcellular localisation and/or ability to interact 
with other proteins. Ubiquitination is one of the most well known of these 
modifications and provides a versatile way of cellular regulation. 
This modification has a well -established role in the degradation of IKB(X, 
which occurs during NF-YB activation. However the involvement of ubiquitin-like 
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modifications in the NF-KB pathway had not been reported. To identify and purify 
proteins involved in the I-KB(x signalling pathway a Yeast Two Hybrid Screen was 
used as primary strategy. Proteins able to interact with the N-terminal regulatory 
domain of 1-KBa were isolated. One of the isolated proteins, Ubch9, turned out to 
be involved in a novel ubiquitin-like modification, SUMO-1 conjugation. Further in 
vivo and in vitro characterisation of this specific interaction was carried out to 
investigate a possible role for SUMO- I modification in the regulation of the NF--KB 
pathway. 
Specific objectives of this work involved the identification and 
characterisation of the enzymes responsible for SUMO-I conjugation and the 
definition of the biological relevance for this novel ubiquitin-like modification in 
1'l1'O. 
In order to achieve the last obejctive, the involvement of SUMO-1 
modification in the metabolism of another transcription factor, p53, which is also 
regulated by ubiquitin mediated protesomal degradation was investigated. 
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2. Materials and Methods 
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2.1. Materials 
Human recombinant TNF(x was provided by the MRC ADP reagent 
program. Human recombinant Interleukin 10 (ILI) was purchased from Sigma and 
Okadaic acid (Oka) was obtained from Calbiochem. Ubiquitin was purchased from 
Sigma. 
2.2. Antibodies 
IKBu. (C-21, Santa Cruz) is a rabbit polyclonal antibody raised against a 
peptide (amino acids 297-317) corresponding to carboxyl terminus of 1-KB(x of 
human origin and used in western blots at 1: 2000 dilution. 
Rabbit polyclonal antibody raised against purified human recombinant I-KB a 
was described previously (Arenzana-Seisdedos et al., 1995) and used at 1: 2000 
dilution in westem blotting. 
21C7 (Matunis et al., 1996) is a mouse monoclonal antibody which 
recognises GMPI (SUMO-1) and was purchased from Zymed. It was used in 
western blots at 1: 2000 dilution. 
SV5 Pk tag monoclonal antibody (Hanke et al., 1992) was obtained from 
R. E. Randall, University of St. Andrews and was used to inimunodetect (1: 2000) 
and immunoprecipitate proteins containing either an N-tem-tinal or Gterrnýinal SV5 
epitope tag of 14 aminoacids (GKPIPNPLLGLDST) of the protein P of Simian 
Virus 5 (SV5). 
HA-tagged proteins were detected using a monoclonal antibody 12CA5, 
specific for a9 amino acid HA peptide sequence (YPYDVPDYA) from influenza 
HA, obtained from Babco. It was used in westem blots at 1: 5000 dilution. 
Monoclonal antibody DO-1 (Vojtesek et al., 1995) recognises the N- 
terminus of human p53 and used at 1: 1000 dilution in western blotting. 
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Polyclonal rabbit seruni CM-1 was raised against human p53 expressed in 
E. coli (Midgley et al., 1992). Both DO- I and CM- I antibodies were obtained from 
D. P. Lane, University of Dundee. 
2.3. Bacterial Strains 
E. coli DH5 a (genotype: (D80dlacZAM 15, rec A 1, end A 1, gyr A96, thi- 1, 
hsd R 17 (rk-, Mk+)' sup E44, rel A], deoR, A(lacZYA-argF)U169)was used for 
routine DNA preparation. E. coli B834 (F, ompT, hsdS B, (rB-, MBA dcm, gaO 
was used for protein expression. Bacteria were grown in Luria-Bertani (LB) broth 
with antibiotics added when required 
2.4. Plasmids and expression vectors 
pGEXT-2T was obtained from Pharmacia. The transient mammalian 
expression vector pcDNA3 was purchased from Invitrogen Corporation. The 
luciferase reporter vectors 3EnhConALuc, ConALuc, HIVLTRLuc and AKBHIV 
LTRLuc were a kind gift from F. Arenzana-Seisdedos (Institut Pasteur). pG13-luc 
reporter plasmid was a kind gift from David P. Lane (University of Dundee). 
pV44ER. LexA and pACT/ pACT-cDNA were received from Colin Goding (Marie 
Curie Research Institute, Oxted, United Kingdom) and Stephen Elledge (Baylor 
College of Medicine, Houston, Texas), respectively, and both have been described 
previously (Durfee et al., 1993; Jayaraman et al., 1994). 
Vector maps of all constructs generated during this work are shown in 
Appendix 1. 
2.4.1. DNA preparation 
All the DNA preparations ( minipreps, maxi-preps and gel extraction ) used 
for cloning and transfections were prepared with Qiagen kits in accordance with 
manufacturers instuctions. DNA restriction enzymes for cloning were obtained from 
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New England Biolabs (NEB) and Promega. The Vent DNA polymerase used for 
PCR (polymerase chain reaction) was obtained from NEB. A Boeringher "TitanTM 
one tube RT-PCR System" was used for reverse transcription followed by PCR- 
amplification (RT-PCR). Quality and quantity of DNA was analysed by 
spectrophotometric readings at 260 nm and 280 nm and by electrophoresis in an 
agarose gel in the presence of ethidium bromide, followed by U. V. (Sambrook et 
al., 1989). 
2.4.2. cDNA Cloning 
2.4.2.1. Preparation of Electrocompetent Bacteria (DH5(x) 
A 10 " overnight culture grown in LB at 37'C was used to inoculate one 
liter of LB which was maintained in culture at 25'C until an OD600 of approximately 
0.5. Cells were then chilled on ice for 30 minutes and centrifuged 15 minutes at 
4000 rpm. Bacteria were resuspended in one liter of cold IniM Hepes pH 7 and 
then centrifuged as described previously. Bacteria were resuspended in 500 ml of 
cold I mM Hepes pH 7 and centrifuged at 4000 rpm for 15 minutes. Bacteria were 
then resuspended in 20 n-ý of cold 10% Glycerol and centrifuged as described 
previously. Finally the bacteria were resuspended in a final volume of 2 to 3 ml of 
cold 10% glycerol, frozen in dry ice and kept at -70'C in small aliquots. All 
solutions were previously autoclaved and kept at 4'C. 
2.4.2.2. Transformation of electrocompetent bacteria 
40 [LI of electrocompetent bacteria were incubated with either plasmid DNA 
or ligation mixtures, on ice for at least I minute. I ng of known plasmid DNA or no 
DNA were added to electrocompetent cells as positive and negative controls. After 
incubation the transformation mixture was transferred to a2 mm electroporation 
cuvette (Flowgen), previously chilled on ice and the following electroporation 
conditions were used: V= 2500; C= 201; T= 5 msec. I n-d of LB/20 niM Glucose 
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was immediately added to the transformed bacteria and the cells were incubated one 
hour at 37 'C before plated on LB-Agar containing the relevant antibiotic. 
Two Hybrid screen plasmids 
The yeast two hybrid system (Fields and Song, 1989) was used to screen a 
human cDNA expression library for proteins that interact with N-terminal regulatory 
domain of IKBa (arnino acids 1-74). The pV44ER. LexA expression vector was 
used to generate a fusion of the LexA DNA binding domain with the N-terminus of 
IKB(x (1-74). A second vector pACT was used to express a fusion of Ga14 
activation domain with proteins encoded by cDNAs in a library generated from 
human lymphocytes (Durfee et al., 1993). Interacting species were identified in 
yeast L40a displaying histidine independent growth and P-galactosidase activity. 
pcDNA3/SV5-N 
The DNA sequence encoding the Pk-SV5 peptide (IPNPLLGLE) was 
inserted into pcDNA3 using KpnI and BamHI cloning sites and the following 
oligonucleotides 
CATGGGAAAGCCGATCCCAAACCCTTTGCTGGGATTGGACTCCACCG-3' and 5'- 
GATCCGGTGGAGTCCAATCCCAGCAAAGGGTTTGGGATCGGCTTTCCCATGGTAC-3'). 
pcDNA3/HA-N 
The DNA sequence encoding the HA peptide (YPYDVPDYA) was inserted 
into pcDNA3 using KpnI and BamHI cloning sites and the following 
oligonucleotides 
5'CATGGGCCTTCATATCCTTACGATGTTTCCAGACCTACGCCCTTTCCCCTTG3' and 
5'GATCCAAGGGAAAGCCGTTAGTCTGGAACATI'CGGTAAGGATATGAAGCCATGGTAC 
3' . 
pcDNA3/6xHis-N 
DNA encoding 6 histidines was inserted into pcDNA3 using Kpnl and 
BarnHI cloning sites and the following oligonucleotides: 5'- 
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CATGGCTCATCATCATCATCATCATGGTG-3' and 5'- 
GATCCACCATGATGATGATGATGATGAGCCATGGTAC-3' 
Ubch9 
A full length Ubch9 cDNA was isolated from a human cDNA library. The 
entire open reading frame of 474 nucleotides was amplified by polymerase chain 
reaction (PCR) using primers (5'-ACAAACGGATCCATGTCGGGGATCGCCCTCAGC-3' 
and 5'-GCCGCGGAAT-FCT-rATGAGGGCGCAAACTTCT-fGGC-3') with additional 
restriction enzyme cleavage sites to facilitate insertion into pGEX-2T such that a 
glutathione-S-transferase-Ubch9 fusion protein can be produced in E. coli. Ubch9 
cDNA was cloned with a C-terminal SV5 tag in BamHI and Xhol cloning sites of 
pcDNA3 after PCR using the following primers, 5'- 
ACAAACCATGGATCCATGTCGGGGATCGCCCTCAGC-3' and 5'- 
TCCGAGCTCGAGTTAGTCCAATCCCAGCAAAGGGTrTGGGATTGAGGGCGCCGCCGCA 
AACTTCTTGGC-3'. 
Ubch5 
cDNA from human Jurkat cells was produced by reverse transcription of 
total RNA and the complete open reading frame of Ubch5 isolated by PCR- 
amplification with specific primers (5'- 
ACAAACGGATCCATGGCGCTGAAGAGGATTCAG-3' and 5'- 
GCGCGGGATCCTTACATFGCATATTTCTGAGTCC-3') and inserted into pGEX-2T as 
described above. 
SUMO-I 
A cDNA encoding the complete open reading frame of SUMO-I was 
obtained by reverse transcription followed by PCR-amplification (5'- 
GCCGCGGGATCCCTAAACTGTTGAATGACC-3' and 5'- 
ACAAACGGATCCATGTCTGACCAGGAGGCCAAA-3') and inserted into pGEX-2T. 
PCR amplification, using a downstream primer containing a stop codon after 
nucleotide 291 of the open reading frame (5'- 
GCCGAGGGATCCCTAACCCCCCGT-FTGTTCCTG-3') was used to create a modified 
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form of SUMO- I in which the C-terminus of the protein is G97. To express NH 2- 
ten-ninal hemagglutinin (HA)-tagged SUMO- 1, SUMO- I cDNA (Desterro et al., 
1997) was inserted into the BamHI cloning site of the constructed pcDNA3/HA-N 
vector in frame with the HA sequence. To generate a histine tagged version of 
SUMO-1, SUMO-1 cDNA (Desterro et al., 1997) was inserted into the BarnHI 
cloning site of the constructed pcDNA3/6XHIS-N vector. 
SAE1 
A cDNA encoding the complete open reading frame of SAM was obtained 
as a single fragment by reverse transcription followed by PCR (RT-PCR) using 
Boeringher "TitanTM one tube RT-PCR System". The following primer containing 
an EcoRl restriction site was used as the downstream primer for reverse 
transcription (5'-GCGGGAATTCTCACTTGGGGCCAAGGCACTCCACAA-3'). The 
upstream primer used for PCR amplification (5'- 
AACGGATCCATGGTGGAGAAGGAGGAGGCTGGC-3') contains a BamHI site at the 5' 
end. PCR products were cloned as a BamHI/EcoRI insert in pGEX-2T 
(Pharmacia), or in pcDNA3 (Invitrogen) with an N-tenninal Pk-SV5 tag antibody 
(pcDNA3/SV5-N) which is recognised by the 336 monoclonal (Hanke et al., 
1992). 
SAE2 
The cDNA of SAE2 was obtained from two different RT-PCR reactions and 
a final PCR. An intermediate upstream and downstream primer (5'- 
GATATCAAATCAATGGCAGGGAAC-3' and 5'-GTrCCCTGCCAT-fGATI'rGATATC-3') 
were used in each RT-PCR reaction to generate two different fragments which were 
later used in the final PCR reaction as template with the folowing primers (5'- 
GAGGAATrCATGGCACTGTCGCGGGGGCTG-3' and 
GAGGAATTCTCAATCTAATGCTATGACATC-3') both containing an EcoRl restriction 
site. The final PCR fragment was inserted into the EcoRl restriction site of 
pcDNA3. 
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p53 mutants 
PCR was used to generate a wild type version of the p53 coding sequence 
containing a BamH I site at the sequence corresponding to G36 I. /S362. Full length 
p53 was cloned into HIndIII-EcoRl sites of pcDNA3 vector. All p53 mutants were 
generated by site-directed mutagenesis using PCR strategy. The wild type p53 
BamHI-EcoRI cassette was replaced to generate each K to R mutant. 
Others 
IKB(x ctag and mutants in pcDNA3, ConALuc, 3EnhConALuc, 
HIVILTRLuc and AkBHIVILTRLuc reporter vectors were as previously described 
(Rodriguez et al., 1996). 
2.4.3. DNA sequencing 
AH constructions were used to transform E. coli DH5(x to ampicillin 
resistance. Plasnfid DNA of all constructs was isolated and inserts sequenced 
(AB1377) by Alex Houston of the University of St Andrews DNA sequencing 
facility. 
2.5. Expression and purification of recombinant proteins 
GST-Ubch9, GST-Ubch5, GST-SAEI, GST-1-KBa and both GST-SUMO-I, 
full lenght and 1-97 a. a., constructions were expressed in Escherichia coli strain 
B834. Induction of expression, glutathione agarose affinity chromatography and 
thrombin cleavage of fusion proteins was as described (Jaffray et al., 1995). Both 
SUMO-1 proteins were further purified over an anionic exchange column (FPLC, 
Mono Q H5/R5) equilibrated with 50 mM Tris pH7.5 and eluted with a0 to IM KCI 
gradient in 50 niM Tris pH7.5. Human El ubiquitin activating enzyme was purified 
from HeLa cell extracts or from recombinant baculovirus infected insect cells by 
covalent affinity chromatography on ubiquitin-Sepharose as described (Haas and 
Bright, 1988; Rolfe et al., 1995). Arabidopsis thaliana El was produced in E. coli 
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BL2 I DE3 using the pET expression system (Hershko et al., 1983) and purified by 
ubiquitin affinity chromatography as described (Haas and Bright, 1988). Human 
Mdm2 (residues 6-491) was expressed in bacteria and purified as described for p53 
(Midgley et al., 1992) and was obtained from Carol Midgley, University of Dundee. 
2.6. Quantitation of protein 
Protein concentrations were deten-nlned using Bradford's method (Bradford, 
1976). Protein samples were mixed with Bradford's reagent ( Biorad) and the 
absorvance at 595 nm was measured on a spectrophotometer. Protein absorbances 
were converted to mg/ml concentrations using a standard curve constructed by 
measuring the absorbances of a range of bovine serum albumin (BSA) concentrations. 
2.7. SDS-PAGE and Western blot analysis 
Protein samples were resuspended in disruption buffer (IX: 20 m. Mt Tris/ 
HCI pH6.8,2% SDS, 5% P-mercaptoethanol, 2.5% glycerol and 2.5% 
bromophenol blue) and denaturated at 100'C for 5 minutes before loading on a 8.5- 
12.5% SDS-plyacrylamide gel (acrylarnide percentage appropriate for the size of 
proteins to be separated). Bio-Rad mini gel equipment was used in accordance with 
the manufacters instructions. New England Biolabs protein molecular weight 
markers were used as standards to establish the apparent molecular weights of 
proteins resolved on SDS-polyacrylamide gels. Separated polypeptides were either 
stained with Coomassie Blue (0.2% Coomassie brilliant blue R250; 50% methanol; 
10% acetic acid) for 30 minutes and then destained (20% methanol; 10% acetic acid) 
or tranferred to a polyvinylidene difluoride membrane (Sigma) using a wet blotter 
(Biorad Systems). The membranes were blocked with PBS containing 5% skimmed 
milk powder and 0.1% Tween 20 then incubated with monoclonal or polyclonal 
antibodies diluted in blocking buffer. Horseradish peroxidase conjugated anti- 
mouse IgG and anti-rabbit IgG (Amersham) were used as secondary antibodies. 
58 
Western blotting was performed using ECL detection system. After ECL detection 
and when necessary western blots were stripped as described (Roff et al., 1996). 
2.8. N-terminal peptide sequencing 
The protein sample was fractionated by SDS-PAGE using freshly prepared 
acrylamide: piperazine diacrylamide solution (30: 0.8) and with the addition of 
sodium thioglycolate to 0.1 rnM in the upper electrophoresis buffer. Proteins were 
electrophoretically transferred to PVDF membrane (Amershan) and proteins stained 
with 0.1% An-fido Black in 40% methanol, I% acetic acid, for 30 seconds before 
bands were excised. Excised membrane bands were extensively washed in distilled 
water and the peptide sequence determined using a Procise microsequencer (Applied 
Blosystems) with on line phenylthiohydantoin analysis. Protein sequence analysis 
was carried out by Paul Talbot and Graham Kemp at the University of St. Andrews 
Protein Sequence Facility. 
2.9. "In gel" trypsin digestion 
Samples to be digested in the gel were fractionated by SDS-PAGE as 
described for N-terminal peptide sequencing. The gel was stained in 0.1% 
Coomassie Brilliant Blue R250/ 20% Methanol/ 0.5% Acetic acid and then 
destained in 30% Methanol until the bands were visible above a clear background. 
After excision, gel slices were washed for at least one hour in 100 in1\4 NH4HCO3 
pH 8.0 and 30 minutes at 60'C in IOOmM NH4HCO3 pH8/ 3 mM DTT. 
lodoacetamide was added to a final concentration of 6 mm and after 30 minutes of 
incubation at room temperature in the dark, gel slices were washed with 50% 
acetonitrile/ 100 mM NH4HCO3 pH 8.0 for one hour with shaking. Acetronitrile 
was added to shrink gel pieces and after 10- 15 minutes of incubation the solvent 
was removed and the samples dried in a rotatory evaporator. Gel slices were 
reswollen with 25 mM NH4HCO, pH 8.0 containing modified trypsin (Promega) 
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and incubated for 4 hours at 37'C. The supernatant was acidified by adding TFA to 
a final concentration of I% and peptides extracted from gel slices twice with 60% 
acetonitrile/ 0.1% TFA for 20 minutes. All supernatants were combined and, after 
evaporation to near dryness, peptides fragments were reconstituted in 20[tl of 0.1 % 
TFA and separated by HPLC using a microbore HPLC System. The arnino acid 
sequence of selected peptides was determined as described for N-terminal peptide 
sequencing. 
2.10. In vitro transcription translation 
In vitro transcription/translation was performed using 1-2 [tg of plasmid 
DNAs and a TNT Coupled Wheat Germ Extract System (Promega) according to the 
instructions provided by the manufacter. "S-methionine (Amersham) was used in the 
reactions to generate radiolabelled proteins. 
2.11. lodination of Ubiquitin and SUMO-1 
Human Ubiquitin from Sigma and recombinant 
SUMO- 1 
-97 expressed in 
Escherichia coli, were radiolabeled with carrier-free Na 1251 (Amersham) by the 
Chloran-iine-T method (Ciechanover et al., 1980). 1251_SUMO was fully reduced by 
incubation with 100 mM DTT and after removal of the reducing agent by passing 
through a Biogel P6 spin-column, free sulphydryl groups were acetylated by 
incubation with 10 mM lodoacetamide. After 10 minutes at room temperature the 
lodoacetamide was quenched by the addition of DTT to 20 mM. 
2.12. Thioester assay 
Formation of thioester adducts between recombinant E2s (GST-Ubch5 and 
Ubch9) and Ubiquitin was determined essentially as previously described (Haas et 
al., 1982). Reactions contained the indicated amount of Arabidopsis thaliana El or 
human El, IU of inorganic pyrophosphatase (Sigma), 0.5 gg of "51-ubiquitin and 
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recombinant E2s in a final volume of 20 ýtl of 50 mM Tris/HCI pH7.6,10 mM 
MgC'2ý I mM ATP. Reactions were incubated at 30'C for 10 minutes and 
terminated either by boiling for 10 minutes in the presence of 2% (w/v) sodium 
dodecyl sulphate and 4% (v/v) 2-mercaptoethanol, or by incubating the samples at 
30'C for 15 minutes in the same buffer containing 4M Urea instead of 2- 
mercaptoethanol. Samples were subjected to SDS-PAGE (12,5%) and dried gels 
analysed by phosphorimaging (Fujix BAS 1000, MacBAS software). Formation of 
thioester adducts between recombinant ubch9 and 
1251_SUMO_ I 
was determined 
using the above procedure with 0,5 ýtg of 1251_SUMO_ I and instead of purified El 
enzyme, either SAE immunoprecipitated on protein A beads (rSAE) or 5 gl of HeLa 
cell fraction containing SAE activity (FrII. 4). To detect the activity of SUMO- I 
activating enzyme, formation of thioester adducts between either 
immunoprecipitated or affinity purified SAE and SUMOGG- 'was determined as 
described above in absence of Ubch9 activity. 
2.13. Preparation of HeLa cell fractions 
HeLa cell extracts were prepared by lysis in hypotonic buffer containing 20 
mM Tris pH 7.5,1 rnl\4 EDTA, I niM DTT, phosphatase inhibitors (5niM NaF, 
ImM sodium orthovanadate) and protease inhibitors (ImM PMSF, 2 mM 
Benzamidine, 5mg/ml Leupeptin, 10mg/ml pepsatin). Following incubation on ice 
for 15 minutes the cells were disrupted with a dounce homogeniser. After 
centrifugation at 40 000 rpm for 30 minutes at 4'C the supernatant was loaded onto 
a Q-sepharose column equilibrated with 50mM Tris pH 7-5/ 0.5 MM DTT. The 
flowthrough was collected (Fr 1) and bound proteins were eluted stepwise with 0.1, 
0.2,0.3,0.4 and 0.5M KCI in 50mM Tris pH 7.5/ 0.5 mM DIT (Fr II. I -FrII. 5). 
All fractions were further concentrated and fractionated by ammonium sulphate 
(40%) precipitation. After overnight dialysis against 50 mMTris pH 7.5/0.5 mM 
DTT the fractions were stored at -700C. 
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2.14. SUMO-I affinity chromatography 
Five milligrams of recombinant purified SUMOGG -1 (1-97 a. a. ) were 
coupled to aI ml NHS-activated Hi-Trap column (Pharmacia) according to the 
manufacturer's instructions. 40% of the added protein was coupled to the beads. 
Following the affinity chromatography procedure, the column was regenerated by 
washing with 10 column volumes of a buffer containing 50 mM Tris/HCI pH9.0, I 
M KCL 2 mM dithiotheitrol, followed by 10 column volumes of 50 mM Tris-HCI 
pH 7.2 buffer containing 0.02% NaN3. The affinity column was stored at VC. 
HeLa Fr 11.4 and Fr 11.5 (eluted with 0.4 M and 0.5 M of KCI ) containing SUMO- 
I activating enzyme activity (tested by a thioester assay) were dialysed overnight 
against 50 mM Tris pH 6.8/ 0.2 mM DTT and affinity chromatography carried out 
essentially as described for ubiquitin (Ciechanover et al., 1982). Following 
dialysis, fractions were adjusted to 50 mM Tris pH 6.8,2 mM ATP, 5 rnMMgC'21 
0.2 n-AM DTT, 2.5 U/mI of yeast inorganic pyrophosphatase, 10 nil\4 creatine 
phosphate, 2 U/n-d of creatine kinase and applied, at a flow rate of approximately 
0.5 n-fl/min, to the SUMOGG_ 1 Sepharose column pre-equilibrated with 3 column 
volumes of a buffer containing 50 mM Tris/HCl pH 6.8,2 m1\4 ATP, 5 r"M MgC'2, 
0.2 mM DTT (Buffer A). The column was washed with 3 column volumes of 
buffer A followed by 5 column volumes of 50 mM Tris/HCl pH 7.5,1 M KCI and 
then 50 mM Tris/HCI pH7.5. SUMO-I El activity was eluted with 3 column 
volumes of 50 m. M Tris/HCI pH 7.5 , 0.2 mM DTT, 2 rnM AMP, 2 rnM sodium 
pyrophosphate (AMP eluate) and finally with 3 column volumes of 50 MM 
Tris/HCI pH9.0 containing 10 nil\4 DTT and IM NaCl. Column eluates were 10 
fold concentrated using Centricon 30 microconcentrators which had been pre-treated 
with BSA to reduce non-specific adsorption. The buffers were changed by 3 
successive 10 fold dilutions in 50 mM Tris/HCI pH7.5, I mM DTT followed by 10 
fold reconcentration using the same microconcentrator. The final volume of the 
column eluates was brought to 10% of the starting volume of loading fraction. 
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Column operations were carried out at room temperature but all -fractions were 
collected on ice. The enzymatic activity present in each fraction was determined 
using a thioester assay. 
2.15. Cell Culture and transfections 
COS7 (Monkey African Green kidney cells containing the SV40 large T- 
antigen gene) were maintained in exponential growth in Dulbecco's modified 
Eagle's medium, containing 10% foetal calf serum. 1-2 ýtg of plasn-fid DNAs were 
transfected for 14 hours in subconfluent 75 cm' flasks using Lipofectan-ýine TM 
according to instructions provided by the manufacturer (Gibco). After 36 hours of 
expression, cells were washed in PBS and cellular extracts prepared for futher 
analysis. 
Wild type p53 U20S (osteosarcome cells) and p53 null Saos-2 cell lines 
were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% foetal bovine serum (FBS). Cells were transfected by electroporation (950mF, 
20OV, Equibio Easyject plus) as described (Arenzana-Seisdedos et al., 1997). A 
total of 10 ýLg of plasMid DNA encoding the 6- His-SUMO-I and p53 were co- 
transfected into 5X 106 cells. After transfection, cells were seeded in 75 CM3 flasks 
and incubation continued for a further 36h. 
2.16. Luciferase assays 
2.16.1. NF-KB transcriptional activity 
HeLa (Human Negroid cerivix epitheloid carcinome), COS7 and human 
embryo kidney 293 cell lines were maintained in exponential growth in Dulbecco's- 
modified Eagle's medium, containing 10% foetal calf serum. týtg-2ýLg of plasn-ýd 
DNAs (an NF-kB dependent, 3EnhConALuc or HFVLTRLuc or independent, 
ConALuc or A-KBHIVLTRLuc, luciferase reporter vector) were co-transfected with 
described plasmids for 14 h in subconfluent cells seeded in 25 cm' flasks using 
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Lipofectarnine"Im according to instructions provided by the manufacturer (Gibco). 
After transfection, cells were trypsinized, aliquots were seeded into six-well plates 
and cultured for an additional 36 hr. Cells from a single transfection were incubated 
for 8 hr. with medium containing IL- IP (10 ng/ml), TNFec (10 ng/ml), okadaic acid 
(75 nM) or control medium and processed for luciferase reporter activity as 
described (Rodriguez et al., 1996). 
2.16.2. p53 transcriptional activity 
To measure p53 transcriptional activity 10' Saos-2 cells were electroporated 
with I ýtg of pG I 3-luc reporter plasmid together with I [tg of SUMO- I expression 
plasrnId and I ng of p53 (wild type and K386R) expression plasmid. pCDNA3 
empty vector was used to bring the total amount of DNA to 10 ýtg. After 
electroporation cells were grown in 6 well plates for 24 hours and processed for 
luciferase reporter activity as described (Rodriguez et al., 1996). Results are the 
mean of 4 independent transfections, with error bars representing one standard 
deviation 
2.17. Preparation of cell extracts 
Cell extracts were prepared either by lysis in 20 n-A4 Na phosphate buffer 
pH 7.5,50 mM NaF, 2 n-iM EDTA, 0.5% NP40,5 mM tetra-sodium 
pyrophosphate, 1 mM sodium orthovanadate, 10 mM P-glycerophosphate, 
containing complete@ protease inhibitor cocktail (Boehringer Mannheim) as 
described (Roff et al., 1996) or in SDS sample buffer (5% SDS, 0.15 M Tris HCI 
pH 6.7,30% glycerol) diluted 1: 3 in RIPA buffer ( 25 niM Tris/pH8.2,50 nM 
NaCI, 0.5% Nonidet P40,0.5% Deoxycholate, 0.1% SDS, 0.1% Azide), 
containing 10 mM lodoacetamide and complete@ protease inhibitor cocktail 
(Boehringer Mannheim). Both lysates were sonicated briefly and cleared by 
centrifugation. Supernatants were diluted 1: 10 in PB S/O. 5% NP40 plus complete@ 
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protease inhibitor cocktail and used for immunoprecipitations. 10 ýtl of each lysate 
was fractionated on either 10% or 12.5% SDS-PAGE and transferred to a 
polyvinylidene difluoride membrane (Sigma). Protein expression was checked by 
Western blotting. 
2.18. Protein interaction assays 
2.18.1. SAE Immunoprecipitations 
Extracts from COS 7 transfected cells or in vitro transcribed/translated SAE 
proteins were incubated for I hour at 4'C with 336 anti-SV5 antibody either in lysis 
buffer or 50 mM Tris pH 7.5,10 n-A4MgCl2 buffer containing I mM ATP and 
complete@ protease inhibitor cocktail, respectively. Antigen -antibody complexes 
were collected by adding 20 ýtl of protein A-Sepharose beads and incubation 
continued for an additional 2 hours on a rotating shaker. The beads were collected 
by brief centrifugation and after extensive washing with ice cold 50 mM Tris/HCI 
pH 7.5,10 n1M MgC'2 containing complete@ protease inhibitor cocktail, antigen- 
antibody complexes were used, as source of SUMO-1 activating enzyme in 
thioester or conjugation assays. 
2.18.2. SAE pull downs 
Glutathione S-transferase (GST) or GST-SAEI beads were incubated with 
"S-methionme labelled in vitro transcribed/ translated SAE2 for I hour at room 
temperature. Beads were collected by centrifugation and washed 4 times with 50 
mM Tris/IiCI pH 7.5,10 MM 
MgC'2, lmg/ml BSA containing complete@ protease 
inhibitor cocktail and 0.5% NP40. Washing buffer was removed and beads, after 
resuspension in 3X disruption buffer (5% SDS, 0.15 M Tris HCI pH6.7,30% 
glycerol, 0.72 M P-mercaptoethanol, were fractionated in a 10 % polyacrylamide 
gel. Dried gels were exposed to a phosphorimager screen to detect 
35 S radioactivity. 
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In vitro transcribed/translated SAE proteins were incubated for I hour at 40C with 
336 anti-SV5 in 50 m1\4 Tris pH7.5,10 MM MgC'2 containing Imm ATP and 
complete@ protease inhibitor cocktail. Antigen -antibody complexes were collected 
on protein A-Sepharose beads and analysed as described for GST pull downs. 
2.18.3. SUMO-I-IKBa Immunoprecipitation 
Immunoglobulins from a preimmune rabbit serum or from anti-l-KBa rabbit 
antisera were covalently cross-linked to protein A-Sepharose beads (Sigma) using 
dimethylpimelimidate as described (Arenzana-Seisdedos et al., 1995). Cells were 
lysed in SDS sample buffer diluted in RIPA buffer containing 10 mN4 
lodoacetamide and complete@ protease inhibitor cocktail (Boehringer Mannheim). 
The lysates were sonicated briefly and cleared by centrifugation. Supernatants were 
diluted 1: 10 in PBS/0.5% NP40 plus complete@ protease inhibitor cocktail and 
incubated for 3 hr. at room temperature with the antibody coated beads. The beads 
were sedimented by brief centrifugation, washed 5 times with ice-cold PBS/0.5% 
NP40 plus complete@ protease inhibitor cocktail and the antigen-antibody 
complexes were recovered by boiling in SDS sample buffer. 
2.18.4. SUMO-I-IKB(x/p65 pull downs 
Glutathione agarose beads were added to an in vitro SUMO-I conjugation 
assay (purified proteins) containing either 1211 SUMO-I and GST-p65 or GST 
instead of p65 recombinant protein. After 10 Minutes of incubation at room 
temperature the beads were collected by centrifugation and washed 5 times with 
PBS/0.1% Tween 20. Affinity purified proteins were recovered by heating to 
100'C in SDS sample buffer containing P-mercaptoethanol, fractionated in a 12.5% 
polyacrylamide gel and the dried gel analysed by phosphorimaging. 
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2.19. Purification of 6XHIS-tagged SUMO-1-p53 
conjugates 
36 hours after transfection cells from a 75 cm' flask were lysed in 4 ml of 6 
M guanidinium-HCI, 0.1 M NaHP04/NaH2P04 , 0.01 M Tris/HCI , pH 8.0 plus 
5mM irrfldazole and 10 mM P-mercaptoethanol. After sonication, to reduce 
viscosity, the lysates were mixed with 50 [tl of Ni"-NTA-agarose beads prewashed 
with lysis buffer and incubated for 2 hours at room temperature. The beads were 
successively washed with the following: 6M guanidinium-HCI, 0.1 M 
Na2 HP04/NaH2po4' 0.01M Tris/HCl , pH 8.0 plus 10 niN4 P-mercaptoethanol; 8 
M Urea, 0.1 M Na2HP04/NaH2P04 , 0-01 M Tris/HCI , pH 8.0,10 mM 
ß- 
mercaptoethanol; 8M Urea, 0.1 M Na2HPO4 /Nall2P04 , 
0*01 M Tris/HCI , pH 
6.3,10 mM P-mercaptoethanol (buffer A) plus 0.2% Triton X-100; buffer A and 
then buffer A plus 0.1 % Triton x- 100. After the last wash with buffer A the beads 
were eluted with 200 mM imidazole in 5% SDS, 0.15 M Tris HCI pH 6.7,30% 
glycerol, 0.72 M P-mercaptoethanol. The eluates were subjected to SDS-PAGE 
(10%) and the proteins transferred to a polyvinylidene difluoride membrane 
(Sigma). Western blotting was performed with a monoclonal antibody against p53, 
DO-1. 
2.20. In vitro SUMO-1 conjugation assay 
"S-methionine labelled in vitro transcribed/translated proteins (I [d) were 
incubated with 2 [LI of HeLa cell fraction containing SUMO- IEI activity (Fr. 11.4) 
in a 10 [d reaction including an ATP regenerating system (50 mM Tris pH 7.6,5 
111M MgC'2,2 mM ATP, I OmM creatine phosphate, 3.5 U/ml of creatine kinase and 
0.6 U/ml of inorganic pyrophosphatase), SUMO-I (1 [Lg/ýLl), Ubch9 (60 [tg/ml). 
Reactions were incubated at 37"C for 2 h. After terminating the reactions with SDS 
sample buffer containing P-mercaptoethanol, reaction products were fractionated by 
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SDS-PAGE (8.5%) and the dried gels analysed by phosphorimaging (Fujix BAS 
1500, MacBAS software). 
SUMO-1 conjugation using purified proteins was accomplished in a 10 ýtl 
reaction containing 50 mM Tris pH 7.6,5 mMMgC'2,2 mM ATP, lOmM creatine 
phosphate, 3.5 U/ml of creatine kinase and 0.6 U/ml of inorganic pyrophosphatase, 
0.6 ýig of human recombinant I-KB(x (or mutants), 0.5 [tg 1251_SUMO_I, 0.5 ýtg 
Ubch9 and either SAE immunoprecipitated protein A beads (rSAE) or 90ng of SAE 
purified by affinity chromatography on immobilised SUMO-1. Reactions were 
incubated at 370C for 2h and terminated by boiling in SDS sample buffer 
containing P-mercaptoethanol. Samples were subjected to SDS-PAGE (12.5%) and 
dried gels analysed by phosphorimaging. 
2.21. In vitro Ubiquitination assay 
"S-methionine labelled in vitro transcribed/translated p53 proteins (I ýtl) 
were incubated in a 10 ýtl reaction including an ATP regenerating system (50 mN4 
Tris pH 7.6,5MM MgC'2,2 mM ATP, 10 mM creatine phosphate, 3.5 U/ml of 
creatine kinase and 0.6 U/ml of inorganic pyrophosphatase), 10 ýtg ubiquitin, 10 ng 
human EI, 60 ng Ubch5 and 60 ng Mdm2. After incubation at 370C for 2h the 
reactions products were treated as mentioned for the SUMO- I conjugation assay. 
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3. RESULTS 
69 
3.1. Ubch9 conjugates SUMO-1 but not Ubiquitin 
70 
3.1-1. Summary 
Modification of proteins by ubiquitin is the critical step in targeting proteins 
for degradation via the proteasome. Ubiquitin conjugating enzymes participate in the 
thioester cascade that leads to protein ubiquitination. Ubc9 is homologous to E2 
ubiquitin conjugating enzymes and has been isolated repeatedly from yeast two 
hybrid screens in association with a wide variety of proteins. However, it has not 
been possible to demonstrate that ubc9 has the enzymatic activities that would be 
expected of a ubiquitin conjugating enzyme. We demonstrate that while ubch9 is 
unable to form a thioester with ubiquitin it is capable of forming a thioester with the 
small ubiquitin-like protein SUMO-1. Thus, Ubc9 is a SUMO-I conjugating 
enzyme rather than a ubiquitin conjugating enzyme. Futhermore, , we show that 
transacetylation of Ubch9 by SUMO-1 is not mediated by the El ubiquitin 
activating enzyme, but by a distinct enzymatic activity. 
The X-ray crystal structure of recombinant Ubch9 has been obtained to a 
resolution 2.8 'A. The differences observed in the structure surrounding the reactive 
cysteine of Ubch9 may reflect the specificity of Ubch9 for SUMO- I and its distinct 
El activity. SUMO-1 conjugation to target proteins is mediated by a different, but 
parallel pathway to ubiquitination. 
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3.1.2. Ubch9 is unable to form a thioester with ubiquitin 
The NF-KB/Rel proteins are sequestered in the cYtoplasm of unstimulated 
cells in association with IKBoc. In response to external signals, the N-ten-ninal 
region of I-KB(x is phosphorylated and ubiquitinated prior to degradation by the 
proteasome. Released NF-'KB translocates to the nucleus and activates a large 
number of responsive genes. To identify proteins involved in I'KBU signalling, a 
yeast two hybrid screen was used to isolate human cDNAs encoding proteins that 
could interact with the N-ten-ninal regulatory domain of I-KB(x (1-74). Such a human 
cDNA was isolated and sequenced to reveal an open reading frame of 474 
nucleotides encoding a 158 amino acid protein, identified as the human protein 
Ubch9, which is homologous to ubiquitin conjugating enzymes. Although this 
protein has been repeatedly isolated in yeast two hybrid screens evidence that the 
protein has ubiquitin conjugating activity has not been reported. To characterise the 
enzymatic activity of Ubch9 the protein was expressed as a GST fusion in bacteria 
and purified. A known ubiquitin conjugating E2 enzyme, Ubch5 (Scheffner et al., 
1994), was expressed and purified in sirrular fashion (Figure 6). The ability of 
purified Ubch9 and GST-Ubch5 to form a thioester with 125 1-ubiquitin in the 
presence of MgATP and recombinant El from A. thaliana was analysed by SDS- 
PAGE under non-reducing conditions. While a thioester was formed between GST- 
Ubch5 and 125 1-ubiquitin none could be detected using Ubch9 (Figure 7A). To rule 
out the possibility that this result was a consequence of incompatibility between 
plant EI and human E2 enzymes, the human EI enzyme was affinity purified from 
HeLa cells and tested in the same assay with identical results (Figure 7B). Thus, 
under the conditions employed Ubch9 did not display ubiquitin conjugating activity. 
3.1.3. Ubch9 forms a thioester with iodinated SUMO-I 
Recently a small ubiquitin-like protein known variously as UBLI, SUMO- 
1, Sentrin and PICI has been found covalently linked to RanGAPI and associated 
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Figure 6. PurWication of recombinant proteins. 
Recombinant proteins were purified from E. coli as described in Materials and Methods, subjected to 
SDS-PAGE (12,5%) and stained with Coornassie Blue. Lane 1,1.5 ýtg GST-Ubch9 (44 kDa); Lane 2,1 
[tg Ubch9 (18 IcDa); lane 3,1 ýtg GST-Ubch5 (42 IcDa); lane 4,1.5 ýtg GST-SUMO-11_, (38 kDa); lane 
5,1 ýtg SUMO- I 1_ý, 
(12 kDa); lane 6,1 ýtg A. thaliana EI (123 IcDa). The molecular weight of protein 
markers (M) is shown at the left of the figure. 
A. A. thaliana EI 
Ubch9 GST-Ubch-5 
Al 
125 1-Ub-El 
«w» *MW o -4 GST-Ubch5 ý2*51-Ub 
125 1-Ub-El 
.4 
-4 GST-Ubch5 ý251-Ub 
.4 
125 
I-Ub 
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Figure 7. Ubch9 is unable to form a thioester with ubiquitin. 
Assay for thioester formation between '251-ubiquitin and Ubch9 (0.9 ýtg lane 2,1.8 Vg lane3) or GST-Ubch5 
(0.7 [tg lane 5,1.4 [tg lane 6) in the presence of recombinant A. thaliana El (A) or human El from HeLa 
cells (B). After 10 minutes at 30'C reactions were terminated and products fractionated by SDS-PAGE 
under non-reducing conditions. '211 radioactivity in the dried gel was detected by phosphorimaging. The 
positions of 1251_ ubiquitin and thioester adducts with El and E2 proteins are indicated. 
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with Ubc9 (Boddy et al., 1996; Kamitani et al., 1997b; Mahajan et al., 1997; 
Matunis et al., 1996; Saitoh et al., 1997; Shen et al., 1996b). We therefore 
investigated whether Ubch9 might be a SUMO- I conjugating enzyme rather than a 
ubiquitin conjugating enzyme. Ful I length SUMO- I or a modified form lacking four 
amino acids from the C-terminus, which is thought to be the active form of SLTMO- 
I (Kamitani et al., 1997b), were produced in bacteria and purified. To determine if 
ubiquitin activating enzyme could activate SUMO- 1, human and A. thaliana EI were 
used in a thioester assay with Ubch9 but were unable to promote thioester formation 
between Ubch9 and SUMO-1 (data not shown), although these EI enzymes were 
active for the formation of a thioester between ubiquitin and GST-Ubch5 (Figure 
7). Thus it seemed likely that SUMO-1 activation would require a distinct El 
activity, distinct from that involved in ubiquitin activation. To explore this 
possibility a cytoplasmic extratct from HeLa cells was incubated with 1251_SUMO_ I 
in the presence or absence of Ubch9. An activity capable of catalysing formation of 
a Ubch9- 1251_SUMO_l thioester in an ATP dependent fashion was detected with the 
97 amino acid form of SUMO- I (Figure 8) but not with full leright SUMO- I (data 
not shown). Fractionation of the HeLa extract by anion exchange chromatography 
revealed that the SUMO- I El activity was eluted with 0.4 and 0.5 M KCI (Figure 
8) and was distinct from the ubiquitin EI activity which elutes with 0.3 M KCI (data 
not shown). An apparent background activity detected in the absence of ATP could 
be explained by formation of a linkage between Cys52 in SUMO-I and Ubch9. 
This activity was eliminated by acetylation of Cys52 by treatment of SUMO- I with 
iodoacetamide. The ability of Ubch9 to forrn a thioester with acetylated 1251_SUMO_ 
I in the presence of the SUMO-I EI activity contained in Fr 11.4 was determined. 
1n presence of ATP, Ubch9 forms a conjugate with 
1251_SUMO_l that is labile to 
reducing agents, such as 2-mercaptoethanol (Figure 9), indicating that the two 
molecules are linked by a thioester bond. Under the same conditions GST-Ubch5 
was unable to form conjugates with 
1251_SUMO_ 1. Thus Ubch9 has the properties 
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Figure 9. Ubch9 is a SUMO-I conjugating enzyme. 
Ubch9 (I ýtg) and GST-Ubch5 (I ýtg) were assayed for their ability to be transacetylated by "51-SUMO-1 (treated 
with iodoacetamide) in the presence of the SUMO-I activating enzyme present in HeLa fraction 11.4. Assays 
were conducted either in the absence (-) or presence (+) of ATP and reaction products analysed as described in 
the legend to Figure 7. The indicated samples (+SH) were analysed under reducing conditions after treatment 
with 2-mercaptoethanol. 
of a SUMO-1 conjugating enzyme that can act in concert with a unique SUMO-1 
activating enzyme. 
3.1.4. Structure of Ubch9 
To determine the structure of Ubch9 a large batch of Ubch9 was purified to 
homogeneity by a combination of affinity chromatography of the fusion protein on 
glutathionc agarose and a second affinity chromatography after thrombin cleavage. 
Using the purified protein, crystallisation trials were set up and conditions 
developed for crystal growth. The three-dimensional structure of recombinant 
Ubch9 was obtained in collaboration with Marie-France Giraud and Jim Naismith 
using molecular replacement followed by a combination of automated refinement 
and graphical intervention. The protein appears to be a monomer in the crystal and 
consists of four a helices ( HI, Ee4 - Lys18; H2, IleIO9 - Asn121; H3, Alal31 - 
Asn139; H4, Argl_41 - Lys154) and an anti-parallel P-sheet composed of four 
strands (SI, Va125 - Pro28; S2, Asn40 - Pro46; S3, Leu57 - Leu63; S4, Lys74 - 
Phe77) (Figure 10). The N-terminus is located on the opposite face from the C- 
terminus. Helices HI, H2 and H3 form one side of the protein, while the other side 
is composed mostly by one face of the P-sheet. The reactive cysteine (Cys93) is 
located in a region of the molecule (residues 78 - 108) consisting of four turns and 
a 31, helix (Glu98 - Leu97). Residues Thr9l to Leu97 form a small depression in 
which Cys93 lies. 
Sequence alignments show that Ubch9 has two small insertions compared with the 
other ubiquitin-conjugating enzymes. These two insertions consist of residues 
Pro32 - Met36 and AsplOO - LyslOl and create the main differences with the other 
ubiquitin-conjugating enzymes. The two-residue insertion (Asp 100 and LyslOl) is 
located as a lip near to the active site Cys93. This insertion forms a small accessible 
loop. Interestingly, insertions at this position are also found in other ubiquitin 
conjugating enzymes but they are much longer and structurally different to that in 
Ubch9. The region of the five-residue insertion Pro32 - Met36 is a flexible loop and 
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Figure 10. Schematic representation of Ubch9. 
The four cc-helices are represented in red (H 1, H2, H3,144) and the four 
strands (SI, S2, S3, S4) in yellow. The 3,0 helix is symbolised by a pink 
ribbon. Turns are indicated in blue. The N- and C-terminus and the reactive 
cysteine are labelled. 
the main chain of the loop must form a protruding region near the N-terminal (X- 
helix. Residues near the reactive cysteine such as His83, Pro84, Asn85, Ile96 and 
Leu97 are highly conserved suggesting that they may be important to maintain the 
cysteine in the appropriate conformation. A noticeable feature of the active site of 
Ubch9 is the presence of Lys 10 1, which is located close to the S atom of Cys93 
(Figure It). 
The non-catalytic face of Ubch9 is much more positively charged than other 
Ubc enzymes and is a reflection of the much higher pl of Ubch9 compared with 
ubiquitin conjugating enzymes (8.7 versus <6.5) (Figure 11). In contrast to the 
positive non-catalytic face, Uch9 has a negatively charged ridge close to the reactive 
cysteine (Figure 11). The ridge is composed of Asp67, Glu98, AsplOO, Aspl02 
and Asp 127. Thus, Lys 10 1 in Ubch9 generates a positively charged lip close to the 
reactive cysteine in the midst of the negatively charged ridge (Figure 11). This lip 
may discrirrunate between SUMO-1 (pI 5.4) and ubiquitin pI (7.2), since without 
LyslOl, the active cysteine of Ubch9 sits in a very negative pocket which could 
favour ubiquitin binding. 
Discussion 
Ubch9 was isolated in a yeast two hybrid screen as a protein that could 
interact with the N-terrninal region of I-KB(x. As IKBec undergoes signal induced 
ubiquitination within the N-ten-ninal domain our expectation was that Ubch9 could 
participate in the ubiquitination of I-KBa. Using an in vitro system for the 
phosphorylation and ubiquitination of IKBoc (Chen et al., 1996; Kroll et al., 1997) 
we were unable to demonstrate a role for Ubch9 (data not shown). Furthermore 
Ubch9 was unable to form a thioester with ubiquitin, in the presence of the El 
ubiquitin activating enzyme, under conditions where this activity could be clearly 
demonstrated with Ubch5 (Figure 7). 
As it has been reported (Shen et al., 1996b)that the ubiquitin like protein 
SUMO-1 is found in complexes containing Ubc9 it has been suggested that Ubc9 
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The SG atom of the reactive cysteme is shown in yellow. The right pictures corre- 
spond to the back face of the left pictures (1800 rotation about a vertical axis in the 
plane of the paper). The x, y and z axes are shown. The colour spectrum from red to 
blue corresponds to changes from negative to positive potential. 
Figure 11. Electric surface potentials of Ubch9 and plant Ubc I (Ubc I p). 
might be involved in SUMO- I conjugation rather then ubiquitination (Saitoh et al., 
1997). Here we demonstrate that this is indeed the case as Ubch9 can form a 
thioester with SUMO-1 (Figures 8 and 9) provided that a SUMO-1 activating 
enzyme is present. It seems likely that SUMO-1 conjugation is carried out by a 
series of transacetylation reactions that is similar but distinct from the ubiquitination 
pathway. Others have reported an interaction between Ubch9 and I'KB(X in yeast 
(Tashiro et al., 1997) and interpreted this as an involvement in I-KB0C ubiquitination 
and degradation. Given the inability of Ubch9 to conjugate ubiquitin in vitro it 
seems unlikely that Ubc9 is involved in I-KB(x degradation, but a role for SUMO-1 
modification in other aspects of IKBoc metabolism, such as nuclear import 
(Arenzana-Seisdedos et al., 1995) can not be ruled out. 
A remaining puzzle is why Ubc9 is isolated from yeast two hybrid screens 
by such a wide variety of proteins. One possible explanation is that "bait" proteins 
are modified by SUMO-1 in yeast and it is the association between SUMO-1 and 
Ubc9 that mediates the apparent interaction between. Ubc9 and bait proteins. 
However, Ubch9 possesses a distinct electrostatic potential distribuition that may 
provide another explanation to its remarkable ability to interact with other proteins 
(Figure 11). Since Ubch9 can recognise a wide range of substrate proteins, 
adjustments of its conformation may also be required to fit a range of different 
contact surfaces. Thus, the substrate binding site on Ubch9 is likely to have high 
conformational flexibility. The flexible regions of Ubch9 are localised at the N- and 
C-terininus (Liu et al., 1999) which are located at opposite sides of the active site 
Cys93. The region near the N-terminus of Arabidopsis UBCI has been shown to 
interact with EI -ubiquitin conjugate (Sullivan and Vierstra, 199 1). The five residue 
insertion of Ubch9 which forms a flexible loop close to the N-terminal helix may be 
important for the ability of Ubch9 to discriminate between ubiquitin-like proteins 
and/or may participate in interactions with the SUMO-1 activating enzyme. The 
region near the C-terminus, which has a positive electrostatic potential may be 
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important for substrate binding and catalytic activity given the proximity to the 
active site Cys93. 
77 
3.2. Identification of the Enzyme required for Activation 
of the Small Ubiquitin-like modifier SUMO-I 
78 
3.2.1. Summary 
SUMO-1 and Smt3p, a yeast homologue of SUMO-1, are conjugated to 
target proteins by a pathway that is distinct from, but analogous to, ubiquitin 
conjugation. A separate El-like enzyme is responsible for SUMO-1 modification 
(Desterro et al., 1997) and in yeast the enzyme responsible for Smt3p activation has 
been shown to consist of a heterodirner of Uba2p and Aos1p (Johnson et al., 
1997). We have purified by affinity chromatography the SUMO-1 activating 
enzyme from human cells and shown that it contains two subunits of 38 and 72 
kDa. Isolation of cDNAs for each subunit indicates that they are homologous to 
ubiquitin activating enzymes and to the Saccharomyces cerevisiae enzymes 
responsible for conjugation of Smt3p and Rub-1p. In vitro, recombinant 
SAEl/SAE2 (SUMO-1 Activating Enzyme) was capable of catalysing the ATP 
dependent formation of a thioester linkage between SUMO-1 and SAE2. Addition 
of the SUMO-1 conjugating enzyme Ubch9 results in efficient transfer of the 
thioester linked SUMO- I from SAE2 to Ubch9. Thus, SAEl/SAE2 is the enzyme 
responsible for the activation of the small ubiquitin modifier SUMO- 1. 
Identification of the human SAE should allow a more detailed 
characterisation of the SUMO-1 conjugating pathway. 
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3.2.2. Purification of SUMO-1 activating enzyme 
The purification procedure for the SUMO-1 activating enzyme (SAE) used 
an affinity procedure previously described (Ciechanover et a/., 1982); (Hershko et 
al., 1983), for isolation of ubiquitin activating enzymes, based on covalent binding 
of the enzyme to ubiquitin Sepharose beads in the presence of ATP. FrIIA 
containing SUMO-1 activating activity from HeLa cells (Figure 8) (Desterro et al., 
1997) was thus applied to SUMO-1 Sepharose beads in the presence of ATP and 
inorganic pyrophosphatase, to suppress the reverse reaction. Under these 
conditions SAE activates the immobilised SUMO-1 forming a thioester bond which 
retains the SAE on the column. The affinity column was washed sequentially with 
buffers containing ATP, IM KCI, Tris buffer alone and AMP + pyrophosphate. 
Column eluates were assayed for their ability to fon-n a thioester with "'I-SUMO- I 
(Figure 12). SAE activity was detected in the column load and was substantially 
reduced in the column flow through, indicating that the activity was bound to the 
column (Figure 12A). The bulk of the SAE activity was eluted with AMP and 
pyrophosphate, which reverses the activation reaction (Figure 12A). Eluates were 
fractionated by SIDS PAGE and proteins detected by staining with Coomassie 
Brilliant Blue. Two polypeptide species with apparent molecular weights of 40,000 
and 90,000 were detected in the AMP eluate, in addition to BSA which was added 
to the fractions to prevent non-specific adsorption to surfaces during concentration 
(Figure 12B). 
3.2.3. cDNA cloning of human SUMO-I activating enzyme 
Proteins present in the AMP eluate were fractionated by SDS PAGE, 
transferred to PVDF membrane and the location of bound species detected by 
Amido Black staining. Both the 90 kDa and 40 kDa species were excised and 
subjected to direct N-terminal sequencing. Although the N-terminus of the 90 kDa 
species appeared to be blocked a unique sequence was obtained from the N- 
terminus of the 40 kDa species. To obtain sequence from the 90 kDa species and 
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Figure 12. Purification of SUMO-1 Activating Enzyme by SUMO-I covalent affinity chroma- 
tography. 
HeLa cell extracts were initially fractionated on aQ Sepharose column. FrIIA containing SAE activ- 
ity, was supplemented with ATP and inorgat& pyrophosphatase and fractionated on a SUMO GG -1 
Hi-trap column. (A) Equivalent amounts of SUMO- I column load (Fr 11.4, lane 1,2), flow-through 
(F/T lane 3,4) and AMP eluate (lane 5,6) were assayed for the ability to form thioester adducts with 
1251_SUMO_ I either alone (-) or in the presence of recombinant Ubch9. After 10 min at 30')C reac- 
tions were stopped and products subjected to SDS-PAGE (12.5%) under non reducing conditions. 
Dried gels were analysed by phosphorimaging. The positions of 1251_SUMO_ I and thioester adducts 
with SAE and Ubch9 are indicated. (B) Fractions indicated in A were fractionated by SDS-PAGE 
(10%) and stained with Coomassie blue. Prior to concentration the AMP eluate was supplemented 
with BSA which was also loaded on lane 6 as a control. The molecular weight of protein markers (M) 
and SAE components are indicated. 
additional sequence from the 40 kDa species, peptides generated by ill-gel trypsin 
digestion were fractionated by microbore HPLC. Unambiguous sequence was 
obtained from three 40 kDa, and eight 90 kDa derived peptides (Figure 13, 
underlined sequences). BLAST searching of the EST public database allowed the 
identification of ATCC clones which were used, in combination with RT-PCR, to 
construct full length cDNAs for each species. The 40 kDa species was designated as 
SAEI and has a predicted molecular weight of 38 kDa while the 90 KDa species 
was designated as SAE2 and has a predicted molecular weight of 72 kDa (Figure 
13). 
Amino acid sequence alignments of different EIs demonstrate that SAE is 
similar to Smt3p (Aoslp/Uba2p) and Rublp (Ulalp/Uba3p) activating enzymes 
(Johnson et al., 1997)(Liakopoulos et al., 1998). Although SAEI displays 
significant similarities to the N-terrninus of human and Saccharomyces cerevisae 
Ubal, the SAE2 protein contains the putative active-Cys (Cys 173) and is 
homologous to the C-terminus of Ubal. The apparent molecular mass of the 1251_ 
SUMO-SAE thioester conjugate of 100 kDa (Figure 12) confirms the presence of 
the active-site cysteine in SAE2. Most of the sequence similarity (Figure 14) is 
concentrated in a limited number of previously identified domains (Liakopoulos et 
al., 1998) (Johnson et al., 1997). 
3.2.4. SUMO-1 is activated by an El-like enzyme 
containing two subunits 
cDNA corresponding to SAE I and SAE2 obtained by RT-PCR was cloned 
into a eukaryotic expression vector permitting proteins to be produced and "S- 
labelled by coupled in vitro transcription and translation (Figure 15A). SAEI was 
fused at the N-terminus to an epitope from Simian virus 5 that is recognised by the 
previously characterised (SV5 Pk Tag, 336) monoclonal antibody (Hanke et al., 
1992). Although SAEI and SAE2 copurified in equimolar amounts (Figure 12B) 
during SUMO-1 affinity chromatography it was not clear that they were associated. 
81 
C) CD CD [-- CD CD C) C: ) CD CD C) 
kýD ; zfi (N zzji CD w (, q CD 00 k'D T 
00 1--1 C\l (111) cr) 00 --1 (Y) zzT -ý' U-) w 
CD F-, 0 ý- Ol CD > W E-A f2ý k-ý w n co 0 ýi4 n (n 0c) U) >-' U) r: ý > 9 ý-ý 
Ký > 
PQ 
r L 
114 ý4 H 
w 
ol Q 
- 4 
ýr4 F14 
&A ý4 01 ý4 w w 
> H 9 
CD U) CD 
1-- 0 E--i Q P-4 > fý) 0' 
4 04 Ol cf) 
E--l a a H -I ý14 P-L4 E--l W <1 
> (n 
C) CA 0 
U) 
a 
CY 
E--' ý4 4 
ýo Pý 
(ý 
cn ý4 ý4 
C CL 
c: v, 
1 
H 
Q CL4 U O 4 
41 
4 
P DL4 
124 W Qý 
FZ4 E-' n W Co 
H 4 r14 E-' < 0 ý4 P 
CD W ý4 n C) n V. ol > 
Ln F: 
ý w Ln 4 C) f: ) U) w U) 
0 ý4 P4 P-4 (D Q4 P-1 
4 M > 
Ol W-0 4 EA E-1 C14 cn 0 114 w co 
ý: ) 
:: 4 
r--) 
1-1 
> 
> U) H -q, ý14 
m CD f14 104 
CD (21 4 
i 
0 > 
0 04 j p Pý 
] 
4 
ý4 ý-l 
PI 4 Ol M 
cn F-ý 
> F14 ý4 M 04 F-ý M 
ý-l C4 E-1 
04 Pý f2l 
CY 
4 
ý4 
ý 
> f:: ) co w 
C) E-1 P 44 F114 
C1 H Ol 4 
CD > CD U H > 0 > 
11 
ý 
(y) ýL4 04 ýLA H 
>1 Ol Q ý4 W ý4 > 
rZ4 
ý-l ý4 ý4 
04 ý14 u >A n Pý 
04 N 0 W ýii nq 
Ol ý-l f< 
ý 
C14 C: ) ý14 CY 
Pý ýý > F-I W ýý 
w F-) w a F: ý 
C: D Q 0 ýý Q > c) > n co ý41 9 ý4 F: ý E--' U) H N 04 a4 F141 0 ý4 w m 
m 0 P 121 i--ý r E--i w P U) W W C14 
- 
ýE: ,4 
H 0 121 w C -) Co H W 
4 
a > 12ý 
114 CD DQ 
w m 
(j) 9 ý11 n Q 
C1 2 
m 
1 H E-1 ý14 4 
1 4 
CD U Pý F4 C) > 4 t F-)l H Cf) 0 p rL4 4-1 fo: ý H &j ýH ý-l ý4 
CD ý4 f24 1: ý CD P 0 
> D a 6-, Pi 
R 
W 
H 
U 
ý4 
Fq 
H 
w U) C14 
C 
w P > 
04 ý4 U) H 
a r14 U) X Fý, ý4 ý4 
12L4 Prý C14 ý3: w P-ý 
D 
ý-] 
n C 
U 
W 
ý4 
44 
4 
C 
w 01 >', FT4 r4 
H H H ýl r-I H H 
00 k. 0 "Zil cq 00 ý. o (lq C) 00 ý-o 
r-ý cq ry) N rn '14 , zJ' LO 
CID 
0 
Ic 
cn 
(D 
4- 
-C 
-Cý Con W 
C-. ýr, 
C/) C: 
U 
03 
CIO 
ct3 
ct 
CIO 
u 
CA 
Cys632 
hUbal 
54-197 361-4-38 450-606 608-664 826-913 1058 
Cys60 
S. c. Ubal I ýý Irl'. 11 
II IV I 
18-162 322-403 416-574 576-632 798-885 1024 
SNIT3 
Aoslp -"i Cy 
I 
sl77 
Uba2p 
15-161 266-347 
1 IV 
3-151 153-209 303-395 636 
RUB1 
UILAI 
4-148 381-462 
Cy 
I 
s16 
UBA3 I 1=] 
4-138 200-276 299 
143-199 
sumo SAEI sm Cy 
I 
s173 
SAE2 
18-164 263-347 111 iv 
9-147 641 
Figure 14. SAEI/SAE2 sequence analysis. 
Schematic representation of homologous domains in human ubiquitin El enzyme, hUbal (Handley et al., 1991); 
S. cerevisiae ubiquitin El, S. c. Ubalp (McGrath et al., 1991); S. cerevisiae Smt3p activating enzyme, Aoslp 
(Johnson et al., 1997) and Uba2p (Dohmen et al., 1995); RUB I activating enzyme, Ula Ip and Uba3p (Liakopoulos 
et al., 1998) and SUMO-1 activating enzyme, SAEI and SAE2. The domains shown correspond to those of 
Johnson et al. ( 1997). 
To obtain direct evidence for such an interaction different mixtures of "S-labelled in 
vitro transcribed translated proteins were immunoprecipitated with a specific (336) 
and a non-specific (214) monoclonal antibody. In presence of SV5 tagged SAE I, 
SAE2 was co-immunoprecipitated with anti-SV5 antibody (336). Labelled SAE2 
protein was not immunoprecipitated with either the control antibody (214) or when 
SAE2 was in i, itro transcribed translated in the absence of SAEl (Figure 15C). 
Confirmation of the interaction between SAEl and SAE2 was obtained when 
glutathione-S-transferase SAEl beads were used to pull down 35S-labelled in vitro 
transcribed translated SAE2. (Figure 15B). To determine the composition of the 
SAE complex, COS7 cell extracts co-transfected with SAE1 and SAE2 were 
analysed by gel filtration chromatography on a Superose 6TM, FPLC (Pharmacia 
Biotech). SAE1 and SAE2 co-eluted at approximately 130 KDa (data not shown) 
suggesting that the SUMO- I activating enzyme is a SAE I/SAE2 heterodimer 
To demonstrate that SAE I and SAE2 are required for SUMO- I activation in 
vitro, its ability to form a stable adduct with radioactively labelled SUMO-1 in an 
ATP-dependent reaction was tested. SAE proteins were either in vitro transcribed 
translated or expressed in transfected COS7 cells. In both situations, the activity 
was immunoprecipitated using anti-SV5 protein A beads. The ability of recombinant 
SAE to form a thioester with 
1251_SUMO_ I in presence of MgATP was analysed by 
SDS-PAGE under non-reducing conditions. This immunoprecipitated activity was 
capable of catalysing formation of a Ubch9-"'I-SUMO-1 thioester when 
recombinant Ubch9 was added to the reaction (Figure 16A and 16B). The linkages 
formed between SAE2 and 
1251_SUMO_l 
or Ubch9 and 
1251_SUMO_l 
were labile to 
reducing agents, such as DTT (Figure 16A), indicating that they are likely to be 
thioester bonds. Neither SAE I nor SAE2 alone were capable of forming a thioester 
complex with SUMO-1. Some activity is detected when SAE1 is 
immunoprecipitated from COS7 SAEl transfected extracts, probably due to 
endogenous SAE2 activity (Figure 16B). These results together suggest that the 
SUMO-I activating enzyme is composed of SAEl/SAE2. 
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Figure 15. Interaction of SAE1 with SAE2. 
(A) SV5 tagged SAE1 (lanel) and SAE2 (lane2) were either separately in vitro transcribed, translated 
JVTT) and labelled with "S-methionine or labelled cotranslationaly (lane 3). (B) Glutathione S-Trans- 
ferase (GST) or GST-SAE1 beads were used to pull down 35S-methionine labelled IVTT SAE2. After 
extensive washing bound proteins were analysed in a 10% SDS-PAGE and 35 S radioactivity in the 
dried gel detected by phosphorimaging. (C) 35S-methionine labelled fVTT SV5 tagged SAE1, SAE2 
or cotranslated SV5 tagged SAE1 and SAE2 were immunoprecipitated either with 336 anti-SV5 
monoclonal antibody or with an unrelated antibody (214). After extensive washing with 50 mM Tris 
HCl pH7.5,10 mM MgCl 2' 
0.5% NP40 immmunoprecipitates were analysed as described in panel B. 
The IVTT protein present and antibody used for the immunoprecipitation are shown for each reaction. 
35S -methionine labelled SAEl tag and SAIE2 proteins are indicated. 
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Figure 16. Both SAEI and SAE2 are required for SUMO-I activating activity. 
(A) IVT`T SV5 tagged SAE I or cotranslated SV5 tagged SAE I and SAE2 were incubated with 336 anti-SV5tag 
monoclonal antibody and immunoprecipited with protein A beads. The ability of these complexes to form a 
thioester bond with 1251_SUMO_l was tested either in absence (-) or presence of 0.6 ýtg of Ubch9- Samples treated 
with 100 mM DTT before SDS-PAGE fractionation are indicated (+DTT). (B) COS7 cells were either transfected 
with control pcDNA3, SV5 tagged SAEI, SAE2 or co-transfected with SV5 tagged SAEI and SAE2. After 36 
hours of expression cell extracts were prepared and immunoprecipitated with anti-336 SV5 monoclonal anti- 
body. Immunoprecipitates were assayed for the ability to form thioester adducts with 1251_SUMO_ I either alone 
(-) or in the presence of 0.6 ýtg of Ubch9. SUMO- I column AMPfraction was tested in the same thioester assay 
as a positive control. Reactions products were analysed as described in the legend to Figure 12A. 
3.2.5. Discussion 
Targeting of proteins for ubiquitin mediated proteolysis is an irrevocable 
decision and as such the process needs to be highly specific and tightly regulated. 
This specificity appears to be accomplished by a combination of E2 ubiquitin 
conjugating enzymes and E3 ubiquitin protein ligases. In many cases the E3 appears 
to consist of a multiprotein complex that recognises the substrate and brings it in to 
intimate contact with the E2 which catalyses addition of ubiquitin to the substrate. 
As the E I, ubiquitin activating enzyme is unique it does not appear to play a role in 
selecting protein substrates for ubiquitination. However, ubiquitin co-exists with a 
number of ubiquitin-like molecules and the El enzymes must distinguish between 
these molecules. As distinct El activities have been described for ubiquitin 
(Handley et al., 1991), Smt3p (Johnson et al., 1997) and Rub lp (Larnmer et al., 
1998; Liakopoulos et al., 1998) we undertook the isolation and characterisation of 
the SUMO- I activating enzyme (SAE). 
By taking advantage of the mechanism of ubiquitin activating and 
conjugating enzymes, which involves formation of a thioester intermediate with 
ubiquitin, we have used SUMO-I affinity chromatography to isolate a novel 
enzyme that catalyses the ATP-dependent activation of SUMO-1, the first step in the 
conjugation pathway. Furthermore this enzyme could also transfer activated 
SUMO-I to Ubch9, the conjugating enzyme involved in this process (Desterro et 
al., 1997; Johnson and Blobel, 1997; Saitoh et al., 1998; Schwarz et al., 1998) 
(Figure 16). Although the El activity for ubiquitin is contained within a single large 
polypeptide the EI activity of SUMO- 1,1 ike that of Smt3p and Rub Ip is partitioned 
between two smaller polypeptides, SAEl and SAE2. Sequence comparisons 
between the El enzymes indicates that SAEl is homologous to Aoslp, Ulalp and 
the N-terminus of the ubiquitin activating enzymes (Figure 14) while SAE2 is 
homologous to Uba2p, Uba3p and the C-tenninus of the ubiquitin activating 
enzymes. The association between SAEI and SAE2, confirmed by 
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immunoprecipitations and GST pull downs (Figure 15), brings together conserved 
domains present in each subunit. As purified SAE contains equirnolar amounts of 
SAEI and SAE2 and the two proteins associate in vitro it is probable that, like the 
Smt3p E 1, the activating enzyme is a heterodimer. The heterodimeric nature of SAE 
was confirmed by gel filtration. Each SAE subunit contains a conserved nucleotide 
binding motif, GXGXXG, (positions 24-29 in SAE2 and positions 43-48 in SAE I, 
Domain 1, figure 14). The putative cysteine (Cys 173) which forms a thioester bond 
with the C-terminal glycine of SUMO- I is in an active site consensus sequence 
(KXXPZCTXXXXP) found in conserved domain 111. Conserved domain 11 is 
present in SAE1, while conserved domain IV is found in SAE2. The function of 
conserved domains 11 and IV has yet to be detenrnined. The C-terrninal extension of 
SAE2 contains a region that matches with two consensus sequences for nuclear 
localisation signals (RKRK, 610-613 and RKRKLDEKENLSAKRSR, 610-626) 
which are also present in the C-ten-ninal region of Uba2p (Dohmen et al., 1995). 
Within the cell it appears that virtually all of the SUMO-1 is present in 
protein conjugates and there is a very low concentration of free SUMO- I (Matunis et 
al., 1996). Thus it is likely that the availability of free SUMO-I is tightly controlled 
by a dynamic equilibrium between SAE/TJbc9 mediated conjugation of SUMO-I 
and deconjugation mediated by the highly active, but as yet uncharacterised, 
SUMO-I deconjugating and processing enzymes. However the cellular signals 
which regulate this process have yet to be defined. 
The large number of ubiquitin-specific proteases (UBP) and ubiquitin C- 
terminal hydrolases (UCH) already identified(Wilkinson, 1997) suggest that they 
may be involved in the recognition of different types of ubiquitin conjugates 
but 
little is known about their biological roles. It is likely that some of the known UBPs 
and UCHs will be responsible for processing of ubiquitin like proteins. UCH-1-3, a 
putative ubiquitin C-terminal hydrolase, was recently identify as a 
NEDD8 
(Kamitani et al., 1997a) interacting protein and able to cleave the C-terminus of 
NEDD8 but the same did not bind to sentrin- 1, sentrin-2 or sentrin-3 (Wada et al., 
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1998). The first ubiquitin-like specific protease, Ulp I, was very recently identified 
in yeast and able to cleave proteins from Smt3 and SUMO- I but not from ubiquitin. 
This novel protease is unrelated to any known deubiquitinating enzymes and is 
required for cell-cycle progression in yeast (Li and Hochstrasser, 1999). 
The availability of the genes for the SUMO-1 activating and conjugating 
enzymes SAEl/2 and Ubc9 will facilitate further biochemical and cell biological 
studies aimed at defining the role of these proteins in vivo. 
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3.3. SUMO-1 Modification of IwBu inhibits NF--KB 
activation. 
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3.3.1. Summary 
Activation of NF-kB is achieved by ubiquitination and proteasome mediated 
degradation of IKB(x. As we had previously isolated Ubch9 as an IKB(x interacting 
protein in a yeast two hybrid screen we searched for physiological situations in 
which IKB(x is modified by SUMO- 1. In a number of cell types IKBcc is modified 
by SUMO-1 to a form that is resistant to TNFa induced degradation. SUMO-1 
modified I-KB(x remains associated with NF--KB. In the presence of SUMO-1 
activating enzyme, Ubch9 and ATP SUMO-1 was efficiently conjugated to I-KBu. 
primarily on K2 1, which is also utilised for ubiquitin modification. Thus SUMO- I 
modified I-KBu. cannot be ubiquitinated and is resistant to proteasome, mediated 
degradation. As a result overexpression of SUMO-I inhibits signal induced 
activation of NF-KB dependent transcription. Unlike ubiquitin modification, which 
requires phosphorylation of S32 and S36, SUMO-1 modification of I-KBa is 
inhibited by phosphorylation. Thus, while ubiquitination targets proteins for rapid 
degradation, SUMO-1 modification creates a privileged pool of IKBo( that is 
resistant to signal induced degradation. 
In vitro reconstitution of the conjugation reaction with recombinant purified 
proteins revealed that in the presence of SUMO-I activating enzyme, Ubch9 was 
capable of directly transferring SUMO-1 onto IKB(x. Thus, it appears that SUMO-I 
conjugation of I-KB (x in vitro does not require the equivalent of an E3 ubiquitin 
protein ligase. 
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3.3.2. Detection of a modified form of IKB (x resistant to 
signal induced degradation 
As described in the first chapter, a yeast two-hybrid screen, using the N- 
terminus of I-KB(x as "bait", indicated a strong and highly specific interaction 
between I. KBa and Ubch9. Although Ubch9 is homologous to ubiquitin 
conjugating enzymes the substrate for this enzyme is not ubiquitin but SUMO-1 
(Desterro et al., 1997). While ubiquitinated IKB(x can be detected in the presence of 
proteasome inhibitors there have been no reports of SUMO-1 modified I'KBu,. A 
number of cell lines were therefore surveyed for the presence of a more slowly 
migrating form of I-KBot that would be consistent with SUMO-I modification. 
Western blotting of cell extracts prepared using standard NP40 lysis procedures 
failed to show any SUMO-1 modified IKB(x (Figure 17A). However it had been 
reported that SUMO-I modification of RanGAPI and PML (Mahajan et al., 1997; 
Matunis et al., 1996; Muller et al., 1998) was rather labile and the cells were 
therefore lysed directly in SDS before analysis by Western blotting. In this instance 
a more slowly Migrating form Of IKB(x consistent with SUMO-1 modification 
(IKB(x*) was detected in substantial amounts in 293, COS7 and HeLa cells with 
smaller amounts in Jurkat cells (Figure 17A). To rule out the possibility that the 
more slowly migrating form of I-KB(x detected in Figure 17A was a peculiarity of 
the antibody preparation another well characterised IxBu antibody raised against 
recombinant I-KBu (Arenzana-Seisdedos et al., 1995; Mellits et al., 1993) was also 
employed. COS7,293 and Jurkat cells revealed the same slowly migrating species 
(I-KB(x*) when Western blot analysis was conducted with the antibody to 
recombinant IKBa (Figure 17B). As SUMO-1 modified proteins do not appear to 
be targets for proteasome mediated degradation the fate of the modified form of 
I-KB(x was determined after treatment of 293 cells with TNF(x. Prior to activation 
NF-KB is held in the cytoplasm by the inhibitor protein IKB(x but exposure of cells 
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Figure 17. A modified form of IKB(x, present in different cell lines, is resistant to 
signal induced degradation. 
(A) Extracts (20 ýtg protein) of different cell lines prepared either by standard NP40 lysis 
or by direct lysis in SDS buffer, were fractionated by SDS-PAGE and IKBCC protein ana- 
lysed by Western blotting using the IKB(x antibody C21. (B) Extracts lysed in SDS were 
analysed as inAusing a rabbit polyclonal anti- IKBu antibody. (C) 293 cells were exposed 
to 10 ng/ml of TNRx for the indicated times. Extracts were lysed in SDS, separated by 
SDS-PAGE and proteins analysed by Western blotting using the C21 antibody. Positions 
of prestained. molecular weight markers, IKBct and the modified forrn of the protein (IKB(X*) 
are indicated. 
to TNF(x activates NF-KB by signal induced ubiquitination and proteasome 
mediated degradation of IxBa. Western blotting of SDS isolates of 293 cells 
reveals that while the unmodified form of IKB(x undergoes signal induced 
phosphorylation and degradation as expected, the modified form of I-KB(x appears 
to be resistant to TNF induced degradation as its level is unchanged over the time 
course of the experiment (Figure 17C). 
3.3.3. SUMO-1 is conjugated to IKBoc in vivo 
To demonstrate directly that I-KB(x was conjugated to SUMO-1, SDS cell 
lysates were immunoprecipitated with the antibody raised against recombinant IKB(x 
and associated proteins analysed by Western blotting with the SUMO-1 specific 
mouse mAb 21C7 (Matunis et al., 1996). In HeLa, Jurkat, COS7 and 293 cells 
IKBa antibodies immunoprecipitated a polypeptide of about 55 kD, recognised by 
the SUMO- I -specific mAb, that is consistent with addition of a single molecule of 
SUMO-1 to I'KBa. A more slowly n-iigrating immunoreactive species was also 
detected with the SUMO-1 specific mAb. This species remains unidentified, and 
failed to react with antibodies to NF-KB family members (data not shown). Under 
identical conditions no SUMO- I reactive species were immunoprecipitated with the 
preimmune serum (Figure 18A). 
To confirm these findings pcDNA3 expression plasmids containing cDNAs 
for HA tagged SUMO-1, IKBu. -ctag (Rodriguez et al., 1995) and Ubch9 were 
transfected in various combinations into COS7 cells and SDS lysates prepared as 
described. To monitor expression of HA-SUMO-1 a fraction of the lysate was 
analysed by Western blotting using the HA-specific mAb 12CA5. When HA- 
SUMO-1 alone is exogenously expressed a substantial amount of unconjugated 
protein is detected along with a series of higher molecular weight species that 
presumably represent conjugation to a range of polypeptides (Figure 18B). When 
IKB(x-ctag is cotransfected less free HA-SUMO-I is detected and this amount is 
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further reduced by the additional presence of plasmid expressing Ubch9 (Figure 
18B). To detect IKB(x-SUMO-1 conjugates SDS cell lysates were subjected to 
immunoprecipitation with IKB(x antibodies and the associated proteins analysed by 
Western blotting using either antibodies to HA, ctag or SUMO-1. When IKB(x-ctag 
and HA-SUMO-1 are cotransfected, either in the presence or absence of Ubch9, 
conjugates between IKB(x-ctag and SUMO-I are detected using antibodies specific 
for HA (Figure I SQ, SUMO- I (Figure 18D) or ctag (SV5 PKtag) (Figure 18E). 
Thus SUMO-1 modification of I-KBa is detected on endogenous, as well as 
exogenously expressed, proteins. 
3.3.4 SUMO-1 expression inhibits NF-KB dependent 
transcription 
As it was demonstrated that SUMO-1-modified IKB(x was resistant to 
signal-induced degradation and that exogenously supplied SUMO-I could be 
conjugated to IKIB a, it was of interest to determine the effect of expressed SUMO- I 
on signal induced activation of NF-KB. To measure NF-KB activation an NF-KB 
dependent luciferase reporter (3enhConALuc) (Rodriguez et al., 1996) was 
cotransfected into COS7 cells along with expression plasmids for SUMO- 1, Ubch9 
or IKB(x and reporter activity measured after treatment of the cells with the NF-KB 
activators TNF(x, IL- IP or okadaic acid. When the empty vector is cotransfected 
with the KB reporter substantial transcriptional activation is obtained with TNF (9.8 
fold), IL-I (98 fold) and okadaic acid (85 fold). As expected cotransfection of the 
reporter with a plasmid expressing IKB(x reduced TNF, IL-1 and okadaic acid 
induced activation. When the reporter was cotransfected with a plasmid expressing 
SUMO- 1, or the SUMO- I conjugating enzyme Ubch9 the extent of activation was 
also reduced with TNF, IL- 1, and okadaic acid. Cotransfection of the reporter 
plasmid with combinations of plasmids expressing I-KB(x, SUMO-1 and Ubch9 
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demonstrated a more complete inhibition of transcriptional activation than either 
plasmid alone. Thus the combination of I-KBcc and SUMO-1 expression results in 
an 80% inhibition of TNF induced transcriptional activation whereas expression of 
either I'KBa or SUMO-1 alone only gives about 50% inhibition. Reporter activity 
from a plasmid lacking NF-KB binding sites (conALuc) was not increased by TNF, 
IL-I or okadaic acid and the basal level of reporter activity was unchanged by 
exogenous expression Of IKB(x, SUMO-1 or Ubch9 (data not shown). To 
investigate the specificity of the SUMO-I mediated inhibition of NF-'KB dependent 
transcription an alternative reporter plasmid and an expression plasn-tid for ubiquitin 
were employed. While activation of the HIV-LTR by TNF and IL- I is almost 
entirely dependent on NF-KB, activation of the HIV-LTR by okadaic acid has both 
NF-KB dependent and independent components. Thus AYBHIVLTR can still be 
activated by okadaic acid (Vlach et al., 1995). Like the 3enhConALuc reporter the 
HIV LTR is activated by TNF (12 fold), IIL-I (35 fold) and okadaic acid (I I fold) 
and the activation is reduced by cotransfection of plasmids expressing I-KBa or 
SUMO-1. Cotransfection of a plasrnid expressing ubiquitin has little inhibitory 
effect. Cotransfection of the combination Of IKBoc and SUMO-I substantially 
inhibits transcriptional activation mediated by TNF, IL-1 or okadaic acid whereas 
cotransfection of both IKBoc and ubiquitin expression plasmids has a relatively 
minor effect on transcriptional activity. The AKBHIVLTR reporter was activated by 
neither TNF nor IIL- 1 but was activated approximately 3 fold by okadaic acid. Co- 
transfection of the AKBHIVLTR reporter with IKB(x, SUMO-1, ubiquitin or 
combinations of I-KBcc and SUMO-1 or IKB(x and ubiquitin had no substantial 
effect on basal activity and did not influence the Y'B independent okadaic acid 
induced activation of the reporter (Figure 19). Thus SUMO- I appears to specifically 
inhibit NF-KB dependent transcriptional activation. 
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3.3.5. Requirements for SUMO-1 conjugation to IwBa in 
vitro 
To investigate the biochemical requirements for SUMO-I modification of 
I-KBa an in vitro system which could accurately recapitulate the in vivo 
phenomenon, was developed . 
35S-Met-labelled IKBu generated by in vitro 
translation was used as substrate in the presence of recombinant SUMO-1, 
recombinant Ubch 9 and a fraction from HeLa cells containing SAE activity (Fr. 
11.4) (Desterro et al., 1997). SUMO- I modification of I-KBcc required the presence 
of each of these components and was dependent on the addition of ATP (Figure 
20). Other HeLa fractions such as 11.1 failed to substitute for fractions 11.4 and 
SUMO-I was only fully active if it was truncated by four arruno acids at the C- 
terminus to expose G97. In fact some conjugation activity was observed with the 
full length SUMO- 1, but it is thought that this is due to the presence of a SUMO- I 
C-terminal hydrolase in the column fractions which cleaves the C-terminus of 
SUMO-1 after G97 to generate the active form of the protein (Figure 20). 
3.3.6 Identification of lysine residues in IKB (x that are 
conjugated to SUMO-1 
Prior to signal induced degradation, I-KB(x is ubiquitinated on residues K21 
and K22 and to a lesser extent on residue K38 and K47 (Baldi et al., 1996; 
Rodriguez et al., 1995; Scherer et al., 1995). To determine the sites at which I-KB(x 
is modified by SUMO- I the previously described (Rodriguez et al., 1996) series of 
molecules containing K to R changes in I-KB(x was employed . 
35S labelled I-KB a 
proteins were incubated in vitro under conditions which permit SUMO-1 
modification of IlcB(x. The K21R mutant of ficBoc is severely compromised as a 
substrate for SUMO-I modification in vitro, while this is less so for the K22R 
mutant. When both lysines are changed to arginine (K21R, K22R) SUMO-1 
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Figure 20. Requirements for SUMO-I conjugation of IKBcc in vitro. 
In vitro expressed IKBa 256 (aa 1-256) labelled with 35S -methionine, was incubated at 37'C 
for 2 hours in a reaction mix containing an ATP regenerating system and in presence (+) or 
absence (-) of different components as indicated in the figure. Reactions products were 
fractionated by SDS-PAGE and the dried gel analysed by phosphorimaging. The positions 
of IKBa, the phosphorylated form of lKB(x (IKB(x-P) and IKBot-SUMO are indicated. 
35 S-IKBct W/T 
Assay mix - 
K21R K22R 
+ 
K21,22R 
Imp- '.. - - --j 
ýý 400 qMW 000 4000 ýý 1800 
. 49ýý djjoýý 4EMONOM 
Figure 21. Identification of lysine residues in IKBa that are conjugated to SUMO-1 
In vitro expressed IKBcc (WT, K2 I R, K22R and K21,22R) labelled with "S-methionine were incu- 
bated in an assay mix containing an ATP regenerating system, recombinant p65, Ubch9, SUMO,, 
and HeLa MIA containing SUMO El activity for 2 hours at 370C. Reactions products were 
fractionated by SDS PAGE and the dried gel analysed by phosphorimaging. 
modification is abolished (Figure 21). Thus the major site of SUMO-1 modification 
is K2 1, which is also used to conjugate ubiquitin. 
3.3.7. Role of IKBoc phosphorylation in SUMO-I 
modification 
As ubiquitination of I-KB(x is dependent on signal induced phosphorylation 
of S32 and S36 we investigated the role of these residues in SUMO-1 modification. 
Previously described mutants in IKB(x where these serine residues were changed to 
either alanine, aspartic acid or glutamic acid (Rodriguez et al., 1996; Roff et al., 
1996) were labelled with 
35 S methionine and tested for their ability to be modified 
by SUMO-I in vitro. The S32A, S36A mutant of IKBcc that is resistant to signal 
induced phosphorylation is efficiently modified by SUMO-1 as is the S32D, S36D 
mutant. However, SUMO-1 modification of the S32E, S36E mutant, which most 
closely numics phosphorylated I-KB(x, is severely compromised, suggesting that 
phosphorylation of I-KBa on S32 and S36 is inhibitory for SUMO-1 modification 
(Figure 22A). To demonstrate that phosphorylated IKBa is not a substrate for 
SUMO-1 modification residues 1-70 of IKB(x fused to GST (GST- IKB(xN) were 
phosphorylated in vitro with purified IKB kinase (Regnier et al., 1997) in the 
presence of 7-32 P ATP . 
32 P GST- IKBuN was recovered and tested for its ability to 
act as a substrate for SUMO-1 conjugation in vitro. Under conditions where 
unlabelled GST- IrBaN is efficiently conjugated to SUMO-I (data not shown) the 
labelled material was not conjugated to 
SUMO_I. 35S labelled unphosphorylated 
IkBU256 was efficiently modified in the same assay (Figure 22B). 
In vivo the C-terminus of I-KB(x is required for signal induced degradation 
and is phosphorylated by CKII. A mutant of I-KBa containing amino acids 1-256 
which is resistant to signal induced degradation (Kroll et al., 1997) was efficiently 
modified by SUMO-1 in vitro, indicating that the C-terminal region of the protein 
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Figure 22. Role Of IKBa phosphorylation in SUNIO-1 modification. 
(A) In vitro expressed and "S-methionine labelled wild type IKBcc (W/T) and mutants (256; 
S32,36A; S32,361); S32,36E) were assayed for SUMO-I conjugation in vitro as described in the 
legend of Figure 21. Assays Of IKBcc WT and 256 were conducted either in the presence (+) or 
absence (-) of recombinant p65. (B) The N-terminus Of IKBcc (1-70) fused to GST (GST- IKBcLN) 
was phosphorylated in vitro with purified IKB kinase in the presence of y32PATP. I'S Met labelled 
in vitro expressed lKB(x 1-256 and 
32P labelled GST- IKBcc N were assayed for SUMO-I conjugation 
in vitro. 
(amino acids 257-317) is dispensable for SUMO-I modification (Figure 22A). The 
HeLa extract used in these assays is capable of phosphorylating I-KBa on S32 and 
S36 to a more slowly migrating species of IKB(x that is detected after incubation 
with wild type I"KBoc and IKBa 1-256 but not with S32A, S36A or S32D, S36D. 
Under these conditions wild tYpe IKBa, which undergoes phosphorylation in vitro, 
is a less efficient substrate for SUMO-1 modification than either I-KB(x S32A, S36A 
or S32D, S36D (Figure 22A). While most assays contained recombinant NF-KB 
p65, its omission was without consequence for SUMO-1 modification of IKBa 
(Figure 22A). 
3.3.8. SUMO-1 modification of IKB(x with purified 
proteins 
Although SUMO- I conjugation of I-KB a is dependent on Ubch9, ATP and 
FrHA (Figure 20) (Desterro et al., 1998), a complete description of the biochemical 
activities present in the HeLa cell fraction or in the in vitro transcribed translated 
substrate was lacking. The SAE was affinity purified from Fr. 11.4, as described in 
the second chapter, but by analogy with ubiquitin modification it is not clear if other 
activities, such as an E3 equivalent, would be required. In presence of recombinant, 
immunoprecipitated SAE, Ubch9 and ATP, 1251_SUMO_ I was efficiently 
conjugated to recombinant I-KBa (Figure 23A). This reaction was dependent on 
SAE, Ubch9, ATP and IxBa substrate (Figure 23B). The enzymatic properties of 
rSAE were identical to those of the protein isolated from HeLa FrII. 4. As SUMO- 1, 
Ubch9 and IKB(x are all homogeneous, recombinant proteins expressed in bacteria 
and the SAE is either highly purified (Figure 23B) or recombinant anti-SV5 
inimunoprecipitated (Figure 23A) it appears that SUMO-1 conjugation of I-KB(x in 
vitro does not require an equivalent E3 activity and that after SUMO- I being 
activated by SAE, the SUMO-I activating enzyme Ubch9 is capable of recognising, 
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then transferring SUMO-1 onto IKB(x. To demonstrate specificity in vitro two 
deleted forms of I-KB(x and GST were used as substrates in reactions also 
containing purified SAE, Ubch9 
1251_SUMO_ I and ATP. SUMO-I is efficiently 
conjugated to IKBa and I-KBuAC (lacks the C-terminal 61 amino acids) but is not 
conjugated to either AN I-KB(x (lacks the N-terminal 70 amino acids) or GST 
(Figure 23C). As the lysine involved in SUMO-I modification is present in wild 
type I-KBa and IKB(xAC, but absent in AN IKB(x this indicates that the purified 
conjugation system is displaying the expected specificity. 
If SUMO- I modified IKB(x blocks NF-KB activation then it is likely that 
SUMO- I modified IKB(x remains associated with NF-KB. To address this question 
directly I-KBa was conjugated to "'I-SUMO-1 in vitro and incubated with either a 
GST-NF--KB fusion protein (GST-p65) or GST alone. A control SUMO-1 
modification reaction which lacked ftcffix substrate was analysed in parallel. GST- 
p65 efficiently bound 
1151 
_SUMO_ 
I modified IK]3(x (Figure 24). This species was 
not bound by GST alone and was not present in reactions which did not contain 
I-KB(x substrate (Figure 24). Thus SUMO-1 modification does not interfere with the 
-11 ability of IKBa to interact with NF-KB. 
3.3.9. Discussion 
In uninduced cells the transcription factor NF-KB is held in an inactive state 
by its inhibitor IKIB oc. After exposure of cells to activators such as IL- 1P or TNF(x 
the I-KB(x inhibitor is marked by phosphorylation and targeted for degradation by 
site specific ubiquitination. A specific quantity of NF-KB is thus released for 
transcriptional activation. In any particular cell type the amount of active NF-KB 
released is therefore detemuned simply by the amount of NF-KB bound to inclucibly 
degradable forms of IKB . Here we 
demonstrate that IKB oc is modified by SUMO- I 
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Figure 24. IIII-SUMO -1 Conjugated IKBoL interacts with recombinant NF-KB p65. 
An in vitro "I SUMO-1 conjugation assay was set up as described in the presence of 
either recombinant GST or GST-p65 protein. After 2 hours incubation at 371C the reac- 
tion products were incubated with glutathione agarose beads for 10 minutes at room tem- 
perature. The beads were washed with PBS/O. I% Tween2O and bound proteins fractionated 
on a 12.5% acrylamide get and analysed by phosphorimaging. The position of lKB(x 
conjugated with 1251 S UMO_ I is indicated. 
(Figures 17 and 18) on lysine 2 1, which is also used for ubiquitin conjugation 
(Figure 2 1). Thus SUMO- I modified IKBoc cannot be ubiquitinated and is therefore 
resistant to proteasome mediated degradation. As SUMO- I modified IKBa remains 
bound to NF--KB (Figure 24), this creates a "privileged" pool of NF-KB/IKB(X- 
SUMO-I complexes that do not respond to signal induction (Figure 17C). As a 
consequence exogenous expression of SUMO-I has a strong inhibitory effect on 
NF--KB dependent transcription measured in reporter assays. The inhibitory effect 
of SUMO-1 appears to be specific to NF--KB dependent transcription as other 
promoters are not affected. As the amount of SUMO-1 modified I-KB(X appears to 
vary between different cell types this may provide a mechanism by which the cell 
can precisely regulate the quantity of NF-KB available for transcriptional activation. 
However, it is likely that SUMO-1 modification is controlled in a dynamic fashion 
with the overall level of SUMO- I -conjugated I-KB(x being determined by a balance 
between SUMO-I modification and hydrolysis of the IKB-SUMO-1 conjugates. 
The existence of hydrolases which cleave the bond between the C-terminus of 
SUMO-I and the lysine to which it is conjugated have been reported (Li and 
Hochstrasser, 1999; Mahajan et al., 1997; Matunis et al., 1996; Muller et al., 1998) 
and the activity of these enzymes is such that the detection of IKB(x-SUMO-1 
conjugates is difficult unless special precautions are taken to quickly inactivate these 
enzymes (Figure 17). Removal of the four C-terminal amino acids of SUMO-I is 
required to expose G97 (Figure 20) the carboxyl terminus of which is directly 
coupled to the F- amino group of lysine in the target protein (Mahajan et al., 1998). 
Western blot analysis of endogenous SUMO-I indicates that there are many cellular 
proteins that are conjugated to SUMO- 1, and as no free SUMO- I was detected this 
implies that virtually all of the endogenous SUMO-I is conjugated to proteins 
(Matunis et al., 1996) and data not shown. This is also the case in yeast where all of 
the SUMO-I hornologue Smt3p is present in conjugates (Johnson et al., 1997). 
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These data indicate that SUMO-1 is limiting, suggesting that SUMO-1 
deconjugation is required to release free SUMO- I for further modification. 
While SUMO-I modification of IKB(x can serve to block signal induced 
ubiquitination and thus degradation Of I'KB(x, SUMO-1 modification of RanGAPI 
serves to direct the modified protein to the nuclear pore complex (Mahajan et al., 
1997; Mahajan et al., 1998; Matunis and Blobel, 1997; Matums et al., 1996). 
SUMO-1 modification of RanGAPI creates, or exposes, a binding site for 
NUP358, a nucleoporin associated with the cytoplasmic fibres of the nuclear pore 
complex (Matunis et al., 1998). The only other reported substrates for SUMO-1 
modification are the nuclear dot (ND) associated proteins PML and SplOO and in 
this case SUMO-1 modification appears to regulate the subnuclear partitioning of 
these proteins (Muller et al., 1998; Sternsdorf et al., 1997). 
Although we have not shown that SUMO-1 modification alters the cellular 
location of 1-KB a one feature that the known SUMO- I substrates (RanGAP 1, PML, 
Sp1OO and I-KB(x) have in common is that they undergo regulated transport between 
the cytoplasm and the nucleus. Nuclear transport is required for IKBa to mediate 
post-induction repression of NF-KB dependent transcription (Arenzana-Seisdedos 
et al., 1995; Beg et al., 1995a; Cressman and Taub, 1993; Zabel et al., 1993). 
However mutation of K21 and K22 does not appear to affect the ability of IKB(X to 
accumulate in the cell nucleus (Zabel et al., 1993). Thus it is unlikely that SUMO- I 
modification has a major role in the nuclear import of IKB(x. 
Although targeting of protein for ubiquitination appears to be highly specific 
it is often the case that multiple lysine residues can act as acceptor sites with 
modification of either residue being sufficient to target the protein for degradation 
(Hou et al., 1994; King et al., 1996b). In contrast, SUMO- I modification appears 
to be highly specific. I-KB a appears to be modified by SUMO- I predominantly on 
K21 (Figure 21) while RanGAPI is conjugated to SUMO-1 solely via K526 
(Mahajan et al., 1998). To further investigate the enzymatic requirements of 
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the SUMO-1 conjugation reaction an in vitro system with recombinant components 
was developed. In the purified in vitro system SUMO-1 is efficiently conjugated to 
recombinant I-KBa in the presence of only the SAE and Ubch9. Thus under the 
conditions employed in this assay SUMO-1 conjugation does not require the 
presence an E3 protein ligase. However, we can not rule out the possibility that in 
14vo such proteins may increase the efficiency of the conjugation process. As our 
initial yeast two hybrid screen and protein affinity chromatography experiments 
utilising immobilised GST-Ubch9 (data not shown) demonstrated a protein-protein 
interaction between Ubch9 and IKB(x (Desterro et al., 1997), it is likely that 
substrate specificity is achieved by Ubch9. A diverse range of proteins have been 
shown to interact with Ubc9 in yeast two hybrid experiments and this may be a 
direct consequence of substrate recognition by Ubc9. Again it is not possible to rule 
out the participation of yeast proteins in these interactions. 
While signal induced ubiquitination of I-KB(x requires the phosphorylation of 
S32 and S36 this is not the case for SUMO-1 modification, as an S32A, S36A 
mutant is more efficiently conjugated to SUMO-1 than the wild type protein. In 
contrast an S32E, S36E mutant, which may mimic the phosphorylated protein, or 
IKBa phosphorylated in vitro on S32 and S36 are poor substrates for SUMO-1 
conjugation. Thus, SUMO-1 acts antagonistically to ubiquitination: while 
multiubiquitination of I-KB(x targets the protein for destruction, SUMO-1 
modification creates a pool of IKBa that is resistant to degradation. This function of 
SUMO is rather similar to that observed when mutations are introduced into 
ubiquitin in the lysine residues that are used for multiubiquitination. K29R and 
K48R mutants in ubiquitin generate proteins that can be conjugated to substrates but 
which cannot form multiubiquitin chains. As such the modified proteins are 
resisitant to degradation (Johnson et al., 1995). Although only a few substrates for 
SUMO-1 modification have been identified it is evident that many cellular proteins 
are modified in such a fashion. The balance between ubiquitination and this newly 
98 
described activity of SUMO- I may be a general mechanism for controlling the level 
of critical proteins within the cell. 
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3.4. SUMO-I modification activates the transcriptional 
activity of p53 
100 
3.4-1. Summary 
The p53 tumour suppressor plays a significant part in the response of the 
cell to genotoxic damage. The important role of p53 in maintenance of genome 
integrity is illustrated by the loss of p53 function in most human tumours (Harris 
and Hollstem, 1993) and the high rate of tumour development in p53 knockout mice 
(Armstrong et al., 1995; Donehower, 1996). p53 is a transcription factor that binds 
to specific sequences in the upstream region of many genes whose protein products 
regulate cell cycle progression and apoptosis (Ko and Prives, 1996). Thus cells 
with damaged DNA do not proliferate and the loss of this protective function allows 
the uncontrolled growth of cells containing oncogenic mutations (Lane, 1992). 
The p53 tumour suppressor protein is regulated by ubiquitin mediated 
proteasomal degradation (Maki et al., 1996). In normal cells p53 is constitutively 
ubiquitinated by the Mdm2 ubiquitin ligase (Bottger et al., 1997; Haupt et al., 1997; 
Honda et al., 1997; Kubbutat et al., 1997). Exposure of cells to a range of different 
stress signals, including DNA damage, hypoxia and heat shock activates the p53 
response and p53 levels rise due to inhibition of this degradative pathway. Here we 
show that p53 is modified by the small ubiquitin like protein SUMO-1 at a single 
site, K386 in the C terminus of the protein. Modification in vitro requires only 
SUMO- 1, the SUMO- I activating enzyme and ubc9. SUMO- I and ubiquitin 
modification do not compete for the same lysine acceptor sites in p53. Thus 
overexpression of SUMO-1 activates the transcriptional activity of wild type p53, 
but not K386R p53 where the SUMO-1 acceptor site has been mutated. The 
SUMO-1 modification pathway therefore acts as potential regulator of the p53 
response and may represent a novel target for the development of therapeutically 
useful modulators of the p53 response. 
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3.4.2. p53 is modified by SUMO-1 in vivo 
As described in the third chapter ubiquitin mediated proteolysis of I"KB(X, 
could be antagonised by modification with the small ubiquitin-l Ike protein SUMO-I 
(Desterro et al., 1998). As the p53 response to genotoxic insult is also critically 
dependent on ubiquitin mediated proteolysis we investigated the metabolism of p53 
in U20S cells. Preservation of SUMO-1 modifications requires rapid inhibition of 
SUMO- I specific isopeptidases and this is accomplished by direct lysis of cells into 
buffer containing SDS and iodoacetamide. In the absence of any stimulus p53 and 
more slowly migrating products, which we assume to be ubiquitin adducts, are 
detected. Also present is a species of 65 KDa which is consistent with a single 
SUMO-1 addition to p53. Exposure of U20S cells to UV results in a time 
dependent increase in p53 levels and an accumulation of the 65 KDa species (Figure 
25A). The lack of inu-nunoreactive species in Saos-2 cells, which lack p53, 
indicates that the more slowly migrating species are indeed related to p53 (Figure 
25A, right panel). To establish that the 65 KDa species is indeed the SUMO-I 
modified form of p53, U20S cells were transfected with a 6-His version of SUMO- 
1, either alone or with a p53 expression construct or empty vector as a control. 
Cells were lysed in guanidinium. HC1 and 6-His containing proteins eluted from Ni- 
agarose with iMidazole. Western blotting with an antibody to p53 indicated that 6- 
His SUMO-I linked to p53 could be detected in cells transfected with the 6-His 
SUMO-I expression plasmid, but not in cells transfected with the empty vector. 
Cotransfection with a p53 expression construct strongly increased the quantity of 6- 
His SUMO- I modified p53 (Figure 25B). Treatment of 6-His SUMO- I transfected 
U20S cells with UV results in a time dependent increase in the amount of 6-His 
SUMO-1 conjugated to p53 (Figure 25B, right panel). Thus p53 is covalently 
coupled to SUMO-1 in vivo and this modified form of p53 accumulated after UV 
irradiation. 
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Figure 25. U. V. irradiation leads to accumulation of p53 and SUMO-1 conjugated form of p53 in U20S 
cells 
(A) U20S cells were exposed to 25 J/M2 of UN. radiation and then collected by direct lysis in SDS buffer at 
the indicated times. Samples were fractionated by SDS-PAGE and p53 analysed by Western blotting using a 
p53 -specific monoclonal antibody, DO- 1. Saos-2 cells which lack p53 (right panel) were analysed to demon- 
strate antibody specificity. (B) 6ffis-tagged SUMO-1 is conjugated top53 in vivo. U20S cells were transfected 
with pcDNA3,6-His-SUMO-1 and p53 as indicated and after 36 hours of expression were lysed in buffer 
containing guanidinium. HCL Proteins linked to 6H s-SUMO- 1 were purified using Ni'+-NTA-agarose beads 
and after extensive washing eluted with 200 mM imidazole. Eluted proteins were fractionated by SDS-PAGE 
and transferred to a nitro-cellulose membrane. 6His-SUMO- I p53 conjugates were detected by Western blot- 
ting using anti-p53 antibody (DO-1). Molecular weight markers are shown on the right. The position of 
SUMO-1 conjugated p53 is indicated on the left. In the right panel 6His SUMO-1 transfected cells were 
exposed to UV and analysed as indicated above. 
3.4.3. SUMO-I modification of p53 takes place on K386 
To investigate the site of SUMO- I modification in p53 the in vitro system 
for SUMO- I modification, previously described was employed (Desterro et al., 
1998) . 
35S-labelled in Otro translated p53 was incubated with a source of SUMO-1 
activating enzyme (SAE]/2) (Desterro et al., 1999) and SUMO-1 conjugating 
enzyme (Ubc9) (Desterro et al., 1997) in the presence of SUMO- I and ATP. Under 
these conditions 35S-labelled p53 was converted to a more slowly migrating form 
that is consistent with SUMO-I modification. To confirm that this species was 
indeed SUMO-1 modified p53, GST-SUMO-I was substituted for SUMO-1 in the 
reaction, resulting in the detection of a modified species with altered electrophoretic 
mobility (Figure 26). SUMO-I modification was abolished if either SUMO-1, 
SAE, Ubc9 or ATP was ornýitted from the reaction (Figure 26). A series of p53 
molecules in which regions of the N- and C-termini had been deleted (Hansen et al., 
1998) were used as substrates for SUMO-modification in vitro (Figure 27C). p53 
molecules lacking parts of the N-terminus were efficiently SUMO-I modified 
whereas p53 molecules lacking parts of the C-terminus were not modified by 
SUMO-1 (Figure 27A). Deletion 4M, which lacks the Gtem-ýinal 30 an-ýino acids, 
was not modified thus indicating that this region is required for modification and 
may in fact be the site of modification. As ubiquitin-like proteins modify substrates 
on the F--amino group of lysine a series of mutants was created in which lysines 
within the C-terminal 30 an-ýino acids of p53 were changed to arginine. Modification 
of K370, K372, K373, K381 or K382 was without consequence for SLTMO-1 
modification whereas p53 containing the K386R mutation was not modified by 
SUMO-1 in vitro (Figure 27B). To establish that the in vitro results are an accurate 
representation of the situation in vivo, the same collection of p53 mutants was co- 
expressed with 6-His SUMO-1 in cells lacking endogenous p53. Proteins 
conjugated to 6-His SUMO-1 were isolated by chromatography on Ni-agarose and 
p53 detected by Western blotting. Again mutations in K370, K372, K373, K381 
and K382 did not affect SUMO-I modification, while the K386R mutation 
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Figure 26. Requirements for in vitro conjugation of SUMO-I to P53. 
In vitro expressed and "S labelled p53 was incubated with ATP, recombinant SUMO- I or GST-SUMO- 
1, Ubch9, and HeLa Fr 11.4 containing SUMO-1 El activity (SAE) as indicated. Reactions products 
were fractionated by SDS-PAGE, and the dried gel was analysed by phosphorimaging. The positions 
of p53, the SUMO- I conjugated form of p53 and the GST-SUMO- I conjugated form of p53 are i ndi- 
cated. 
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Figure 27. The C-terminus of p53 is modified by SUMO-I in vitro. 
(A) In vitro SUMO-I conjugation of C- and N-ten-ninal p53 deletions. In vitro expressed and "S labelled wild- 
type p53 (WT) and C-and N-terminal deletions were incubated with recombinant Ubch9, SUMO- I and HeLa Fr 
11.4 containing SLTMO-I El activity. Reactions products were fractionated by SDS-PAGE, and the dried gel was 
analysed by phosphorimaging. The SUMO-I conjugated forin of p53 is indicated with an asterisk. (B) In vitro 
SUMO-I conjugation of C-terminal lysine point mutants of p53. In vitro expressed and "S-labelled WT P53 and 
mutants were assayed for SUMO-I conjugation in vitro as in A. The positions of p53 and the SUMO-1 conju- 
gated form of p53 are indicated. (C) Schematic representation of p53 deletions, C-terminal lysine to arginine point 
mutants and their ability to act as substrates for SUMO-I conjugation activity. 
abolished SUMO- I modification in vivo (Figure 28A). Direct Western blotting of 
the cell lysates before Ni-agarose chromatography indicated that each of the p53 
proteins was expressed at comparable levels. Although representing only a small 
proportion of the total, due to overexpression of p53, the SUMO-1 modified forms 
of p53 proteins containing K386 are detected. This SUMO-1 modified form of p53 
is not detected in those proteins containing the K386R mutation (Figure 28B). Thus 
K386R is required for SUMO-I modification and is likely to be the residue to 
which SUMO-1 is conjugated. 
3.4.4. SUMO-1 and ubiquitin modification do not compete 
for the same lysine acceptor site in p53 
It has recently been established (Honda and Yasuda, 1999; Kubbutat et al., 
1998) that the C-ten-ninal 30 amino acids are required for Mdm2 mediated 
degradation of p53. In light of observations with I-KBec the effect of SUMO-1 
modification on p53 ubiquitination was investigated. As expected, in vitro 
ubiquitination of 35S labelled p53 was dependent on the presence of Ubc5 and 
Mdm2 (Figure 29A) and required the C-terrainus of p53 (Figure 29B, 4M deletion). 
To determine if ubiquitination takes place at the same site as SUMO- I modification 
the same lysine to arginine point mutants (Figure 27) were used for in vitro 
ubiquitination. Unlike SUMO-I modification K386R was competent for 
ubiquitination and none of the other point mutations had a substantial effect on 
ubiquitination. Thus, the SUMO-I and ubiquitin modification systems do not 
compete for modification of the same lysine residue in p53. 
3.4.5. SUMO-1 modification induces p53 dependent 
transcription 
To assess the functional consequences of SUMO-I conjugation to p53 we 
detennined the effect of cotransfected SUMO-1 on the transcriptional activity of 
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Figure 28. K386 is required for SUMO-1 modification of p53 in vivo. 
(A) Saos-2 cells were transfected with the indicated plasmids and after 36 hours of expression lysed in buffer 
containing guanidinium HCL 6His linked proteins, eluted from Ni 2+-NTA-agarose, were fractionated by SDS- 
PAGE and analysed by Western blotting with anti-p53 antibody (DO-1). Molecular weight markers and the 
position of His-tagged SLTMO- I conjugated to p53 are indicated. An asterisk indicates a non-specific cross react- 
ing species which is independent of transfection. (B) Saos-2 cells transfected as indicated in A, were directly 
analysed by Western blotting with anti-p53 antibody (DO- 1). 
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Figure 29. SUMO-I and ubiquitin modification do not compete for the same lysine residue in p53. 
(A) 35S labelled p53 generated by in vitro transcription and translation was incubated with recombinant El in the 
presence (+) or absence (-) of different components, as indicated in the figure, in 50 mM Tris pH 7.5,5 mM MgCl 2 
and an ATP regenerating system at 370C for 2 hours. Reactions products were analysed as described in legend of 
figure 26. (B) In vitro ubiquitination of 35S labelled p53, the indicated p53 point mutants and the C-terminal deletion 
4M was carried out as described in A. 
--Im 
wild type p53 and K386R p53 where the SUMO- I acceptor site has been mutated. 
Saos-2 cells, which lack endogenous p53, were cotransfected with the p53 
responsive reporter plasmid pG13-luciferase and expression plasmids for p53 and 
SUMO- 1. Wild type p53 alone activates transcriptional activity by 8 fold while the 
additional presence of SUMO-1 activates transcription by about 18 fold (Figure 30). 
In contrast K386R p53 has an inherently higher transcriptional activity and this is 
not further augmented by co-expression of SUMO-1 (Figure 30). Similar data was 
obtained over a wide range of input p53 expression vector amounts and with 
different p53 dependent reporters, such as the mdm2 promoter (data not shown). 
Western blottin- indicated that neither wild type p53, nor K386R p53 levels were 
dramatically altered by coexpression of SUMO-1 (Figure 30, insert). 
3.4.6. Discussion 
In normal cells p53 is maintained at a low level by mdm2 mediated ubiquitin 
dependent proteolysis. Following genotoxic insult p53 is stabilised and as a 
consequence the protein accumulates and activates p53 dependent transcription. As 
no single unifying hypothesis can yet describe this phenomenon, it is likely that 
multiple pathways lead to activation of the p53 response (Lane, 1998). We 
demonstrate that p53 is modified by SUMO-I and that the amount of SUMO-1 
conjugated p53 increases after exposure of cells to ultraviolet radiation (Figure 25). 
SUMO- I is conjugated to p53 on K386 (Figures 27 and 28) which is located in the 
C-terminus of the protein in a region that is known to be required for mdm2 
mediated ubiquitin dependent degradation of p53 (Honda and Yasuda, 1999; 
Kubbutat et al., 1998). A role for SUMO-I modification in p53 activation is 
consistent with the observation that overexpression of SUMO-1 leads to increased 
p53 dependent transcriptional activity. This increase is dependent on SUMO-1 
modification of p53 as SUMO-I overexpression does not influence the 
transcriptional activity of K386R p53 (Figure 30). It is possible to envisage a 
number of models by which SUMO- I modification may increase the transcriptional 
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bars representing one standard deviation. Shown in the insert is a representative expenment in 
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response of p53. These include an increase in protein stability, a higher intrinsic 
transcriptional activity and alterations in subcellular localisation. Although the site of 
SUMO- I modification may represent a potential site of ubiquitination, mutation 
K386R does not have a dramatic effect on ubiquitination in vitro (Figure 29). While 
the C-terminal region is required for ubiquitination it does not appear that a unique 
lysine is a target for mdm2 as no single lysine to arginine mutation of the 6 lysines 
in this region abolishes ubiquitination (Figure 29). This is different from the 
situation in IK]Boc where one of two lysine residues is the target for signal induced 
ubiquitination. As this also represents the site of SUMO-1 conjugation 
ubiquitination is inhibited simply because the acceptor lysine is already modified by 
SUMO-1 (Desterro et al., 1998). Although the major binding site for mdm2 is 
located in the N-terminal region of p53 (Bottger et al., 1997; Chen et al., 1993; 
Kussie et al., 1996-, Midgley and Lane, 1997; Momand et al., 1992; Oliner et al., 
1993; Picksley et al., 1994) it has also been reported that the ofigornerisation of p53 
is required for efficient interaction with mdm2 (Marston et al., 1995). While the 
extreme C-terrninus of p53 is not required for efficient interaction with mdm2, its 
deletion dramatically reduces mdm2 catalysed ubiquitination in vitro and increases 
the stability of p53 in vivo (Honda and Yasuda, 1999; Kubbutat et al., 1998). It is 
possible that the C-terminal region of p53 is required as the site of ubiquitination by 
mdm2, but ubiquitination can be targeted to any of the 6 lysines in this region. Thus 
while SUMO-1 modification of this region may not directly disrupt the interaction 
between p53 and mdm2 it could inhibit the ability of mdm2 to access the lysine 
residues in the C-terminus which are the substrates for ubiquitination. In addition to 
SUMO-1 modification it has recently been reported that phosphorylation of p53 
with DNA dependent protein kinase reduces the substrate activity of p53 in an 
mdm2 dependent in vitro ubiquitination assay (Honda and Yasuda, 1999). The 
tumour suppressor pI 9ARF blocks ubiquitination of p53, but in this case the target 
appears to be mdm2 rather than p53 (Honda and Yasuda, 1999). Likewise RB has 
also been shown to block mdm2 induced degradation of p53 and in this instance a 
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trimeric, but inactive complex containing p53, RB and mdm2 was detected (Hsieh 
et al., 1999). As an alternative to effects on protein stability SUMO-1 modification 
could increase the inherent transcriptional activity of p53. This could result from a 
change in protein structure which increases DNA binding activity, allows more 
efficient access to p53 dependent promoters embedded in repressive chromatin, or 
has a greater capacity to recruit co-activators such as CBP/p300. In this respect 
K386R p53 elicits a greater transcriptional response than wild type p53 which may 
reflect an increased activity in any one of the above properties. 
It is also possible that SUMO-1 modification alters the subcellular 
localisation of p53, as has been noted for other SUMO-1 modified proteins. 
SUMO-1 modified Ran GAP is recruited to the nuclear pore complex (Mahajan et 
al., 1997-, Matunis and Blobel, 1997) while SUMO-1 modified PML and SPIOO are 
present in PML oncogenic domains or PODs (Duprez et al., 1999; Muller et al., 
1998-, Sternsdorf et al., 1997). IKB(x is predominantly cytoplasmic but shuttles 
rapidly between the nucleus and the cytoplasm and while the cellular localisation of 
SUMO-1 modified I-KBoc has not been deten-nined it is worth noting that I-KB(x, 
trapped in the nucleus by leptomycin B, is resistant to signal induced degradation 
(Rodriguez et al., 1999). Mdm2 also shuttles between the nucleus and the 
cytoplasm (Roth et al., 1998) and blockage of nuclear export results in 
accumulation of p53, mdm2 complexes in subnuclear domains adjacent to the PODs 
(Lain et al., 1999) which are rich in SUMO-I modified proteins. Like I-KBoc, 
nuclear p53 is resistant to degradation (Freedman and Levine, 1998) and it is 
possible that SUMO-1 modification takes place when these proteins are imported 
into the nucleus. The predominantly nuclear localisation of the SAE and Ubc9 
enzymes involved in SUMO-1 modification (recent observations in the laboratory) 
lends supports to this hypothesis. Thus SUMO-I modification could increase the 
nuclear content of p53 or alternatively concentrate the protein in distinct subnuclear 
domains that are active sites of transcription. Diverse stress stimuli activate the p53 
response and are likely to act via separate signalling pathways with distinct 
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activation mechanisms. SUMO-I modification represents an additional route to p53 
activation that may link the p53 response to other aspects of cellular metabolism. 
Manipulation of the SUMO-1 modification pathway may therefore represent a novel 
target for the development of therapeutically useful modulators of the p53 response. 
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4. Conclusions 
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Ubiquitin modification of proteins provides an extremely versatile means of 
cc I lular regulation but over the past few years a family of ubiquitin-like proteins has 
been discovered that raise new and intriguing regulatory and mechanistic questions 
on cell biology. SUMO- I is a member of this new family of ubiquitin-like proteins 
that is covalently linked to target proteins and we undertook the characterisation of 
this modification. 
Several features of the ubiquitin pathway are conserved in the SUMO-I 
conjugation pathway. Like ubiquitin, SUMO-I is proteolytically processed to 
expose its mature C-terminus (Kan-titani et al., 1997b). Then SUMO-I is activated 
in an ATP-dependent manner by an activating enzyme composed of SAEI and 
SAE2. The activated SUMO-1 is then transferred to the active-site cysteine of 
Ubc9. Although Ubc9 is able to recognise the substrate and directly transferred the 
activated SUMO- I to a lysine residue in the target protein in vitro, we can not rule 
out the possibility of E3-like protein ligases increase the efficiency of the 
conjugation process i. n vi . vo. This is rather different from ubiquitin modification 
where an E3 activity is required for target recognition. As almost all identified 
targets for SUMO- I modification are Ubc9 interacting proteins (see Table I and 
Table 2) it is likely that substrate specificity is achieved by Ubc9. To date, there is 
no evidence to suggest that an E3-like activity is involved in this conjugation 
pathway. The C-terminal region of Ubc9 which is thought to be involved in 
substrate binding (Liu et al., 1999) lies close to the catalytic site and favours the 
direct transfer of SUMO-I to substrate proteins. While the SUMO-1 conjugation 
pathway is mechanistically similar to the ubiquitin pathway it utilises specific 
conjugating enzymes (Figure 3 1). 
SUMO-1 +ATR SAE UMO-1-Ubch9 Substrate 
AMP+PPi 
I 
AE-SUMO-l' , Ubch9 
XSUMO- 
I -Substrate 
Figure 31. SUMO-1 conjugation pathway.. 
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It remains to be seen which other proteins are modified by ligation to 
SUMO-1 and whether at least some of the many proteins that interact with Ubc9 
(Table 1) are also substrates for SUMO-1 conjugation. Ubc9 interaction with so 
many proteins in the yeast two-hybrid screen justifies commentary. One possible 
explanation is that in yeast some of the "bait" proteins can be modified by SUMO-1 
and SUMO- I acts as a bridging protein mediating the interaction between Ubc9 and 
bait proteins. However, non-specific interactions between some proteins and the 
positively charged surface of Ubc9 (Giraud et al., 1998; Tong et al., 1997) may 
also explains the large number of Ubc9 interacting proteins. 
A particularly large number of transcription factors interacts with Ubc9. 
This interaction has in many cases a stimulatory effect in transcription activation but 
is not in all the cases directly related to SUMO-1 modification. Ubc9 activates the 
transcriptional activity of ETS (E-26 transforming specific), TEL (ETS-related 
gene) and AR (androgen receptor) transcription factors but the stimulatory activity 
of Ubc9 cannot be inhibited by mutating the Cys93 (Chakrabarti et al., 1999; Hahn 
et al., 1997; Poukka et al., 1999; Tashiro et al., 1997). Thus, Ubc9 is able to act in 
a fashion independent of its ability to catalyse SUMO-1 conjugation. It would be 
interesting to speculate that Ubc9 has additional properties which are not dependent 
directly on its enzymatic activity. As a scaffolding protein giving specificity to 
different protein-protein interactions or by regulating nuclear transport. The 
regulated nuclear import of transcription factors provides an efficient mechanism to 
restrict their access to the transcriptional machinery. The involvement of a Ubc9 
homologue in nuclear import during Drosophila embryogenesis has been reported 
(Epps and Tanda, 1998). Mutation of the Drosophila semushi (semi) gene, which 
encodes an E2 enzyme homologous to Ubc9, blocks nuclear import of the 
transcription factor Bcd during early embryogenesis and results in misregulation of 
the segmentation genes that are Bcd targets (Epps and Tanda, 1998). Ubc9 may 
either regulate transport by modification of pore proteins or modify nuclear proteins 
in a transport coupled manner. 
III 
One feature common to many of the transcription factors which interact with 
Ubc9 is the mechanism of regulation. ATF2, p53, C-Jun and NF--KB are 
transcriptions factors whose activity is regulated by ubiquitin-dependent 
proteolysis. IKB(x, the inhibitor of NF-KB, and p53 are both modified by SUMO- 
I (Table2) and in both cases SUMO- I conjugation increases protein stability. This 
evidence may be particularly pertinent in view of several lines of similarity between 
p53 and NF-kB. 
Ubc9 interacting protein Function Reference 
(Blondel and Clb2, Clb5 M- and S-phase cyclins Mann, 1996; 
Seufert et al., 
1995) 
EIA Adenovirus oncoprotein (Hateboer et al., 
1996) 
(Kho et al., 1997; 
E2A Transcription factor Loveys et al., 
1997) 
(Kovalenko et al., 
human Rad5 I /Rad52 DNA repair 1996; Shen et al., 
1996b) 
human papillornavirus Type 16 Replication protein (Yasugi and 
El Howley, 1996) 
Saccharomyces cerevisiae (Jiang and Koltin, 
centromere DNA-binding core Chromosome segregation 1996) 
complex 
Negative regulatory domain of Zinc-finger DNA-binding (Wang et al., 
the Wilm's Tumor gene product protein (transcription 1996) 
(WT 1) repressor) 
(Becker et al. 
Fas antigen (CD95) Receptor (Tumor necrosis 1997; Wright et 
factor receptor family) al., 1996) 
(Shen et al., 
p53 Transcription factor 1996b) 
(Gottlicher et al., 
c-Jun Transcription factor 1996) 
(Gottlicher et al., 
Glucocorticoid Receptor (GR) Transcription factor 1996) 
Transcription factor (Chakrabarti et al., 
TEL (repressor of gene 1999) 
transcription) 
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Transcription factor (Ras 
ETS I and Ca2+ signalling (Hahn et al., 
pathways) 1997) 
(Saltzman et al., MEKKI Kinase (stress activated 1998) 
protein kinase pathway) 
(Saltzman et al., Type I TNFa receptor Receptor 1998) 
(Saitoh et al., RanBP2 Nuclear transport 1997) 
ATF2 Activating transcription (Firestein and 
factor 2 (ATF/CREB Feuerstein, 1998) 
family) 
(Tashiro et al., 
mouse cRel Transcription factor 1997) 
Inhibitor of NF-KB (Desterro et al., 
IKB (x transcription factor 1998) 
human bleomycin hydrolase Cysteine protease (Koldamova et al., 
1998) 
Member of the steroid (Poukka et al., 
AR, androgen receptor receptor family of ligand- 1999) 
activated transcription 
factors 
(Joanisse et al., 
Hsp23, Hsp26, Hsp27 Heat shock proteins 1998) 
(Masson et al., 
Poly(ADP-ribose) polymerase DNA replication/DNA 1997) 
repair 
(Tarsounas et al., 
Cort, Syn1 Synoptonernal complex 1997) 
components 
Ohsako, 1999, 
N-terminal transcription Corepressor Jbioch 
repression domains of Groucho 
Nuclear phosphoprotein (Boddy et al., 
PML component of PMEL nuclear 1996; Muller et 
bodies al., 1998) 
Sentrin (SUMO-1) Ubiquitin-like molecule (Gong et al., 
(sentrinisation) 1997) 
UBLI (SUMO-1) Ubiquitin-like protein (Shen et al., 
1996b) 
Enhances Fas-mediated (Hancock et al., 
Daxx apoptosis 1999) 
Table 1. Ubc9 interacting proteins and respective function 
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The identified proteins that have been found to be subject to modification by 
SUMO-I are shown in Table 2. Most of the proteins can be found, at least in part, 
inside the nucleus (Table 2). Although the cellular localisation of SUMO_ I modified 
I'KB(x has not been determined, ficBa is predominantly cytoplasmic and newly 
synthesised I-KBa is translocated into the nucleus (Arenzana-Seisdedos et al., 1995) 
where is resistant to signal induced degradation (Rodriguez et al., 1999); SUMO-1 
modified RanGAPI is associated with the cytoplasmic fibbers of the NPC but it 
also appeared to associate with the mitotic spindle apparatus during mitosis 
(Mahaj an et al., 1997; Matunis et al., 1996); unmodified PML and Sp 100 localise to 
the soluble nucleoplasm and cytoplasm respectively, but SUMO-I modified PML 
and Sp 100 are both found in large nuclear multi-protein complexes known as PML 
nuclear bodies (Duprez et al., 1999; Hodges et al., 1998; Muller et al., 1998; 
Sternsdorf et al., 1997); p53, like I'KB(x, shuttles between the nucleus and the 
cytoplasm and blockage of nuclear export by Leptomycin B results in accumulation 
of p53, mdm2 complexes in subnuclear domains adjacent to the PML nuclear 
bodies(Lain et al., 1999). Taking this into account, one could hypothesise that 
SUMO- I modification could involve nuclear import as an obligatory step. Whether 
the modification occurs in the nucleoplasm, during nuclear import or in the nuclear 
pore it remains to be shown, but recent observations on localisation of the SUMO-1 
conjugation enzymes, SAE and Ubc9, support the hypothesis that the modification 
itself occurs in the nucleus. The mutant SpIOO(447E) containing a non-functional 
NLS was severely compromised in SUMO-I modification, which indicates that 
modification of SplOO by SUMO-I is tightly linked to nuclear localisation and gives 
strength to the above hypothesis (Sternsdorf et al., 1999). 
Comparison of the sequences surrounding the acceptor lysines in proteins 
that have been shown to be modified by SUMO-1 reveals a striking similarity 
(Figure 32). Apart from the absolutely conserved SUMO-I acceptor lysine, there 
appears to be an absolute requirement for a hybrophobic residue and a Glu on either 
site of the acceptor lysine. The consensus sequence WKxE, may represent a 
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recognition site for the SUMO- I conjugation machinery. This consensus sequence 
is an useful tool in the identification of additional substrates for SUMO-1 
modification. 
RanGAP-1 523 L L KS E D K 
I-KBa 19 G L KK E R L 
PML 488 V I KM E S E 
PML 158 F L KH E A R 
Sploo 295 D I KK E K P 
P53 384 M F KT E G P 
Consensus V KX E 
Figure 32. Consensus sequence for modification by 
SUMO-1. 
Alignment of SUMO-1 conjugation sites known to 
date. An asterisk indicates the lysine residue covalently 
modified by SUMO-1. Identical aminoacids are in the 
dark shading and similarities are in the light shading. 
SUMO- I modifications have been implicated in the targeting of proteins to a 
particular subcellular compartment and in converting proteins into a form that is 
resistant to ubiquitin-mediated degradation. In yeast the enzymes required for 
SUMO- I conjugation and deconjugation are both essential and their inactivation 
leads to a G2/N4 block (Li and Hochstrasser, 1999; Seufert et al., 1995). Since 
SUMO-I conjugation of PML and Spl-00 is regulated in a cell cycle dependent 
manner (Roger Everret, personal communication) it is likely that SUMO-I 
modification is a dynamic mechanism by which the cell controls diverse processes, 
including cell cycle, differentiation and virus infection. 
Evidence that the SUMO- 1 modification state of target proteins may change 
during certain cell cycle stages was demonstrated with PML. During mitosis PML 
and SplOO become deconjugated and, by this mechanism might regulate PML 
nuclear bodies disassembly, which occurs during this phase of the cell cycle 
(Sternsdorf et al., 1997). SUMO-I plays an important role in the biological activity 
of nuclear body associated proteins and/or may promote the assembly of these and 
maybe other nuclear structures. These nuclear structures may represent storage sites 
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for proteins and nuclear factors, which can be liberated in the nucleoplasm for 
cellular processes such as transcription or cell division. 
Several viral proteins associate with PML bodies and interfere with the 
organisation of these structures. Infection with herpes simplex virus I (HSV-1 
VmwllO or ICPO), adenovirus (E40RF3) and human cytornegalovirus (IE1) 
disrupts PML bodies (Carvalho et al., 1995; Everett and Maul, 1994; Everett et al., 
1997; Kelly et al., 1995; Maul et al., 1993). Although the biological significance of 
the destruction of PML nuclear bodies upon viral infection is still unclear, an 
attractive but speculative hypothesis is that viral proteins interfere with the cellular 
SUMO-1 conjugation/ deconjugation pathway. CMV 1E I can specifically abrogate 
the SUMO- I modification of PML and Sp 100. It has been shown that IE I protein 
itself is a substrate for SUMO- I modification (Muller and Dejean, 1999). Although 
it represents the first viral protein to undergo this posttranslational modification, a 
large number of other viral proteins are potential substrates and one could speculate 
that viral and cellular proteins may compete for the same pool of SUMO-1 during 
virus infection and thus interfere with cellular processes. 
The HSV-1 Vmw11O immediate-early regulatory protein induces the 
proteasome-dependent degradation of several cellular proteins. Vmw I 10 associates 
with PML bodies, which are disrupted within a few hours as a consequence of 
degradation of several PML forms in a proteasome dependent fashion (Chelbi-Alix 
and de The, 1999; Everett et al., 1998; Everett and Maul, 1994; Maul and Everett, 
1994; Maul et al., 1993). VmwllO also binds to centromeres and induces 
proteasome dependent degradation of CENP-C, a centromeric protein. CENP-C 
degradation disrupts kinetochore structure and induces profound defects in n-fitotic 
events (Everett et al., 1999). There are striking similarities between the interactions 
of Vmw I 10 with the PML bodies and centromeres and one could speculate that 
SUMO- I conjugation or deconjugation might have a role in both processes, creating 
a possible connection between these nuclear structures. It would be interesting to 
determine if CENP-C is modified by SUMO- 1. The destruction of CENP-C may be 
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important for the virus to prevent the cell from aborting the viral infection by 
inducing an apoptotic response. 
Centromere assembly, like PML bodies, may be regulated by a mechanism 
involving SUMO-I or a similar ubiquitin-like protein modification. Smt3p, the 
yeast homologue of SUMO- 1, also becomes conjugated to several proteins 
posttranslationally (Johnson et al., 1997). It was originally isolated as high copy 
supressor of mutations in the MIF2 gene (Meluh and Koshland, 1995) which 
encodes a CENP-C like centromere-binding protein, required for normal DNA 
replication and mitotic spindle integrity in yeast (Brown et al., 1993; Meluh and 
Koshland, 1995). Whether Mif2p is a target for Smt3p has not yet been determined. 
The first identified target for this modification in yeast is Cdc3, a component of 
septin rings at the mother-bud neck (Takahashi et al., 1999). Although, the 
biological significance of Smt3p-conjugation is not well understood a function 
similar to SUMO- 1 conjugation is expected as SUMO- I can complement yeast smt3 
null mutants (Johnson et al., 1997). The most plausible function for Smt3p 
conjugated Cdc3 involves its stability. Cdc3 is conjugated to Smt3p during the cell 
cycle but is unstable during cytokinesis and this instability may be related with 
disassembly of the septin structure. The possible involvement of SUMO-t pathway 
in centromere assembly is also demonstrated by the specific interaction of Ubc9 
with all three subunits of the Saccharomyces cerevisiae centromere DNA-binding 
core complex, CBF3 (Jiang and Koltin, t996). Thus, it appears very likely that the 
function of Ubc9p in the G2/M phase of S. cerevisiae could be related to regulation 
of centromere proteins in chromosome segregation during mitosis. In S. pombe, 
pmt3p, homologue of Smt3p is required for a number of nuclear events including 
the control of telomere lenght and kinetochore functions involved in chromosome 
segregation (Katsunori et al., 1999). hDaxx can localise with CENP-C during 
interphase (Pluta et al., t998). hDaxx is a human homologue of a murine protein 
originally identified as a mediator of the Fas/CD95 apoptotic pathway is a substrate 
for SUMO- I modification (Hancock et al., 1999). 
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Recent studies describing a SUMO-I/Smt3 deconjugating enzyme in yeast, 
Ulpl, suggest the presence of SUMO-1 deconjugating homologues in mammalian 
cells and it appears that SUMO- I conjugation and deconjugation of target proteins is 
a dynamic cell cycle regulated process. Deconjugation from one or more proteins by 
UlpI is required for normal cell cycle progression but conjugation must also 
positively regulate the G2/M transition, as Ubc9 mutants show cell cycle arrest. 
Different targets and tirnIngs for SUMO-I/Smt3p conjugation may explain these 
negative and positive cell-cycle regulatory effects. Although human HAUSP 
(herpes associated ubiquiti n -specific protease) has been localised in the nuclear 
bodies (Everett et al., 1997), that contain SUMO-1 modified proteins, the 
involvement of this enzyme in the deconjugation of SUMO-I has not been 
described and human SUMO- I deconjugating enzymes have yet to be characterised. 
As virtually all SUMO-I in the cell is conjugated to target proteins, changes 
in the SUMO-1 modification state of individual proteins must involve not only the 
conjugation enzymes SAE and Ubc9 but also the deconjugating enzymes (SUMO-1 
specific proteases, SSPs). Thus, it is likely that these enzymes are subject to highly 
specific regulation. These control mechanisms are likely to operate during the cell 
cycle and be responsive to signals from the extracellular environment. As the 
nuclear DNA viruses all disrupt the normal cell cycle it is perhaps not surprising that 
they have also targeted the SUMO-1 modification pathway. Using the tools 
described in this thesis it is hoped that the next few years will reveal the details of 
how proteins are selected, in time and at specific subcellular locations, for SUMO-1 
modification. 
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5. Appendix I Vector Maps 
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III 
Comments for peDNA3 (5446 nucleotides) 
Supplier: Invitrogen 
Acession number: IG1046 
CMV promoter: bases 209-863 
T7 promoter: bases 864-882 
Polylinker: bases 889-994 
Sp6 promoter: bases 999-1016 
BGH poly A: 1018-1249 
SV40 promoter: bases 1790-2115 
SV40 origin of replication: bases 1984-2069 
NeoR ORF: bases 2151-2932 
SV40 poly A: bases 3120-32-50 
pUC19 backbone: bases 3272-5446 
AmpR ORF: bases 4450-53 10 
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nHI 
LXI 
oRl 
RV 
stxl 
qotl 
Xhol 
Xbal 
Apal 
-0 
BgIll 
Ubch9 
Xhol 
\Smal 
Cloning primers: 
Upstream (BamHI): 5-ACA AAC CAT GGA TCC ATG* TCG GGG ATC GCC CTC 
AGGY 
Downstream (Xhol): 5'-TCC GAG CTC GAG TTA* GTC CAA TCC CAG CAA AGG 
GTT TGG GAT TGA GGG CGC CGC AAA CTT CTT GGC-3' 
Ubch9: 
Organism: Homo sapiens 
Coding region: 474 bp 
GB acession number: NM003345, U29092, U31882, AJO02385, U31933, X96427. 
Antibodies: 
Mouse 336 monoclonal antibody against PK-SV5 peptide (IPNPLLGLE) 
Sheep anti-Ubch9 polyclonal antibody against Ubch9 c-terminal peptide, 
(. CEYEKRVRAQAKKFAPS) 
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01-4111 
)AEI 
EcoRl 
Bsn 
ISmal 
Cloning primers: 
Upstream (BamHl): 5-AAC GGA TCC ATG* GTG GAG AAG GAG GAG GCT 
GGC-31 
Downstream (EcoRl): 5-G CGG GAA TTC TCA*CTT GGG GCC AAG GCA CTC 
CAC AA-Y 
SAEl: 
Subunit of SLJMO-l activating enzyme 
Organism: Homo sapiens 
Coding region: 1041bp 
GB acession number: NP005491, AAD24433 
Antibodies: 
Sheep anti-SAE1 polyclonal antibody against recombinant SAEI 
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Pvul , -.. -% 
I Bglll 
r--. __ 
/ Ndel 
C: r, r%Dl 
SAE2 
Bsml 
/Smal 
Cloning primers 
Upstream (F-coRl): 5'-GAG GAA TTC ATG* GCA CTG TCG CGG GGG CTG-3' 
Downstream (EcoRl): 5-GAG GAA TTC TCA* ATC TAA TGC TAT GAC ATC-3' 
SAE2: 
Subunit of S UMO- I activating enzyme 
Coding region: 1923 bp 
GB acession number: NP005490, AAD24434 
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12 f-I III 
, pni 
BamHJ 
Cloning primers: 
Upstream (Kpnl): S-CAT GGG AAA GCC GAT CCC AAA CCC TTT GCT GGG ATT 
GGA CTC CAC CG-31 
Downstream (BamFH): 5'-GAT CCG GTG GAG TCC AAT CCC AGC AAA GGG TTT 
GGG ATC GGC TTT CCC ATG GTA C-3' 
PK-SV5 tag: 
Peptide: IPNPLLGLE 
The tag linker codes amino acids 95 to 108 derived from SV5 P and V proteins. 
Antibodies: 
Mouse 336 monoclonal antibody against PK-SV5 peptide obtained from R. E. Randall, 
University of St Andrews (Hanke et al., 1992). 
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BgIll 
Ndel 
Pvul 
Ampicillin PCMV 
.; ddi'--BamHl sumo-I 
(1-97a. a. ) 
pcDNA3 BamHl 
SV5-N/SUMO-1 Sp6 
(1-97 a. a. ) 
SV40ori 
Bsml Neomycin 
\Smal 
Cloning primers: 
Upstream (BamFH): 
AAA-31 
5'-ACA AAC GGA TCC ATG* TCT GAC CAG GAG GCC 
Downstream (Bam-Hl): 5'-GCC GAG GGA TCC CTA* ACC CCC CGT TTG TTC 
CTG-31 
SUMO-1 (1-97 a. a. ): 
C-terminus cleaved fon-n of SUMO- 1, which allows it to be conjugated to other proteins via 
the conserved C-termi-nal Gly residue 
Organism: Homo sapiens 
Coding region: 291 bp, 
GB acession number: NP003343, Q93068, AAC50996. 
Antibodies: 
Mouse 336 monoclonal antibody against PK-SV5 peptide obtained from R. E. Randall, 
University of St Andrews (Hanke et al., 1992). 
Mouse 21C7 moniclonal antibody against full-lenght recombinant GMPI protein obtained 
from Zymed (Cambridge Bioscience). 
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12 rl 11 11 1 
imHl 
5AEI 
EcoRl 
Bsn 
ISmal 
Cloning primers: 
Upstream (BamHl): 5'-AAC GGA TCC ATG* GTG GAG AAG GAG GAG GCT 
GGC-31 
Downstream (EcoRl): 5'-G CGG GAA TTC TCA*CTT GGG GCC AAG GCA CTC 
CAC AA-31 
SAE1: 
Subuni t of S LTMO- I acti vati ng enzyme 
Organism: Homo sapiens 
Coding region: 1041 bp 
GB acession number: NP005491, AAD24433 
Antibodies: 
Mouse 336 monoclonal antibody against PK-SV5 pepetide obtained from R. E. Randall, 
University of St Andrews (Hanke et al., 1992) 
Sheep anti-SAEI polyclonal antibody against recombinant SAEI 
126 
BgIll 
Kpnl 
-BamHl 
Cloning primers: 
Upstream (Kpnl): 5'-C ATG GCT TCA TAT CCT TAC GAT GTT CCA GAC TAC GCT 
TCC CTT G -Y 
Downstream (BamHl): 5'-GA TCC AAG GGA AGC GTA GTC TGG AAC ATC GTA 
AGG ATA TGA AGC CAT GGT AC-3' 
HA tag: 
Peptide: YPYDVPDYA 
The tag linker codes for a9 arninoacid peptide from influenza hemagglutinin protein. 
Antibodies: 
Mouse 12CA5 monoclonal antibody against HA peptide obtained from Babco. 
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BgIll 
Ndel 
Pvul 
Ampicillin PCMV 
BamHI 
sumo-I 
(1-97a. a. ) 
pcDNA3 BamHl 
HA-N/SUMO-1 Sp6 
(1-97 a. a. ) 
SV40ori 
BSMI Neomycin 
\ 
Smal 
Cloning primers: 
Upstream (BamHl): 5'-ACA AAC GGA 
AAA-31 
TCC ATG* TCT GAC CAG GAG GCC 
Downstream (BamHl): 5'-GCC GAG GGA TCC CTA* ACC CCC CGT TTG TTC 
CTG-31 
SUMO-1 (1-97 a. a. ): 
C-terminus cleaved form of SUMCI- 1, which allows it to be conjugated to other proteins via 
the conserved C-terminal Gly residue 
Organism: Homo sapiens 
Coding region: 291 bp, 
GB aeession number: NP003343, Q93068, AAC50996. 
Antibodies: 
Mouse 12CA5 monoclonal antibody against HA peptide obtained from Babco. 
Mouse 21C7 moniclonal antibody against full-lenght recombinant GMPI protein obtained 
from Zymed (Cambridge Bioscience). 
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BgIll 
Pvul 
Ampicillin 
Ndel 
Sp6 
Bsml 
pcDNA3 
HA-N 
(in frame with EcoRl) 
PCMV 
SV40ori 
Neomyci 
BamHl 
EcoRl 
Cloning primers: 
Upstream (BamHl): 5-G ATC CAT GGC TTC ATA TCC TTA CGA TGT TCC AGA 
CTA CGC TTC CCT TG-3' 
Downstream (EcoRl): 5-AAT TCA AGG GAA GCG TAG TCT GGA ACA TCG TAA 
GGA TAT GAA GCC ATG-3' 
HA tag: 
Peptide: YPYDVPDYA 
The tag linker codes for a9 aminoacid peptide from influenza hemagglutinin protein. 
Antibodies: 
Mouse 12CA5 monoclonal antibody against HA peptide obtained from Babco. 
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Pvul, I 
BgIll 
f-%- / 
Ndel 
nCMV 
RI 
SAE2 
Bsml 
/Smal 
Cloning primers 
Upstream (EcoRl): 5'-GAG GAA TTC ATG* GCA CTG TCG CGG GGG CTG-3' 
Downstream (EcoRl): 5'-GAG GAA TTC TCA* ATC TAA TGC TAT GAC ATC-31 
SAE2: 
Subunit of SLJMO- 1 activating enzyme 
Coding region: 1923 bp 
GB acession number: NP005490, AAD24434 
Antibodies: 
Mouse 12CA5 monoclonal antibody against HA peptide obtained from Babco. 
130 
D,, Iji 
f 
, pnl 
BamHl 
Cloning primers: 
Upstream (Kpnl): 5'-CAT GGC TCA TCA TCA TCA TCA TCA TGG TG-3' 
Downstream (BamHl): 5'-GAT CCA CCA TGA TGA TGA TGA TGA TGA GCC ATG 
GTA C-3' 
6XHis tag: 
The tag linker codes for 6 histidines which enables affinity purification of 6xHis-tagagged 
proteins on Ni-NTA-agarose beads. 
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BgIll 
Pvul 
Ndel 
Ampicillin PCMV 
BamHI 
sumo-I 
kl-97a. a. ) 
pcDNA3 
6xHis/SUMO-1 
(1-97 a. a. ) 
Sp6 
BamHl 
SV40ori 
Bsml Neomycin 
\'Smal 
Cloning primers: 
Upstream (BamHI): 5'-ACA AAC GGA 
AAA-31 
TCC ATG* TCT GAC CAG GAG GCC 
Downstream (Bamlil): 5'-GCC GAG GGA TCC CTA* ACC CCC CGT TTG TTC 
CTG-31 
SUMO-1 (1-97 a. a. ): 
C-ten-ninus cleaved form of SUMO-1, which allows it to be conjugated to other proteins via 
the conserved C-terminal, Gly residue 
Organism: Homo sapiens 
Coding region: 291 bp, 
GB acession number: NP003343, Q93068, AAC50996. 
The expression system provides possible affinity purification on Ni-agarose beads of 
proteins conjugated to 6xHis-SUMO-1 
132 
Ptac 
Eco 
BssHl 
Apal 
BstEl 
mful 
II'. 4 I 
Comments for pGEX-2T (4948 nucleotides) 
Supplier: Pharmacia 
Acession number: U13850 
tac promotor-10: bases205-211 
tac promotor-35: basesI83-188 
lac operator: bases217-237 
Start codon for GST: base 258 
Ampr ORE bases 1356-2214 
laclq ORE bases 3297-4377 
Site of replication initiation: base 2974 
Multiple Cloning Site: bases 930-945 
For inducible, high level expression of genes as fusions with glutathione S-transferase 
(GST) gene from Schistosomajaponicum, which forms an, -, dfinity tail on the protein 
products of genes inserted into the multiple cloning site (MCS). Expression is under 
the control of a tac promoter which enables inducible, high-level production of fusion 
proteins. 
BamHl 
Smal 
EcoRl 
%atil 
133 
Ptac 
E 
Bs 
Apa 
BstE 
Mlul 
Cloning primers: 
Upstream (BamHl): 5'-ACA AAC GGA TCC ATG* TCT GAC CAG GAG GCC 
AAA-31 
Downstream (BamHl). 5'-GCC GCG GGA TCC CTA* AAC TGT TGA ATG 
ACC-31 
SUMO-1: 
Organism: Homo sapiens 
Coding region: 303 bp 
GB acession number: NP003343, Q93068, AAC50996 
Antibodies: 
Mouse 21 C7 monoclonal antibody against full-lenght recombinant GMP- I protein 
obtained from Zymed (Cambridge Bioscience) 
Bacterial Expression: 
Expressed as a GST fusion protein in E. coli B834 
ýnHl 
10-1 
; amHl 
Smal 
EcoRl 
134 
Ptac 
E 
Bs 
Apo 
BstE 
Miul 
Cloning primers: 
Upstream (BamHI): 5'-ACA AAC GGA 
AAA-31 
TCC ATG* TCT GAC CAG GAG GCC 
Downstream (BamHl): 5'-GCC GAG GGA TCC CTA* ACC CCC CGT TTG TTC 
CTG-3' 
SUMO-1 (1-97 a. a. ): 
C-terminus cleaved form of SUMO- 1, which allows it to be conjugated to other proteins via 
the conserved C-terminal Gly residue 
Organism: Homo sapiens 
Coding region: 291 bp, 
GB acession number: NP003343, Q93068, AAC50996. 
Antibodies: 
Mouse 21C7 monoclonal antibody against full-lenght recombinant GNIPI protein obtained 
from Zymed (Cambridge Bloscience). 
Bacterial expression: 
Expressed as a GST fusion protein in E. coli B834. 
, nHI 
10-1 
rel ný UOC&oj 
ýamHl 
Smal 
EcoRl 
135 
Ptac 
B 
ApC, 
BstE 
Mlul 
amHl 
)ch9 
EcoRl 
Cloning primers: 
Upstream (Bam. HI): 5-ACA AAC GGA TCC ATG* TCG GGG ATC GCC CTC AGC-3' 
Downstream (EcoRl): 5'-GCC GCG GAA TTC TTA* TGA GGG CGC AAA CTT CTT 
GGC-31 
Ubch9: 
Organism: Homo sapiens 
Coding region: 474 bp 
GB acession number: NM003345, U29092, U31882, AJO02385, U31933, X96427. 
Antibodies: 
Sheep anti-Ubch9 polyclonal antibody against Ubch9 Gtern-ýinal peptide 
(CEYEKRVRAQAKKFAPS) 
Bacterial Expression: 
Expressed as a GST fusion protein in E. coli DH5a 
136 
Ptac 
B1 
Apc, 
BstE 
Miul 
mHl 
ch5 
EcoRl 
Cloning primers: 
I Upstream (Bam]Hl): 5'-ACA AAC GGA TCC ATG* GCG CTG AAG AGG ATT CAG-3 
Downstream (EcoRl): 5'-GCC GCG GAA TTC TTA* CAT TGC ATA TTT CTG AGT 
CC-31 
UbchS: 
Ubiquitin conjugating enzyme 
Organism: Homo sapiens 
Coding region: 459 bp 
GB acession number: X78140 
Bacterial Expression: 
Expressed as a GST fusion protein in E. coli DH5a. The recombinant GST-Ubch5 is not 
digested by Thrombin 
137 
Ptac 
Ap 
Bst 
Mlul 
p 
0 
3mHl 
5AEI 
EcoRl 
Cloning primers: 
Upstream (BamHl): 5-AAC GGA TCC ATG* GTG GAG AAG GAG GAG GCT 
GGC-3f 
Downstream (EcoRl): 5-G CGG GAA TTC TCA* CTT GGG GCC AAG GCA CTC 
CAC AA-31 
SAEl: 
Subunit of SLTMO- I activating enzyme 
Organism: Homo sapiens 
Coding Region: 1041 bp 
GB acession number: NP005491, AAD24433 
Antibodies: 
Sheep anti-SAE1 polyclonal antibody against recombinant SAEI 
Bacterial expression: 
Expressed as a GST fusion protein in E. coli B834 
138 
Ptac 
B 
Ap 
Bstl 
Mlul 
Linker primers: 
Upstream: 5'-GAT CCG CAG GTT CCG-3' 
Downstream: 5'-GAT CCG GAA CCT GCG-3' 
3mHl 
bch5 
EcoRl 
Linker: 
The linker codes for a5 aminoacid peptide (GSAGS) between GST and Ubch5, to facilitate a 
better acess to the Thrombin cleavage site. 
Bacterial expression: 
Expressed as a GST fusion protein in E. coli B834. 
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